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SUMMARY 
Injuries to the peripheral nervous system (PNS) are major and common source of 
disability, impairing the ability to move muscles and/or feel normal sensations, or resulting 
in painful neuropathies. Annually traumatic nerve injuries resulting from collisions, 
gunshot wounds, fractures, motor vehicle accidents, lacerations, and other forms of 
penetrating trauma, affected more than 250,000 patients just in the U.S. The clinical gold 
standard to bridge long non-healing nerve gaps is to use a nerve autograft- typically the 
patient’s own sural nerve. However, autografts are not ideal because of the need for 
secondary surgery to ‘source’ the nerve, loss of function at the donor site, lack of 
appropriate source nerve in diabetic patients, neuroma formation, and the need for multiple 
graft segments. Despite our best efforts, finding alternative ‘nerve bridges’ for peripheral 
nerve repair remains challenging – of the four nerve ‘tubes’ FDA approved for use in the 
clinic, none is typically used to bridge gaps longer than 10 mm due to poor outcomes. 
Hence, there is a compelling need to design alternatives that match or exceed the 
performance of autografts across critically sized nerve gaps. 
Here we demonstrate that early modulation of innate immune response at the site 
of peripheral nerve injury inside biomaterials-based conduit can favorably bias the 
endogenous regenerative potential after injury that obviates the need for the downstream 
modulation of multiple factors and has significant implications for the treatment of long 
peripheral nerve gaps. Moreover, our study strongly suggests that more than the extent of 
macrophage presence, their specific phenotype at the site of injury influence the 
regenerative outcomes. This research will advance our knowledge regarding peripheral 
nerve regeneration, and help developing technologies that are likely to improve clinical 
outcomes after peripheral nerve injury. The significant results presented here are 
complementary to a growing body of evidence showing the direct correlation between 
macrophage phenotype and the regeneration outcome of injured tissues.  
 
1 
CHAPTER 1  INTRODUCTION  
Traumatic injuries during the World Wars in the first half of the last century 
influenced many of the current surgical techniques that are used for nerve repair. Sydney 
Sunderland in the 1940s published studies on the intraneural topography of the ulnar,  
radial, and median nerves as well as of the sciatic nerves and provided the anatomic 
foundation for peripheral nerve repair [1,2]. With the advent of micro surgical techniques 
and advancement of technology, several strides in the field of nerve repair have been 
achieved. For small gap, close to normal functional recovery can be achieved with the 
current techniques. For longer gaps, we still face some of the same challenges that have 
been around for the past century. The gold standard to bridging long gaps for the past 
century has been autographs. However, there are several drawbacks of using autographs 
that prevent them from achieving full functional recovery after nerve injury.  
With the advances made in the field of regenerative medicine, alternatives to using 
autographs have been explored. Several synthetic and natural guidance channels are 
currently used in clinical as well as research settings to bridge nerve gaps. These techniques 
have shown to improve nerve regeneration in small gaps ( less than 10 mm in rats and 30 
mm in human and primates) but fail when the gaps are longer [3]. Even after the last 150 
years of innovation and development of refined surgical techniques and understanding 
nerve injury, we do not have a suitable replacement for autographs [4]. Even though there 
were several tissue engineering attempts to provide a scaffold to repair long nerve gaps, 
match the performance of autograft, none of them have been able to match the performance 
of autograft yet [3]. Although the search for the minimum critical elements continues, it is 
fundamentally challenging to replicate individual aspects of a complex biochemical 
regenerative cascade. This section will discuss the grand challenges of neural tissue 
engineering.   
 2 
1.1 Healing or Scarring1 
Physiological healing, which incorporates the removal of necrotic tissue and its 
clearance, results in two possible outcomes: 1) “regeneration,” which is complete 
replacement of injured tissue with new fully functional tissue, and 2) “scarring,” which is 
the partial repair of injured tissue with limited or no functionality. The intriguing question 
that arises is—what determines these outcomes? Generally, after injury of a tissue, several 
biological pathways become activated and typically local cells undergo changes in 
phenotype, which consequently determine the physiological healing state of the tissue [5]. 
Regeneration occurs when this cellular and tissue response acts in concert to facilitate 
restoration of function. Conversely, scarring occurs when endogenous constraints, which 
mainly evolve to preserve the more “critical” functions, prevent this orchestration of 
regenerative healing [5–7]. 
Regeneration may be defined as the capacity of a tissue to regrow after injury and 
to restore its original function. Consequently, the regenerative capacity is the probability 
of regeneration occurring in an organ/tissue for a given injury [8]. Generally, the 
regenerative capacity of any organ or tissue is limited by endogenous constraints for repair 
that arise when the injury exceeds the threshold of regenerative capacity of the affected 
tissue. Although complex tissues retain the capacity for endogenous regeneration to some 
extent, regeneration is typically constrained by rate-limiting biochemical or cellular 
processes. Rate-limiting biochemical or cellular processes may be thought of as “knobs,” 
which when turned, help increase or decrease the regenerative capacity of specific tissues. 
Hence, the critical question in the context of regeneration is: Is it possible to modulate 
                                                 
 
 
1Mokarram, N., and Bellamkonda, R. V. Overcoming endogenous constraints on neuronal regeneration. 
IEEE Trans. Biomed. Eng. 58:1900–1906, 2011. 
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healing pathway of complex tissues or to turn the “knobs” to facilitate alleviation of 
endogenous constraints and promote regeneration? And if indeed, is this possible, are there 
some “master knobs” that tip the balance favoring regeneration and away from scarring? 
To answer these questions, it is necessary to carefully examine both endogenous constraints 
and healing pathways. 
1.2 Endogenous Constraints and the Role of Inflammation 
There are a number of endogenous constraints, which determine regenerative 
capacity of a tissue, and these vary greatly by species, age, pathophysiological state, tissue 
type, and the extent of injury. For instance, injured fetal tissues, in contrast to adult tissues, 
can occasionally be completely regenerated [6], [9–11] indicating their greater regenerative 
capacity. Although the loss of regenerative capacity from young to old is intuitively 
accepted to be true [12], the differences in the regenerative capacity between age-matched 
individuals are less well understood.  
In the recent years, there is increasing evidence to suggest that inflammation [13–
16] and the biochemical pathways [17,18] triggered by the nature and duration of the initial 
inflammatory response may determine the healing outcomes [19–22].Therefore, it is 
reasonable to assume that regeneration versus scarring responses may be modulated if 
mechanisms to influence this inflammatory cascade post-injury existed. 
During the inflammation process, an array of complex regulatory pathways 
operates. Inflammatory pathways include mechanisms that regulate both “local” factors, 
such as the plasticity of tissue [23,24] and its growth rate [21], and also “long-distance” 
factors, such as signaling mechanisms for the recruitment of circulating stem and immune 
cells, and their homing [25–28] (see Figure 1.1). Inflammatory cells (e.g., macrophages 
and microglia) may secrete either “pro-regenerative” or “pro-scarring” chemokines and 
cytokines (see blue and red arrows, respectively, in Figure 1.1). 
 4 
Studies on various immune cell types over the last several years have brought to 
light the biochemical as well as functional diversities of these immune cells, such as 
macrophages [29–33], which are extant both in normal and injured tissue [13]. 
Macrophages as the “first responder” immune cells after injury potentially offer a valuable 
point of intervention, and strategically employing macrophages could direct the pathway 
toward predisposing the immune response to a “pro-regenerative” one. 
 
 
Figure 1.1: Healing vs. Scarring: Potential pathways and interactions that operate in a 
tissue post-injury.  
The sequence of events in the inflammatory pathway may determine the final outcome 
of healing process (regeneration or scarring) by regulating local and long-distance 
factors via pro-regeneration (blue arrow) or pro-scarring (red arrow) factors. 
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1.3 Regeneration and Scarring in the Nervous System 
If macrophages as well as glial cells determine differential regenerative capacity of 
the the central nervous system (CNS) and peripheral nervous system (PNS), then 
evaluation and characterization of the effects of this response on the processes that thwart 
regeneration after PNS or CNS injury becomes critical. 
1.3.1 Critical Determinants of PNS Regeneration 
The PNS, unlike the CNS, has the ability to regenerate in a limited manner. 
Functional recovery after injuries to the PNS is dependent on factors such as 1) the rate of 
regeneration, which influences the time to reinnervation of target tissue, 2) the plasticity of 
the local peripheral nerve and the central cortical neurons in reestablishment of coherent 
control of target tissue, and 3) the severity of the injury, which may determine the extent 
to which the “pro-regenerative” glial/inflammatory responses can be modulated.  
1.3.1.1 Rate of Regeneration: 
An important challenge and determining factor for functional recovery after PNS 
injury is the time to reinnervation [34]. Based on studies dating back to World War II, delay 
in repairing an injured peripheral nerve leads to feeble functional outcomes most likely due 
to a decrease in the ability of the end organ to be reinnervated and also atrophic changes in 
the regenerating support pathway of Schwann cells [35]. Although the rate of axonal 
regeneration is fairly constant across mammalian species (∼1–4 mm/day) [35], this rate 
decreases with age and contributes to poor regeneration in older adults [36]. Interestingly, 
Fu and Gordon demonstrated that regeneration time dependency is not an intrinsic 
limitation of the neurons, but is controlled extrinsically by signals that originate either in 
glial cells such as Schwann cells, or target tissue such as muscle [37,38]. In other words, 
axons maintain their regenerative capacity over time by the promoting mechanisms that 
stimulate their regeneration. Those promoting mechanisms may decrease over prolonged 
periods due to Schwann cells or target tissue dysfunction. Based on these observations, the 
 6 
rate of regeneration is an important rate limiter of success. This may, in turn, be determined 
by the quality and quantity of supporting healthy Schwann cells. 
1.3.1.2 Plasticity: 
Plasticity may be defined as the ability of the PNS to sprout and make new 
connections with target tissues such as muscle. Plasticity may be governed by the presence 
of inhibitory proteoglycans, such as chondroitin sulfate proteoglycans (CSPGs) found in 
the basal lamina in the PNS [39,40]. Second, plasticity is also dependent on the ability of 
the axons to “sprout” multiple neuritis and axonal branches to increase the probability of 
appropriate target finding and innervation. Neurotrophins such as neurotrophin-3 (NT-3) 
and nerve growth factor may play an important role in enabling this activity [41,42]. Lastly, 
plasticity is dependent on the end organ receiving regenerating nerves and its ability to be 
innervated in a functional manner as nonspecific connections lead to misdirected 
regeneration [35]. 
1.3.1.3 Degree of Injury: 
As with any tissue, the degree of injury has the potential to overwhelm the 
regenerative capability. In the case of PNS injury, this translates to the gap length across 
which regeneration needs to occur. Bringing the two nerve stumps together (coaptation) is 
typically used to repair short distance nerve defects, but for longer nerve gaps (15 mm or 
longer), the current clinical gold standard is to use an autograft [4]. 
1.3.2 Critical Determinants of CNS Regeneration 
As is the case with PNS repair, adult CNS regeneration is hostage to the 
biochemical and cellular processes triggered by neural injury. Functional recovery is 
dependent on survival of the injured neuronal cell body, regeneration of the damaged axon, 
remyelination, and functional synapse formation [43].However, contrary to the neurons in 
the PNS, severed CNS axons fail to regenerate beyond the lesion site [44]. The difference 
 7 
between regenerative capabilities of these two systems stems from the differential glial 
response after injury, resulting in vastly different degrees of “permissiveness” of the injury 
environment to regenerating axons [45]. Hence, nonpermissive regenerative environment 
after injury stemming from the astroglial scar tissue and inhibitory adult CNS myelin 
represent formidable barriers to CNS regeneration. 
1.3.2.1 Astroglial Scar Tissue: 
After CNS injury, astrocytes, oligodendrocyte precursors, meningial cells, and 
microglia, are recruited to the injury site and form an astroglial scar tissue that “walls off” 
the CNS lesion [7]. Although some of these events have advantageous effects (like 
isolating the injury site, minimizing the area of inflammation, and cellular degeneration), 
many astrocytes in the lesion site become hypertrophic and adopt a “reactive” phenotype, 
releasing inhibitory extracellular matrix (ECM) molecules such as CSPGs [7].CSPGs are 
also present in perineural nets that stabilize CNS synapses and limit plasticity in the CNS. 
Overcoming astroglial scar tissue represents a grand challenge as it negatively impacts 
regeneration and limits the integration of implanted electrodes or transplanted engineered 
constructs into the CNS.  
1.3.2.2 Myelin-Associated Inhibition and Wallerian Degeneration:  
Myelin, a para-crystalline array of Schwann cell plasma membranes or lipid-rich 
glial, provids a low-capacitance, high-resistance sheath around large axons assisting rapid 
conduction of nerve impulses [46]. After injury in the CNS, immobilized CNS myelin 
inhibits axon outgrowth by varied mechanisms [47].Wallerian degeneration, the process in 
which damaged cells are removed and recycled by glial cells, is slower in CNS in 
comparison to PNS. The rate of Wallerian degeneration is different in these two systems 
because of some distinct differences in the glial clearance responses after PNS and CNS 
injuries. The PNS is more efficient at clearing myelin debris in comparison to the CNS, 
and it is believed that the Schwann cells are the primary reason for this difference [48]. 
 8 
Schwann cells in the PNS, in contrast to their CNS counterparts, oligodendrocytes, do not 
require axon signals to survive. In fact, in their developmental stages, oligodendrocytes 
that fail to make contact to an axon undergo apoptosis [49]. Therefore, unlike Schwann 
cells, oligodendrocytes are not as capable to clean up the myelin sheaths and their debris 
after injury. Moreover, oligodendrocytes are also believe to be incapable of recruiting 
macrophages for debris removal [48].  
1.3.2.3 Blood-Brain Barrier:  
Another important determinant in CNS regeneration is the blood-brain barrier 
(BBB). The BBB is the separating system of circulating blood and cerebrospinal fluid in 
the CNS. One of the main roles of the BBB was believed to be the separation of the 
systemic immune system from the CNS. Although studies have shown that resident CNS 
macrophages (microglia) present within the CNS actively interact with peripheral immune 
cells [50], the CNS is largely thought to be restricted in its capacity to deliver antigens to 
local lymph nodes and subsequently activation of T cells [48]. In an uninjured tissue, 
antigens are taken up by antigen presenting cells such dendritic cells, and transported to 
the lymph nodes. Soluble antigens can also be drained into the lymph nodes. However, in 
the CNS, although dendritic cells are present in the choroid plexus and meninges, they do 
not exist in normal parenchymal tissue or perivascular space as the result of BBB [51]. 
Moreover, in contrast to the PNS, the barrier disruption in the CNS is only limited 
to the site of injury, whereas in the PNS, the permeability enhances throughout the whole 
distal stump. The decreased permeability in the CNS could also explain the difference in 
the number of infiltrated macrophage to the site of injury [48]. 
1.3.3 Common Determinants of PNS and CNS Regeneration 
Besides the aforementioned rate-determining processes in the PNS and CNS, there 
are some other critical determinants of regenerative fate that are common in both systems. 
One such factor is the number of available local stem or progenitor cells in the immediate 
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vicinity of the site of injury. Besides resident neural stem cells [52], stem cells can be either 
transplanted [53] or endogenously recruited to the site of injury [54]. However, in spite of 
encouraging data, which indicate that replacement of cells is promising [55–57], the 
functional impact and reliability have been underwhelming. Moreover, despite intrinsic 
plasticity of endogenous stem cells, they are incapable of providing complete recovery in 
severe trauma [4].  
Another rate limiter is the ability of an injured tissue to form blood vessels 
(angiogenesis and vascularization). Angiogenesis is not only a vital process in growth and 
development, but also play a critical role during wound healing process. Besides vascular 
endothelial growth factor and the fibroblast growth factors are two long-known effective 
factors in vessel formation, there are many other critical growth factors which are involved 
in the process of blood vessel formation and their physiological regulation [58]. These 
factors should act in concert with each other temporally and spatially in order to form a 
functioning vascular network [59]. Enhancement in neurogenesis by increasing 
vascularization has been reported [60]. 
1.4 New Insights into Regeneration: Immune System as the Key Determinant of 
Regeneration 
There is evidence that secretory products of immune cells are capable of affecting 
most of the critical determinants of regeneration in the CNS and PNS that makes the 
immune system the key determinant of regenerative fate. Therefore, the inflammatory 
cascade post-injury and the role of the immune system has the potential of being the 
linchpin upon which regeneration versus scarring responses are determined.  
Considering the complexity of the biochemical and cellular responses to neural 
injury, targeting an individual point in the cascade may or may not be the most efficient 
approach to bias the response to regeneration versus scarring. In this context, the 
inflammatory response as well as the resulting immune reaction to the injury represent a 
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promising point of intervention and could potentially represent one of the “master knobs” 
for eliciting regeneration. Before discussing the effects of different inflammatory 
responses, a brief introduction to microglia and macrophages as the most studied and 
diverse inflammatory cells will be provided. 
1.4.1 Macrophages and Their Different Activation States 
Macrophages are present in all tissues with the different resident names: osteoclasts 
in bone, histocytes in connective tissue, Kupffer cells in liver, and microglia in the CNS. 
They migrate as monocytes into the tissue in a steady-state fashion or in response to an 
inflammation. Although macrophages have been known as the professional phagocytes and 
the executers of the innate immunity, recent studies illustrate their homeostatic as well as 
regenerative roles [30,32,33]. In fact, remarkable plasticity of macrophages makes them 
capable of effectively responding to the different environmental signals by changing their 
phenotype and physiology. Mosser and Edwards suggest that there exist many shades of 
activation of macrophages, resulting in a spectrum of macrophage population rather than a 
few distinct groups [33]. However, there is consensus that macrophage phenotypes roughly 
fall into three classifications: classically activated, wound-healing, and regulatory (see 
Table 1-1) [20,30,32,33]. These macrophage phenotypes can sequentially change to each 
other in response to signals in their respective microenvironments [61,62].  
Classically activated macrophages become activated by injury-triggered 
endogenous inflammatory signals like Th1 cytokine interferon gamma (IFNγ), or by 
exogenous inflammatory signals like lipopolysaccharide (LPS) [61]. These cells are 
prototypical immune effector cells, which kill pathogens by production of oxygen, nitrogen 
radicals as well as phagocytosis. Classically activated macrophages are beneficial for the 
survival of the organism. However, resolving the injury and restoring normal tissue 
homeostasis requires an innate immune response that supports replacement of lost and 
damaged cells and restructuring of the damaged ECM.  
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Wound healing macrophages represent a second class of macrophages that help in 
the tissue repair by producing anti-inflammatory cytokines, which mediate angiogenesis as 
well as ECM deposition. One of the well-established activating signals of this phenotype 
is interleukin-4 (IL-4). Moreover, the induction of arginase in these cells may lead to 
polyamine and proline biosynthesis, promoting cell growth and collagen formation.  
The third broad category of macrophages is regulatory macrophages that are 
induced by exposure of macrophages to apoptotic cells and are associated with a robust 
suppression of the innate immune response. This phenotype allows macrophages to engulf 
apoptotic cells without inducing a classically activated immune response [19,30,32].  
In the nervous system, although other glial cells (like astrocyte [63]) and neurons 
[64] may also play an immune role, the primary cells involved in the generation of innate 
immune response are microglia cells. It has been demonstrated that microglia, as the CNS 
resident macrophages, are also capable of transiting between the three activation states 
previously described upon receiving an appropriate activating signal (see Table 1-1) 
[19,20]. 
Generally, a pro-regenerative bias in activation of these populations in the 
inflammatory cascade at the appropriate time and location will lead to regeneration, and 
any inappropriate triggering of pro-scarring macrophages/microglia/glial cells will lead to 
scarring. For example, in cancer, macrophages inappropriately switch from the classically 
activated to regulatory phenotype [33], or in autoimmune diseases, such as Alzehimer’s or 
multiple sclerosis (MS), microglia cells become chronically inflammatory (coexistence of 
wound healing and classically activated phenotypes) in the brain [19,20,65]. Interestingly, 
many parasitic organisms also alternate the macrophage activation state to the wound 
healing as a means to enhance their survival within cells or tissues [66]. 
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1.4.2 Harnessing the Immune Response to Enhance Nerve Regeneration   
Regenerative biochemical cascade is sometimes halted by lack of critical 
component, such as resident pluripotent cells, or weak “homing” signals to recruit 
circulating stem cells, or poor permittivity to regeneration at the site of injury (e.g., gliotic 
scar). Although the precise effect of each phenotype of microglia is not completely 
understood, there is strong evidence to support the notion that macrophages can modulate 
regeneration in the nervous system. The Schwartz laboratory has demonstrated that 
appropriate activation of microglia by IL-4 or IFNγ differentially induces neurogenesis as 
well as oligodendrogenesis from adult stem cells [21]. This data suggests that both 
oligodendrogenesis and neurogenesis of adult neural progenitor cells are blocked by 
classically activated microglia cells in the mice. However, this process can be altered to be 
“pro-regenerative” by wound healing associated cytokines (IL-4) in combination with low 
levels of IFNγ. Therefore, controlled levels of appropriate cytokines can overcome the 
inhibition of neurogenesis in an inflamed brain. These studies also suggest that the 
duration, combination, and order of biochemical signals after injury ultimately determine 
the outcomes [67].  
It has also been shown that exposing microglia cells to low concentrations of 
classically activated cytokine IFNγ (5 ng/mL) enables them to buffer the excitatory 
neurotransmitter glutamate (a common player in neurodegenerative diseases) and 
subsequently afford protection to neural tissue [68]. Schwartz group has demonstrated that 
the cytotoxic effects of microglia exposure to large amounts of IFNγ (>50 ng/mL) is a 
consequence of upregulated neurotoxic cytokine, tumor necrosis factor-alpha (TNFα) [23], 
which is a secretory product of classically activated macrophages. However, treatment of 
the macrophages with TNFα during Wallerian degeneration significantly reduced their 
phagocytic capacity as well as their ability to ingest myelin debris, and in turn, their 
regenerative capacity [69].  
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On the other hand, it has also been demonstrated that lack of TNFα will 
significantly delay remyelination, which is an important regenerative step in the 
autoimmune disease such as MS [24]. In addition, the neuroprotective effect of TNFα 
might be indirectly controlled by astrocytes. Expression of the brain-derived neurotrophic 
factor by cultured astrocytes is usually elevated by increasing the amount of TNFα [70]. 
IL-1β, a pro-inflammatory neurotoxic cytokine, has also been shown to have a similar 
paradoxical effect in promoting regeneration [70]. Thus, although many cytokines such as 
TNFα and IL-1β are traditionally thought to be neurotoxic, their role is context dependent 
as their beneficial function was demonstrated in animals deficient in these cytokines [65]. 
Therefore, macrophages/microglia phenotype has a regulatory effect on the inhibitory 
environment of CNS as a critical determinant of regeneration. Additionally, microglia 
exposure to IL-4 stimulates production of insulin-like growth factor (IGF-1) [33] (see 
Table 1-1), supports neurogenesis [71] and oligodendrogenesis [72], as well as 
ameliorating the age-related decline of those regenerative process [73]. 
Macrophages also play a key role in the regeneration process. They actively 
participate in the cell replacement by the stem cell recruitment and homing, as well as in 
the resident progenitor cell differentiation and proliferation [74]. Besides the granulocyte- 
macrophage colony-stimulating factors (GM-CSF), it has been shown that IL-12 
(upregulated by classically activated phenotype) also mobilizes hematopoietic stem cells 
[26,27]. It has also been demonstrated that the monocyte chemoattractant protein-1 (MCP-
1), a chemokine produced by classically activated macrophages, has an ability to recruit 
neural progenitors to the site of injury [25,28]. Moreover, different phenotypes of 
macrophages by secreting factors like TNF, IL-1, and GM-CSF can cause an increase in 
the production of granulocyte and monocytes (defensive immune cells) by the bone 
marrow, which can contribute in healing pathway in several ways. For example, one type 
of granulocyte, basophils, can release histamine, which leads to dilation and increased 
permeability of capillaries close to them [58]. It has also been shown that secretory 
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products of macrophages influence the different phase of angiogenesis both in vivo and in 
vitro [63,64]. These participations also support the idea of capability of macrophages in 
regulating some other rate-determining factors. 
Unfortunately, detailed molecular mechanisms and healing pathways of all the 
different phenotypes of microglia and macrophages in the nervous system are not well 
characterized yet; preliminary results show that a tightly controlled modulation of these 
cells can potentially enhance the regeneration in CNS and PNS significantly. 
Neuroengineering tools involving electrical stimulation, polymeric fibers, hydrogel 
nanoparticles, and hydrogel microparticles may all offer powerful tools to modulate these 
intricate inflammatory signaling fates in a manner that is spatially and temporally 
controlled [3,75–78].  
Therefore, in order to meet the challenge of regenerating PNS and CNS nerves, it 
is important to explore the full spectrum of the microglial and macrophagic cell phenotypes 
in the inflammatory cascade, and to identify their influence on both local and long-distance 
critical rate limiters to endogenous regeneration, and where necessary, to use biological 
and engineering tools to modulate these critical phenotypes to maximize regeneration. 
In conclusion, one of the greatest grand challenges in neuro-regeneration is 
stimulating endogenous repair of injured peripheral and central neural tissues. Specific 
challenges include bridging long peripheral nerve gaps and overcoming astroglial scar 
tissue to promote regeneration after spinal cord injury. The particular insight afforded here 
is the possibility that modulation of the inflammatory cascade after injury may significantly 
alter the course of healing in the nervous system, thus offering a critical modulation 
opportunity for promoting regeneration and integration of engineered materials and devices 
in the nervous system. 
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Table 1-1: Different activation states of macrophages 
Activation state Classically Activated Wound Healing Regulatory 
General function 
Tissue defense, ROS, 
and NO production 
Tissue repair, fibrosis, 
ECM reconstruction 
Immunosuppression, 
apoptotic cell uptake 
Activating Signals IFNγ, TNFα IL-4, IL-13 
TGFβ, IL-10, apoptotic 
cells 
Secretory 
products 
TNFα, IL-12, IL-6, IL-
1β, MCP-1, ROI 
IL-1RA, IL-10, 
Arginase 1 
IL-10, TNFα, IL-6, 
IL-1β, MHCII 
CD markers CD86, CD80, CCR7 CD163, CD206 CD86, CD163 
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CHAPTER 2  SPECIFIC AIMS AND HYPOTHESES 
Annually over 250,000 Americans suffer from a peripheral nerve injury which 
results in a loss of function and a compromised quality of life. Peripheral nerve gaps usually 
are a consequence of traumatic limb injury or collateral damage to peripheral nerves during 
tumor resection and in more than 50% of cases, no measurable signs of recovery are evident 
[3,79]. The clinical gold standard to repair critically sized non-healing gaps is to use sural 
nerve autografts [4,80,81]. However, autografts are not ideal because of the necessity for 
secondary surgery to ‘source’ the nerve, lack of appropriate source nerve in diabetic 
patients, loss of function at the donor site, neuroma formation, and the need for multiple 
graft segments. Despite our best efforts, finding alternative ‘nerve bridges’ for peripheral 
nerve repair remains challenging – of the four nerve ‘tubes’ FDA approved for use in the 
clinic, none is typically used to bridge gaps longer than 10 mm due to poor outcomes. 
Hence, there is a compelling need to design alternatives that match or exceed the 
performance of autografts in enabling peripheral nerve repair across critically sized gaps. 
Our long term goal is to enhance peripheral nerve regeneration in the critically-sized non-
healing gap model. 
Several approaches to accelerate regeneration have been explored including the 
local delivery of neurotrophic factors and cell transplantation [82–85]. Our group has 
pioneered the use of hydrogels, micro-scale lipid microtubes, and topographical cues to 
bridge nerves gaps larger than 12 mm [3,4,76,77,86–90]. While these approaches show 
promise, matching autograft performance in bridging gaps greater than 15 mm remains an 
elusive goal.  
Here, we propose an entirely different and novel approach – instead of trying to 
augment individual downstream elements of the molecular repair cascade, can we tap into 
and boost the endogenous molecular repair cascades by intervening upstream? 
Specifically, are there master knobs or nodes that act as upstream modulators of the healing 
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cascades/pathways, and if so, is it possible to enhance nerve regeneration by ‘biasing’ 
action at these nodes? The reasoning is that successful nerve repair is the result of a 
complex sequence of cellular events that includes extracellular matrix (ECM) protein 
secretion and remodeling, trophic factor secretion, and Schwann cell migration. 
Replicating element by element of this regenerative sequence using tissue engineering 
approaches is an overly daunting task. The alternative proposed here, is to modulate 
upstream nodes, which initiate these healing cascades.  
Indeed, in multiple animal models and organ systems, the immune system has 
emerged as the master orchestrator of the healing/non-healing fate [13,91–99]. In fact, in 
chapter 3, we will discuss a perspective on immunomodulation and tissue repair. 
Specifically, studies over the past years have shown increasing evidence that the sequence 
of cellular events associated with nerve regeneration is influenced by immune cells, 
especially macrophages which are able to play both detrimental and beneficial roles in the 
tissue regeneration process, depending on their phenotype [95,100,101]. Thus, our central 
hypothesis is that modulation of the innate immune response early after injury 
triggers endogenous repair mechanisms that can stimulate nerve repair across long 
nerve gaps. We will use the following specific aims to test our hypothesis: 
 
Aim 1: Evaluate the effect of modulating macrophage phenotype on peripheral nerve 
repair. Our working hypothesis was that innate immune cells, especially macrophages, are 
playing a key upstream role during the regeneration process and early modulation of their 
phenotype can affect later regeneration outcomes. The objectives for this aim were to 
fabricate nerve conduits containing pro- or anti-inflammatory cytokines, and investigate 
the effect of their early release inside the nerve conduit for creating a regenerative 
environment as evident by quantitative molecular signatures in the nerve gap. The 
outcomes of this aim are discussed in Chapter 4. 
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Aim 2: Investigate the interplay between macrophages phenotype and glial cells 
function. Our working hypothesis was that Schwann cells (SC) play a critical role in 
helping stimulate nerve growth and modulating macrophages could potentially affect the 
SC cellular behavior. The objectives for this aim were to investigate how modulating 
macrophage phenotype potentially contributes to the enhancement of nerve regeneration 
and how that modulation affects SC migration, proliferation, and phenotype in vitro and in 
vivo. The outcomes of this aim are discussed in Chapter 5. 
 
Aim 3: Determine the effect of monocyte recruiting factor on stimulation of 
peripheral nerve regeneration across a critically sized nerve gap. Our working 
hypothesis was that there exist monocyte subtypes that may be predisposed to differentiate 
into macrophages of different phenotypes and recruitment of these precursors (monocyte) 
could have an impact on the nerve regeneration. Our objectives were to fabricate a scaffold 
containing anti-inflammatory monocyte recruiting factor, and evaluate the effect of its 
early release, in comparison to the macrophage modulating strategy, in affecting the final 
regeneration outcome. The outcomes of this aim are discussed in Chapter 6.  
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CHAPTER 3  LITERATURE REVIEW 
Repairing peripheral nerves across long gaps is clinically challenging, even despite 
all the advancement made with autograft transplantation. While scaffolds that present 
extracellular matrix molecules and trophic factors have been designed, matching the 
performance of autograft-induced repair has been challenging. Current approaches focus 
on enhancing axon growth by direct action on nerves, or glial cells, and here we investigate 
an alternative approach to influencing regenerative outcomes by modulating the initial 
inflammatory sequence via macrophages. Since the sequence of cellular and molecular 
events associated with nerve regeneration is influenced by immune cells [95,102], we 
hypothesize that modulating immune cells upstream of action on nerves or Schwann cells 
(SC) triggers endogenous repair mechanisms that can stimulate nerve repair across long 
gaps. In fact, the incredible plasticity of macrophages makes them an interesting case for 
modulation. 
In this chapter, we evaluate the strength of our hypothesis by reviewing the current 
state of understanding regarding the role that different phenotypes of macrophages and 
monocytes play following injury and during the course of remodeling in different tissue 
types. Moreover, we explored recent designs of macrophage modulatory biomaterials for 
tissue engineering and regenerative medicine applications. 
3.1 Introduction2 
Endogenous healing capacity varies extensively across different species. For 
example salamanders have the ability to regrow sophisticated body structures even as 
                                                 
 
 
2 Mokarram, N., and Bellamkonda, R. V. A Perspective on Immunomodulation and Tissue Repair. Annals of 
Biomedical Engineering 42:338–351, 2014. 
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adults [103] while this capacity is more limited in mammals. The diversity in healing 
capacity also exists within tissues of the same species. Mammals are much more successful 
in repairing their dermal tissue, or as the legend of Prometheus suggests, livers, compared 
to their neural tissue [104,105]. Endogenous healing also varies by age as several studies 
have demonstrated that the mammalian embryo retains their ability to repair wounds 
without scar formation, whereas this capability diminishes with age [106,107]. It has been 
hypothesized that a differential immune response to injury contributes strongly to the 
differential capacity for healing [108]. 
3.2 Innate Immune Cells Orchestrating Tissue Repair 
It is increasingly being acknowledged that the innate immune system is actively 
involved during the wound healing by orchestrating a biochemical cascade influencing 
tissue repair [108,109]. The innate immune system is normally the initial-responder to an 
injury. It mainly includes myeloid lineage cells that include monocytes/macrophages and 
neutrophils. Monocytes also falls under the mononuclear phagocyte system, a classification 
that involves several cell types, including macrophages, that share similar ontogeny at 
multiple stages of differentiation and play essential roles in inflammation, host defense, 
and development [31,33]. Circulating monocytes give rise to a diverse number of tissue 
resident macrophages throughout the body, as well as to specialized cells such as dendritic 
cells (DCs) [31]. 
3.3 Monocytes Differentiation to Macrophages 
Monocytes are produced from dendritic cell and macrophage progenitors, in the 
bone marrow [110] and, when matured, they enter the circulation in a chemokine receptor 
CCR2 dependent process [111]. Released monocytes circulate in the peripheral blood for 
several days before migrating to tissues and refill the tissue macrophage population [31]. 
Although most tissue macrophages are derived from peripheral blood circulating 
monocytes, studies have shown that local proliferation has a considerable role in the 
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maintenance and renewal of many tissue-resident macrophage populations. In fact, in some 
of these cases, it has been shown that the recruitment of circulating precursors having little, 
if any, role in this process [31,112,113]. However inflammatory insults, such as infection 
or trauma, can results in an augmented dependence on the recruitment of blood-borne 
circulating precursors to assist with  repopulation of the tissue-resident macrophages in the 
affected tissues [31]. 
3.4 Many Faces of Macrophages 
After injury, the innate immune response is quick and although it lacks the 
specificity characteristic of adaptive immunity [114], it is regulated by a plenitude of 
signals and demonstrates spectrum of activation stages and phenotypes [33,115]. 
Macrophages are important source of both inflammatory and anti-inflammatory signals. 
They arrive in mammalian wound milieu in the first few days after injury, where they clear 
dead cells and debris, release pro-inflammatory cytokines, secrete oxygen radicals, produce 
anti-inflammatory factors that dampen inflammation, stimulate angiogenesis, fibroblast 
proliferation and migration which are all necessary initial steps toward effective tissue 
regeneration [116,117]. A clue to better understanding of these contradictory functions can 
be provided by recognition of the existence of different macrophage and monocyte 
phenotypes. 
Briefly, M1 macrophages have been defined as the classically activated 
macrophages, whereas M2, or alternatively activated macrophages include almost any 
macrophage that does not fall under the M1 classification (Figure 3.1). Some experts 
choose to classify M2 macrophages based on their observed functions—termed 
‘‘alternative’’ M2a, ‘‘Type II’’M2b, and ‘‘deactivated’’ M2c, [115,118] while others 
choose to classify these macrophages based on their functions of classically activated, 
wound-healing and regulatory macrophages [33]. Despite these alternative approaches to 
classification, the characteristics of M1 and M2 macrophages are confirmed. M1 
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macrophages are activated by the well-known pro-inflammatory signals such as IFNγ and 
LPS; secrete major pro-inflammatory cytokines such as TNFα, IL-1β, , IL-23, IL-12, and 
IL-6; secrete high levels of reactive oxygen species (ROS); produce low amount of anti-
inflammatory cytokines such as IL-10; are efficient antigen presenting cells; and leads to 
the formation of effector and inducer cells related to the Th1 pathway [31,33,118]. In 
contrast, M2 cells are activated by molecular cues such as IL-4, IL-13, IL-10 as well as 
immune complexes; secrete high levels of IL-10; results in expression of mannose, 
scavenger, and galactose receptors; produce polyamines  and ornithine and instead of ROS; 
and are involved in polarization toward Th2 type response [33,118,119].  
It is likely that, with the increase in our appreciation of macrophage activation 
states, the number of generally recognized phenotypes expands. Moreover, since 
macrophage phenotype plasticity can be determined by remarkably complex signals from 
their microenvironments, it is more accurate to be described as a spectrum between the M1 
and M2 extreme, in which  any given macrophage may express particular components of 
various M1 or M2 phenotypes [33]. 
3.5 Different Subtype of Monocytes 
Circulating precursors of macrophages, monocytes, also display heterogeneity in 
both mouse and human [31,120–122]. In mouse, Ly-6Chigh (Gr1highCCR2+ CX3CR1low) 
monocytes efficiently infiltrate inflammatory sites and give rise to classically activated 
macrophages (M1) [31,122] (Figure 3.1). Their counterparts, Ly-6Clow 
(Gr1lowCCR2−CX3CR1high) monocytes, accumulate at inflammatory sites less efficiently 
and are thought to differentiate to resident and alternatively activated macrophages (M2) 
[31,112,122] (Figure 3.1). Regarding human, studies indicated that monocytes can be 
categorized into two subsets based on the expression of CD14 and CD16. The dominant 
subset which expresses high level of CD14 and low or negative level for CD16 (CD162) 
represents ~85% of the monocyte pool (inflammatory), while the minor subset expresses 
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low level of CD14 and high level of CD16 (CD16+) (anti-inflammatory) (Figure 3.1) 
[31,122]. Ly-6Chigh mouse monocytes roughly correspond to CD14highCD16− human 
monocytes, which are also CCR2+ CX3CR1low, and Ly6Clow mouse monocytes 
approximately correspond to CD14lowCD16+ human monocytes, which also express large 
amounts of CX3CR1 and low level of CCR2 [31]. 
3.6 Innate vs. Adaptive Immune Response in the Context of Regeneration 
Macrophages, in contrast to lymphocytes which regulate the later phases of 
regeneration, modulate the early sequence of cellular events which can determine the fate 
of healing process. Conditional macrophage depletion studies have shown reduction in 
formation of vascularized granulation tissue and scar formation as well as impairments of 
epithelialization [123]. In mice, macrophage disruption or depletion of macrophage 
transcriptional regulation after skeletal muscle injury leads to induction of fibrotic scarring 
and subsequently incomplete muscle repair [124]. A recent study has shown that systemic 
macrophage depletion during the first 24 h after salamander limb amputation results in 
permanent failure of limb regeneration which is associated with extensive fibrosis and 
dysregulation of gene expression in extracellular matrix (ECM) component [103]. 
Moreover, macrophages, unlike T-cells, appear to acquire an incredible plasticity. 
Multiple studies have shown the phenotype switching from M1 to M2 and reverse order 
[62,125,126]. This plasticity can play a protective role by providing an appropriate 
response to pathogen as well as   effectively resolving such a response without causing 
excessive local or systemic damage. Although it is still debatable if inflammatory 
macrophages are changing their phenotype at the site of injury to form regulatory and 
wound-healing macrophages [127], or if the progressive changes of signals during course 
of inflammation results in alternation of macrophages functional phenotype [62], the  
dynamic plasticity of macrophages can be controlled by type, duration, and concentration 
of plethora of  stimulating signals. Therefore, it is not unexpected that analysis of 
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macrophage phenotype population at different time points may demonstrate a combination 
of macrophage phenotypes. It is also not surprising that there exist phenotypes that express 
markers of both M1 and M2 phenotypes. In fact it has been shown that dysfunction in 
macrophage phenotype transition and plasticity are an underlying mechanism to multiple 
of diseases including cancer, fibrosis, insulin resistance, and  atherosclerosis [128]. 
In the context of tissue regeneration, macrophage phenotype has also been shown 
to be a critical player during tissue regeneration process following  skeletal muscle, cardiac, 
heart, skin and nerve injuries as well as others [94,114,129,130]. An increasing body of 
evidence based on the studies in different animal and organ models have shown that 
untimely polarization of macrophages, prevention of macrophage polarization, or inability 
to resolute a chronic polarization can results in a detrimental effect on regeneration 
outcome [105,128,129,131]. Therefore, macrophages are able to play both detrimental and 
beneficial roles during the regeneration process, and timely and efficient switch of their 
phenotype is essential for preventing a harmful or scar tissue outcome, in many cases.  
The incredible plasticity of macrophages makes them an interesting target in the 
context of immunomodulation. In the next section, we provide some examples that explore 
the potential role of macrophage activation and polarization during the regeneration 
process of different tissues. We then review examples of macrophage modulatory 
biomaterials. Finally, in the concluding remarks, we discuss the challenges and 
opportunities of employing macrophages as a therapeutic target for regeneration. 
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Figure 3.1: Schematic of heterogeneity, source, and potential tissue remodeling targets 
of monocytes/macrophages.  
Monocytes are produced from dendritic cell and macrophage progenitors, in the bone 
marrow [110] and, when matured, they enter the circulation [111], circulate in the 
peripheral blood for several days, and finally and especially during an inflammatory 
insult (such as injury),  migrate to tissues to refill the tissue macrophage population 
[31].  
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3.7 Macrophage Phenotypes during Tissue Regeneration 
3.7.1 Cardiac Tissue 
A myocardial infarction (MI) occurs when a coronary artery becomes occluded, 
resulting in oxygen supply deficiency which leads to necrosis of cardiac myocytes. These 
events stimulates the complement cascade and initiates an inflammatory response, 
primarily composed of neutrophil and macrophage infiltration [132]. A potential approach 
in preventing heart failure is to boost the intrinsic wound healing cascade that happens 
during the first 2 weeks after MI [133]. During this critical period, the area of infarct is 
very active with rapid turnover of cells and ECM components; the vulnerable wound is 
under the mechanical stress of myocardial contraction  as well as cycling intraventricular 
pressure which can result in serious damages in ventricular function as well as geometry 
[134]. Although studies have confirmed that monocytes and macrophages participate in 
infarct wound healing and dominate the cellular infiltrate for the first two weeks following 
MI [114,134], the residence time of cardiac tissue monocytes is very short [135]. Even 
days after the initial inflammation, there is a rapid turnaround time of about 24 h for the 
monocyte population to be completely replaced [135]. Surgical removal of the spleen (the 
main supplier of monocytes after MI) several days after coronary ligation substantially 
reduced the number of monocytes leading to impaired wound healing and heart failure 
[135].  
A study in a mice model of coronary ligation has shown that there is a temporally 
biphasic response regarding monocytes involvement in the myocardium. Pro-inflammatory 
Ly-6Chigh monocytes arrive first at the site of MI and are the dominant population during 
the first phase (1-4). These monocytes and promote removal of necrotic debris and 
digestion of infarcted tissus. In the second phase (days 4-8), reparative Ly-6Clow monocytes 
dominate the wound and results in resolution of inflammation and propagation of repair 
[114]. This sequential recruitment of monocyte were explained by their different subsets 
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of chemokine receptors expression [31]. During the first phase, MCP-1 release increases 
and Fractalkine (CX3CL1) release decreases which leads to recruitment of Ly6Chigh 
(CCR2+CX3CR1low) monocytes preferentially [114]. However in the second phase  
Fractalkine expression is increased, which suggests that recruitment of Ly-6Clow (CCR2–
CX3CR1high) monocytes during the second phase should preferentially be enhanced [114]. 
Once recruited, these monocyte subsets mediate distinct biological activities: Ly-6Chigh 
monocytes exhibit proteolytic and inflammatory functions, whereas circulating Ly-6Clow 
monocytes have attenuated inflammatory and pro-angiogenic properties [114]. These 
biological functions are regulated by secretion of cytokines and growth factors: Ly-6Chigh 
monocytes express IL-1β, TNF-α, myeloperoxidase, matrix metalloproteinases, 
cathepsins, and plasminogen activator urokinase and are therefore potently inflammatory, 
whereas Ly-6Clow monocytes express transforming growth factor-β (TGFβ), IL-10, the pro-
angiogenic vascular endothelial growth factor (VEGF), and are therefore reparative [114].  
The sequential recruitment of monocyte subsets to infarcts correlate well with the 
time course of tissue healing process and subsets biological properties: The early 
inflammatory and digestive phase one is followed by active resolution of inflammation and 
tissue repair in phase two. This well-orchestrated biphasic monocyte response is crucial for 
appropriate healing. In fact,  elimination of the first inflammatory phase impairs the 
removal of debris and dead cardiac myocytes, whereas annulment of the second phase 
reduces the deposition of collagen and the generation of microvessels [114].  The non-
inflammatory and pro-angiogenic properties of Ly-6Clow monocytes and their role in 
myocardial healing process suggest that the active role of these cells in terminating 
lingering inflammation.  
Although it has been suggested earlier that direct inhibition of macrophage 
infiltration via the CCL2/CCR2 pathway can contribute to the attenuation of left ventricular 
remodeling after MI [136,137], recent findings utilizing echocardiography revealed that 
deletion of CC chemokine receptor 2 (CCR2) which is responsible for recruiting 
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inflammatory Ly-6Chigh monocytes to the infarcted region improves left ventricular 
remodeling [138]. In fact, employing lipid-based nanoparticle as delivery vehicles for 
CCR2-silencing siRNA prevents inflammatory monocytes accumulation in site of 
inflammation and subsequently attenuates their number in atherosclerotic plaque and 
reduces infarct size after coronary artery occlusion [139]. 
The paradigm shift in the context of monocytes recruitment from a monophasic to 
biphasic monocyte response after MI, offers new opportunities for therapeutic 
interventions. For example, in order to accentuate tissue repair, it could be beneficial to 
modulate the ratio of subsets or timing of recruitment. The discrete mechanisms for 
recruitment of monocyte subsets (MCP-1-dependent for inflammatory cells, but 
Fractalkine-dependent for anti-inflammatory cells) offer rational targets to control 
inflammation and regeneration process, not only after myocardial infarction but also other 
tissue injuries.  
3.7.2 Dermal Tissue 
Because of its large area covering the body, dermal tissue is very susceptible to 
injuries. Therefore, it represents one of the most extensively studied tissues in the context 
of wound healing. Although the process is known to include macrophages, neutrophils, 
eosinphils, mast cells, as well as T-cells, macrophages play a central role during the 
cutaneous wound healing through production of growth factors, cytokines, and matrix 
metalloproteinases (MMPs) [91,140]. 
In the context of macrophage phenotypes, changes in the gene expression profile 
following human patient skin injuries and during cutaneous wound healing have been 
recently studied [94]. In addition to the up-regulation of a diverse number of genes, during 
the wound healing process, two transiently up-regulated groups of genes related with M1 
and M2 macrophage and their polarization were identified. The first showed an increase of 
gene expression during the early, inflammatory stage of wound healing and included a 
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mixture of M1 and M2 related genes (eleven M1 genes and seven M2 genes). The second 
which happens in the later angiogenesis and tissue remodeling stages of healing 
demonstrated predominantly M2 associated genes (1 M1 gene and 9 M2 genes). This result 
simply suggests that there is a correlation between polarization of macrophage 
subpopulation and cutaneous wound healing process. Although the mechanisms of shift 
from an M1 to an M2 phenotype during dermal remodeling are not well evaluated, they are 
thought to be caused by the phagocytosis of debris and apoptotic cells by M1 macrophages 
[141]. Other studies also demonstrated that depletion of macrophages during the 
proliferative phase of wound healing leads to a non-complete transition to the remodeling 
phase which ultimately results in impaired healing [105,123]. Interestingly, advanced 
aging and diabetes are associated with impaired wound healing, as well as a reduced ability 
to transition from an M1 to an M2 phenotype [142,143]. Taken together, these studies 
suggest a correlation exist between the impaired tissue remodeling and defective 
macrophage polarization. 
3.7.3 Musculoskeletal Tissue 
In contrast to relatively extensive studies of dermal wound healing, the role of 
macrophages in tissue regeneration of skeletal muscle has only been explored more 
recently and more attention was devoted toward the role of different macrophage 
phenotypes during the remodeling process of injured muscle [130]. 
After muscle tissue injury, significant number of inflammatory cells infiltrate at the 
site of injury [144]. In fact, studies have shown that a delay in muscle tissue remodeling 
and slowed removal of cellular debris is attributed to the reduction of monocytes available 
following muscle injury due to the depletion of circulating cells [124,131,145]. Moreover, 
these cells have shown to possess phenotypes that switch from M1 to M2 during the course 
of muscle regeenration [130,145]. During the initial proliferative stage of muscle 
remodeling, M1 macrophages are recruited to the site of injury. Later, during the transition 
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to the early and terminal differentiation stages, these M1 macrophages switch to a more 
M2 phenotype [130]. Arnold et al. also demonstrated that injured skeletal muscle recruits 
monocytes exhibiting inflammatory profiles that operate phagocytosis which rapidly 
convert to anti- inflammatory macrophages that stimulate myogeneinisis and fiber growth 
[145].  
Initial M1 macrophages produce chemokines and cytokines such as IL-6, TNFα, 
and IL-1β that are mitogenic and chemoattractant for muscle progenitor cells, resulting in 
the build-up of satellite and mono-nuclear cells at the site of injury [146–149]. When 
absent, these cytokines have been shown to reduce muscle repair in vivo [148]. On the other 
hand, it has also been demonstrated that these pro-inflammatory cytokines can prevent 
differentiation of muscle progenitor cells and their presence at the site of remodeling can 
negatively affect the later stages of regeneration process [150,151]. Therefore, a switch to 
an M2 environment after initial pro-inflammatory phase is necessary for resolving the 
inflammatory response. In fact, this transition occurs during the initial stages of 
differentiation of muscle satellite cells into differentiated skeletal muscle cells [152]. The 
switch from an M1 to an M2 microenvironment during the early and terminal 
differentiation stages not only mitigates the inflammation as well as production of 
cytotoxic nitric oxide, but also supports the fusion and differentiation of cells [124,130]. 
For example, anti-inflammatory IL-10 secreted by M2 macrophages is believed to both 
induce a polarization from an M1 to an M2 phenotype and support the fusion and 
maturation of myotubes [153]. Moreover, additional studies have suggested that transition 
within M2 phenotypes (from M2a to M2c sub-populations) may also play an important role 
in affecting later stages of differentiation as well as functional recovery [154]. 
Similarly, defective macrophage polarization in the process of muscle atrophy 
which occurs in models of muscular dystrophy causes a continuous recruitment of 
progenitor cells which are unable to differentiate due to concurrent presence of M1 and M2 
population [154,155]. Contrary to the normal process for remodeling of muscle tissue, the 
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environment of this disease inhibits the switch from M1 to M2 which may explain why 
ineffective remodeling happens in these models. 
3.7.4 Neural Tissue  
Nervous system consists of central nervous system (CNS) and peripheral nervous 
system (PNS) which both have their unique recruitment process in response to injury. 
Generally, in contrast to CNS, PNS is more capable of repair. Injury to the PNS induces a 
well-orchestrated cellular process that leads to the complete disintegration of the nerve 
segment distal to the lesion site, termed Wallerian degeneration (WD) [95].  
WD in the distal nerve segment starts within the first 24 h after axotomy, followed 
by fibrin cable formation, and Schwann cell (SC) and fibroblast infiltration from the both 
proximal and distal nerve stumps[156]. The SCs migrating from the proximal nerve stump 
advance along with regenerating axons, which grow through the enriched matrix and span 
the nerve gap. These regenerating axons reach the distal nerve stump and eventually make 
connections to the end organ [3]. Almost immediately after peripheral nerve injury, SCs 
dissociate from axons, dedifferentiate, and, along with fibroblasts, secrete cytokines that 
promote infiltration of immune cells. Neutrophils, the first immune cells to infiltrate, 
accumulate in the distal stump within 8 h, but their presence is short-lived [157]. Around 
the same period of time, circulating monocytes are attracted to the injured nerve where they 
differentiate into macrophages, and within days they take over as the dominant leukocyte 
population and play a critical role in ensuring complete WD. They account for the bulk of 
phagocytosis and debris removal, growth factor production, and remodeling of the ECM 
of the distal nerve [158,159].  
Acute injury in the peripheral nervous system results in triggering of anti-
inflammatory and immunosuppressive response, rather a pro-inflammatory response [160]. 
In fact the signal supporting the alternative macrophage activation is produced immediately 
after nerve injury and seemed to be established within the nerve, well before  
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monocytes/macrophages infiltration [160]. Moreover, axotomy of the sciatic nerve in a 
model of WD leads to the expression of multiple negative regulators of the innate immune 
system such as Interleukin-1 receptor antagonist (IL-1RA) and myeloid differentiation 88 
small (MyD88) which negatively regulated the NF-κB activation [161] within 4 h after 
injury [160]. It is suggested that stimulation of alternative macrophage response in the 
nerve seemed to be regulated at the level of IL-13, which is together with IL-4 are the 
central master knobs for M2 phenotype polarization [33,162]. The main anti-inflammatory 
cytokines such as IL-4, IL-10, IL- 13, LIF and TGFβ can support axonal outgrowth by 
modulating the immune cells [163]. For examples IL-4 stimulates immune cells to produce 
Neurotrophin-3 (NT-3) [164] and Neurotrophin-4 (NT-4) [165] which are both neurotophic 
factors belong to Nerve Growth Factor (NGF) family of neutrophins. In fact, the facial 
motoneuron survival after axotomy is significantly lower in IL-4 deficient mice [166]. 
Moreover, TGFβ increases the chemotactic action of NGF in immune cells [167]. 
In Central nervous system (CNS), due to the nature of the neural tissue construct, 
the process and involvement of macrophages and monocytes differs significantly from PNS 
and other previous examples. Tissue remodeling process in response to injury of the CNS 
mainly involves mainly the local immune cells. This is due to the existence of the blood 
brain barrier which is responsible for protecting the central nervous system from the innate 
immune responders. At early time points following injury of CNS, local tissue innate 
immune cells called microglia are recruited. Because of microglia’s predominantly pro-
inflammatory phenotype and the cytotoxic microenvironment developed following injury, 
tissue damage propagates and scar tissue forms [129]. Although tissue remodeling response 
in the absence of blood brain barrier breach does involve a small number of blood-derived 
monocytes at the late time points following injury [168,169], the main pro-inflammatory 
response differs from the tissue remodeling process involved in the periphery. Circulating 
monocytes are involved in the peripheral nerve damage leading to spontaneous recovery 
depending on the extent of the injury. These blood derived monocytes may be capable of 
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adopting an anti-inflammatory and more regulatory phenotype which promotes functional 
recovery and resolution of inflammation [170]. This type of response requires a high 
recruitment of blood-derived monocytes which is unlikely to occur during CNS injury. 
In a recent study, the process of tissue repair following spinal cord injury in the 
context of macrophage polarization has been investigated [129]. It was observed that 
immediately after injury, predominantly M1 macrophages were induced and remained 
within the spinal cord lesions. Although at early time points a small number of M2 
phenotype were observed, these cells were not seen at later time points. The experimental 
results suggest the existence of a unique M1 to M2 shift in the spinal cord which differs 
from that seen in other tissues. In addition, a distinct effect on the survival of neurons and 
neurite outgrowth was observed in this study [129]. Specifically, M1 conditioned media 
decreased neural cell viability while M2 conditioned media improved survival of neural 
cells with greater degree of neurite extension. Therefore, induction of a M2 type response 
may promote a more constructive remodeling tissue environment. This induction will 
improve the outcome compared to the default CNS injury where the dominant M1 type 
decreases neural cell viability [129,171]. Therefore, while in the (PNS), macrophage-
mediated phagocytosis of axons was viewed as essential for regeneration, in the CNS, 
despite infrequent evidence of their potential benefit, the overall role of macrophages was 
considered to be negative [169]. 
There are few reports on the impact of injecting blood derived monocytes and 
polarized macrophages on scar tissue formation and motor function [172–174]. The results 
show that promoting functional recovery is achievable through injecting the macrophages 
incubated with sciatic never fragments [174]. Subsequently, a similar approach was tested 
in clinical trials in human patient, as a therapeutic approach [175]. The Schwartz group’s 
further experiments showed that injecting skin derived macrophages into spinal cord 
lesions also promoted functional recovery [172]. Although the mechanism involved in the 
promotion of recovery by these cells in the CNS are not fully known, it is believed that 
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these cells influence the CNS repair by MMP secretions which can degrade the scar tissue 
and lead to axonal growth [170]. The optimal injection time of the cells was found to be 1 
week post-injury. Similar to the skeletal muscle, the results strongly support the beneficial 
role of initial M1 macrophages in CNS remodeling [176]. While it is traditionally believed 
that tissue damage and lesion propagation are a result of recruitment of macrophages and 
monocytes, these results support the hypothesis that controlled recruitment of appropriate 
phenotypes of monocytes and macrophages encourage functional recovery in the neural 
tissue inflammation and remodeling.  
3.8 Macrophage Modulatory Biomaterials 
As discussed in the previous section, there is significant evidence that during 
healing process macrophages play a critical role and there is a strong association between 
immune responses, inflammation and macrophage activation [108,117,128]. Biomaterial 
experts have focused on the development of materials with ‘‘immunomodulating’’ 
capabilities, taking advantage of the growing knowledge on the wound healing processes. 
Brown et al. has demonstrated that the host macrophage response is not only an acceptable 
but in fact an essential element of a constructive tissue regeneration process for biologically 
derived implant scaffolds [177]. Therefore, it is preferable to focus on strategies which 
include, modulate and even promote the immune response rather than inhibit or suppress 
it. 
In general, the main task of an initial M1 type response is to destroy potential 
pathogens within the wound site and to clean up the wound site from damaged tissue and 
dead cells. On the other hand, M2 type response is associated with tissue remodeling, which 
results in either scarring or healing as an outcome, depending on the timing of the 
phenotype switch [108,170]. In fact, prolonged M1 polarization or overly exuberant 
transition to an M2 phenotype may lead to excessive scarring or a delay in wound-healing, 
respectively [128,178]. Therefore, it is important to note that an effective and timely switch 
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in macrophage polarization is almost always a key component of a positive outcome. 
However, to date, studies investigating the specific effects of macrophage polarization after 
synthetic or naturally derived biomaterials implantation have been few.  
The first simple and rational approach to modulate macrophage phenotypes is to 
control physical cues of biomaterials. Recent studies have shown that porous biomaterials 
elicit less encapsulation and more vascularity compared to non-porous forms [179–181]. 
To determine the importance of porosity for healing, a series of scaffolds were fabricated 
in which pores were spherical, uniformly sized, and interconnected. The result has 
suggested that those materials possessing pores of 30–40 µm healed with very little fibrosis 
and great degree of vascularity [180]. The reason behind the observed pore size effect is 
unknown. However, it is hypothesized that by inhibition of spreading (phagocytic) 
phenotype, large numbers of MØ macrophages in the 30–40 µm pores are being ultimately 
directed to the regenerative M2 pathway rather than the tissue-destructive M1 and foreign-
body giant cell (FBGC) pathway. Although these pores were observed to be heavily 
infiltrated by macrophages, the ratios of M2/M1 macrophages were significantly higher in 
comparison to non-porous solid forms, other uniformly sized pores, and non-uniformly 
sized pores [180,182].  
Modification of surface typography is an alternate strategy for physical modulation 
of macrophages [183–185]. Proliferation, adhesion and migration of cells occur in response 
to ECM components at the nanoscale. However, Paul et al. showed that micro- structured, 
rather than nanostructured topography on polyvinylidene fluoride induced human 
macrophages to an activated state that had the characteristics of both M1 and M2 
macrophages [185]. Parallel gratings imprinted on polymeric surfaces with line width 
ranging from 250 nm to 2 mm were shown to affect macrophage morphology, cytokine 
secretion, and adhesion independent of the biomaterial surface chemistry [184]. Not only 
size scale of topographical structure, but also its 3D spatial orientation modulates the 
macrophage phenotype [186]. In fact, according to a recent study, spatial orientation (2D 
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vs. 3D) has a much pronounced effect than alteration of surface chemistry on monocyte 
adhesion and migration as well as on macrophage phenotype and inflammatory mediator 
profile [186].In addition, independent studies have recently showed that biomaterial 
surface roughness and stiffness can modulate phenotype of macrophages [187,188].  
Together, above studies suggest that modulating macrophage phenotype to M1 or 
M2 with tuning biomaterial physical and morphological properties is possible. However, 
besides physical features, there exists a variety of advanced methods for decorating 
biomaterial surfaces with specific small molecules or biomolecules with known 
immunomodulatory effect as well as methods for delivering immunomodulatory cytokines. 
Although the majority of current methods of modulating immune response which includes 
incorporating bioactive molecules such as adhesion sites, growth factors, and anti-
inflammatory mediators or drugs, focus on controlling the number of inflammatory cells 
at the site of implant (for complete review, refer to [189]), very few studies have 
investigated the delivery of molecules specifically designed to modulate macrophage 
phenotype as part of a tissue engineering and regenerative medicine strategy [190–192] . 
One study demonstrated that local administration of IL-4 can mitigate polyethylene 
particle-induced osetolysis through macrophage modulation by reducing the ratio of 
M1/M2 macrophages [191]. The generation of wear debris is an inevitable result of normal 
usage of joint replacements which incites chronic macrophage-mediated inflammatory 
reaction, and therefore leads to implant failure. Moreover, patients requiring revision 
following total joint replacement had a higher proportion of M1 macrophages than M2 as 
compared to normal, non-operated osteoarthritic synovial tissues [193]. This is consistent 
with the hypothesis that particles produced from wear of prosthetic joints activates 
macrophages and lead to their M1 polarization [193]. These studies strongly suggest that 
strategies which modulate macrophage polarization toward a more balanced M1/M2 or 
predominantly M2 phenotype following the implantation can potentially prevent the 
implant failure [192]. 
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Although immunomodulatory cytokines such as IL-4 are very specific and 
effective, the clinical challenges presented by protein-based therapies make the use of small 
molecule alternatives attractive. In a recent study, the role of sphingosine-1-phosphate 
(S1P), a bioactive signaling lipid, in harnessing endogenous repair mechanisms via 
macrophages to promote neo- vascularization and tissue regeneration in cranial and long 
bone critical size defect model was evaluated [190]. S1P signaling is involved in 
determination of macrophage phenotype and exogenous delivery of S1P promotes 
macrophages to adopt an M2-like phenotype [194]. In vivo delivery of FTY720, a stable 
analog of S1P, to locally injured tissues in a mandibular bone defect model demonstrated 
an increase in recruitment of M2 macrophages (Ly6ClowCD206+) and an enhancement in 
blood vessel formation which led to a significant bone tissue ingrowth. It is suggested that 
local delivery of FTY720 from polymer nanofibers scaffolds influenced the phenotype of 
macrophages at the site of injury by affecting their recruitment, differentiation and/ or 
proliferation [190]. Local delivery of S1P synthetic analog has also been shown to help 
with the recruitment of regenerative anti-inflammatory monocytes and subsequently with 
the enhancement in vascular remodeling [195]. 
Besides local modulation using immunomodulatory molecules, macrophages can 
also be modulated by systemic injection of nanoparticles that target circulating or tissue 
resident macrophages [196]. For example, lipid-based nanoparticles hold great promise as 
delivery vectors in the treatment of cancer, inflammation, and infections and numerous 
strategies based on these nanoparticles are being developed to carry drugs into specific 
target sites [196]. Because liposomes are often first taken up by phagocytic cells, they can 
simply be designed to target these cells. An elegant example for liposomes, which induce 
an anti-inflammatory effect, is demonstrated by the phosphatidylserine (PS)-presenting 
liposomes [120]. This strategy employed intravenous injections of PS-presenting 
liposomes, mimicking the anti-inflammatory effects of apoptotic cells to modulate the 
macrophages phenotype at infarct site. In a rat model of acute MI, targeting of PS-
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presenting liposomes to infarct macrophages, demonstrated improved infract repair [120]. 
The treatment promoted angiogenesis, preservation of small scars and prevented 
ventricular dilatation and remodeling. Following PS-liposome uptake by macrophages in 
vitro and in vivo, the cells secreted high levels of anti-inflammatory cytokines (e.g., TGFβ 
and IL-10) and up-regulated expression of mannose-CD206, concomitant with down-
regulation of pro-inflammatory markers such as TNFα and the co-stimulatory molecule 
CD86 [120]. This PS- presenting liposomes as apoptotic-mimicking particles would act to 
resolve the inflammation after MI while providing a safe acellular, reproducible, and 
accessible approach. 
Biomaterials can also become immunomodulatory when certain cell types are 
incorporated within the material. For example, encapsulation of stem cells in the 
biomaterial can modulate the inflammatory response in a paracrine fashion [197]. MSCs 
mediate their immunosuppressive effects via a variety of mechanisms. One such 
mechanism involves the induction of macrophages with immunomodulatory capacities. 
Macrophages co-cultured with mesenchymal stem cells (MSCs) consistently showed high 
levels of IL-10 (M2 indicators) and low levels of IL-12 (M1 indicator) compared to 
controls [197].Intravenous administration of MSCs after MI in mice suppresses the 
inflammatory response in the myocardium, leading to reduced infarct size, and improved 
systolic function [198]. Encapsulated hMSCs in alginate hydrogel modulates inflammatory 
macrophages both in vitro and in vivo, even in the absence of direct hMSC-macrophage 
cell contact, to an alternative M2 macrophage phenotype [199]. In a rodent spinal cord 
injury model, it is demonstrated that even very few hMSCs encapsulated in alginate 
hydrogel can significantly increase the anti-inflammatory and decrease the pro-
inflammatory macrophages and cytokines [200]. These results suggest that conversion of 
macrophages to the M2 subset as a result of hMSCs effect is responsible, at least in part, 
for tissue protection and illustrate the potential that encapsulated hMSC has as a powerful 
in vivo immunomodulatory tool after trauma. 
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Collectively, these studies suggest that approaches which incorporate, modulate, 
and even encourage the host response rather than inhibit it can be very effective. Future 
strategies may achieve better regeneration outcome through addition of bioactive surface 
ligands, incorporation of soluble factors, formation of rational physical cues, and/or 
modulation of the tissue regeneration environment. 
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CHAPTER 4  EVALUATE THE EFFECT OF MODULATING 
MACROPHAGE PHENOTYPE ON PERIPHERAL NERVE 
REPAIR 
4.1 Introduction3 
The advent of the operating microscope and improved microsurgical techniques 
have improved clinical results and popularized nerve autograft surgeries after injury [81]. 
After nerve trauma, the standard clinical operating procedure is to appose the two nerve 
ends and suture them together without generating tension where possible. If the gap is large 
such that tensionless apposition is not possible, a nerve autograft - typically the patient’s 
own sural nerve - is used as a bridge. Autografts are biocompatible, non-toxic, provide a 
support structure to promote axonal adhesion/extension, and currently are the best clinical 
bridges available. However, besides possibility of neuroma formation and a need for 
secondary surgery, a serious drawbacks to the use of autografts are that the availability of 
disposable nerve segments is limited, and multiple lengths of nerve graft are often needed 
to bridge the gap between the injured nerve stumps [4]. Moreover, only 40-50% of patients 
regain useful function after receiving autografts [79]. In addition, autografts contain 
inhibitory chondroitin sulfate proteoglycans (CSPGs), which may reduce their 
performance as bridges [39,40]. Therefore there is a clear and urgent, unmet clinical need 
to find an alternative approach to the use of autografts that can match or exceed autograft 
performance [3,4,201].  
                                                 
 
 
3 Mokarram, N., A. Merchant, V. Mukhatyar, G. Patel, and Bellamkonda, R. V. Effect of modulating 
macrophage phenotype on peripheral nerve repair. Biomaterials 33:8793–8801, 2012. 
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Driven by this need, several bioengineering strategies to enhance regeneration have 
been explored including the design of novel nerve guidance channels [4,77], fillers within 
nerve guidance channels [202], local delivery of neurotrophic factors [82,83], 
transplantation of cells [84,85], and application of topographical cues [76,87,203]. While 
these approaches are promising, the overall success rate in matching autograft performance 
in bridging long nerve gaps has been limited. Fundamentally, it is challenging to replicate 
individual aspects of a complex biochemical regenerative cascade although the search for 
the minimum critical elements continues and current approaches focus on enhancing axon 
growth by direct action on nerves, or glial cells. 
In this chapter, we investigate an alternative approach to influencing regenerative 
outcomes by modulating the initial inflammatory sequence via macrophages [108]. Since 
the sequence of cellular and molecular events associated with nerve regeneration is 
influenced by immune cells [95,102], we hypothesize that modulating immune cells 
upstream of action on nerves or Schwann cells (SC) triggers endogenous repair 
mechanisms that can stimulate nerve repair across long gaps [108].  
It is evident that the immune response plays an important role during regeneration 
in many tissues [13,97,204]. Macrophages are quite abundant and phenotypically diverse 
immune cell populations presented during nerve degeneration and regeneration 
[95,108,129]. Macrophages arrive at the site of injury within 24 h and their numbers at the 
site peak within 14-21 days [205], whereas it takes at least one week for lymphocyte influx 
to occur [95]. Macrophages, which are mainly recruited from circulation, account for the 
bulk of phagocytosis within days of peripheral nerve injury and play a critical role in debris 
removal, growth factor production, and remodeling of the extracellular matrix (ECM) of 
the distal nerve [158,159]. Thus macrophages might represent an upstream ‘lever’ to 
influence downstream axon and SC regeneration.  
Recently, macrophages have been demonstrated to have a spectrum of activation 
states/phenotypes which has led to categorizing them broadly as classically activated (M1) 
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and alternatively activated (M2) macrophages [32,33,61]. M1 macrophages, which are 
activated by injury-triggered endogenous inflammatory signals, such as T-helper 1 (Th1) 
cytokine IFNγ, considered to be inflammatory, microbicidal, and tumor destructive 
[32,61]. M1 macrophages produce high levels of oxidative metabolites (e.g. nitric oxide 
and superoxide) as well as pro-inflammatory cytokines. On the other hand, M2 
macrophages, which can be activated by Th2 cytokines such as IL-4, IL-10 and IL-13, 
support tissue repair by producing anti-inflammatory cytokines which mediate 
angiogenesis, cell replacement and matrix remodeling while suppressing destructive 
immunity [32,206]. The M2 phenotype has also been shown to have its own subtypes (M2a, 
M2b and M2c) [93,115]. While the exact role of each M2 subtype is not well defined, it 
has been shown that M2a and M2c enhance tissue repair and pro-healing functionality, but 
the M2b subtype possesses regulatory function with some characteristics of both anti-
inflammatory and pro-inflammatory macrophages [93,115]. 
Despite the fact that macrophages constitute a substantial fraction of the post-injury 
cellular milieu, very little attention has been devoted to understanding the contribution 
from different phenotypes of macrophages and the effect of their modulation on 
regeneration after injury, especially in the context of the peripheral nervous system (PNS) 
[95,128]. Here, we designed a biomaterial-based conduit to modulate the phenotype of 
macrophages by employing two principal cytokines (IFNγ or IL-4) for polarizing the early 
innate immune response toward pro-inflammatory (M1) or pro- healing (M2a and M2c) 
phenotypes, respectively. Then, we investigated the influence of macrophage phenotype 
on the peripheral nerve regeneration in a critically-sized, non-healing 15 mm rat sciatic 
nerve gap (Figure 4.1).  
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4.2 Materials and Methods 
4.2.1 Scaffold Implantation 
Polysulfone tubes filled with 0.7% Agarose (SeaPrep Lonza) mixed with 1 mg/ml 
rat recombinant cytokine IFNγ, IL-4 (Antigenix America Inc.) or Agarose only were 
prepared (n=4 per group). The scaffolds were kept cooled in 4°C for 1 h. Adult Lewis male 
rats (250−300 g) were induced to anesthetic depth with inhaled isoflurane at 3−4%. The 
procedure for fabrication of PAN-MA nano-fiber film scaffolds (n=4) were explained 
elsewhere [76]. 15 mm nerve autografts, which were resected from the rat tibial nerve being 
bridged were used as our positive control (n=4). Throughout surgery, the animals were 
maintained at 1.5−2% isoflurane. Microscissors were used to transect the tibial nerve 
branch, and the nerve stumps were pulled 1 mm into each end of the 17 mm (Agarose with 
cytokine) guidance scaffolds (leaving a 15 mm gap) or autografts and fixed into place with 
a single 10−0 nylon suture (Ethicon). The muscles were reapposed with 4−0 vicryl sutures 
(Ethicon) and the skin incision was clamped shut with wound clips (Braintree Scientific). 
After the surgery, the rats were placed under a warm light until sternal, and then housed 
separately with access to food and water ad libitum at constant temperature (19−22°C) and 
humidity (40−50%) on a 12:12 h light/dark cycle. To prevent toe chewing, a bitter solution 
(Grannick’s Bitter Apple) was applied twice daily to the affected foot. Marcaine (0.25% 
w/v) was administered subcutaneously for post-surgical pain relief (0.3 ml/animal). 
Animals were maintained in facilities approved by the Institutional Animal Care and Use 
Committee (IACUC) at the Georgia Institute of Technology and in accordance with the 
current United States Department of Agriculture, Department of Health and Human 
Services, and National Institutes of Health regulations and standards. 
4.2.2 Scaffold Explantation and Analysis 
After three weeks, scaffolds or autografts were explanted for histological analysis 
of nerve regeneration. Explants were fixed in 4% paraformaldehyde in PBS (Sigma 
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Aldrich), washed, and stored in 30% sucrose in PBS for 24 h. Samples were embedded in 
O.C.T. gel (Tissue Tek) and frozen for cryosectioning (CM30505, Leica). Scaffold or 
autografts were sectioned transversely or longitudinally at a thickness of 16 mm and 
reacted with immunofluorescent markers to quantify the different cell types, using 
techniques previously described [76]. Briefly, sections were incubated for 1 h at room 
temperature in a blocking solution of goat serum (Gibco) in PBS, incubated overnight at 
4°C in a mixture of primary antibody and blocking solution, washed and incubated for 1 h 
at room temperature in a solution of secondary antibody mixed in 0.5% triton in PBS. 
Slides were washed twice more with PBS, incubated with DAPI for 10 min and then dried 
and cover slipped for evaluation. Primary antibodies NF160 (1:250, mouse IgG1, Sigma), 
S100 (1:250, rabbit, IgG, Dako Cytomation), CD68 (1:100, mouse IgG1, AbD Serotec 
(ED1)), CD163 (1:200, mouse IgG1, AbD Serotec (ED2)), CCR7 (1:200, rabbit, IgG, Cell 
Application), and CD206 (1:100, rabbit, IgG, Santa Cruz Biotechnology) were used. The 
following secondary antibodies were used: goat anti-rabbit IgG Alexa 488/594 (1:220, 
Invitrogen), goat anti-mouse IgG1 Alexa 488/594 (1:220, Invitrogen). 
4.2.3 Statistical Analysis 
Data were analyzed using the Student’s t-test for unpaired data where appropriate 
or one-way ANOVA followed by a Tukey’s least significant difference post-hoc test where 
warranted to determine significant differences between groups with 95% confidence; A p 
value < 0.05 was considered to represent a statistically significant difference. 
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Figure 4.1: Schematic of rat sciatic nerve model and the nerve guidance channel 
structure. 
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4.3 Results 
4.3.1 Effect of Immunomodulatory Cytokines, IFN-γ or IL-4, on the macrophages 
within the nerve scaffold, in vivo 
The influence of delivering either IFNγ or IL-4 on the phenoltypes of macrophages 
and the subsequent impact on the rate of peripheral nerve regeneration in rodents was 
assessed in vivo. IFNγ or IL-4 (1000 ng/mL) mixed with an Agarose hydrogel was injected 
inside a 17 mm, semi-permeable, hollow Polysulfone tube that was in turn used to bridge 
a 15 mm sciatic nerve gap in rats (Figure 4.1). Based on the in vitro study, these cytokines 
diffuse out from the hydrogel within 24 h (Figure 7.2). 
After three weeks, animals were euthanized, followed by immunohistochemical 
staining with CD68, CD163, CCR7 and CD206 to identify total number of activated 
macrophages, alternatively activated macrophages (M2), pro-inflammatory macro- phages 
(M1) and anti-inflammatory/pro-healing macrophages (M2a and M2c), respectively. 
Previously established immunohistochemistry techniques for quantifying fluorescent pixel 
intensity of aforementioned antibodies were used to quantify macrophages and their 
subtype [76,92,177,207]. The majority of macrophages remained on the outer layer of the 
regenerative cable (nerve bundle) and their density decreased approaching the center of the 
cable (Figure 4.2a). Although both IFNγ and IL-4 increased the total number of 
macrophages in comparison to non-cytokine treated scaffold (Figure 4.2b), this increase 
was not significantly different between IFNγ and IL-4 samples. However, the numbers of 
M1 (CCR7+) and M2 (CD163+) macrophages as well as M2 subtypes, M2a and M2c 
(CD206+) macrophages, were significantly different between IFNγ and IL-4 treated 
scaffolds (Figure 4.2Figure 4.3). The ratios of CCR7+ cells to CD68+ cells were 
significantly lower in both IFNγ and IL-4 containing scaffold (n= 4, P < 0.001, Student’s 
t-test) (Figure 4.3b). However, the ratios of CD163+ and CD206+ cells to CD68+ cells 
indicating different subtype of M2 macrophages were higher in IL-4 containing scaffold in 
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comparison to control (n=4, P<0.01 and P<0.001, Student’s t-test) while in IFNγ containing 
scaffolds, these numbers were significantly different from the control scaffold (Figure 4.2c 
andFigure 4.3c). 
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Figure 4.2: Effect of IFNγ and IL-4 on the macrophages and their phenotypes at the site 
of sciatic nerve injury in the scaffold.  
(a) Cross-sectional images of CD68+ cells and CD163+ cells representing number of 
macrophages and alternatively activated macrophages (M2) at the distal end, 
respectively. Blue represents the DAPI. Scale bar = 500 μm (b) Quantitative analysis of 
number of macrophages. Mean ± s.d. n = 4. **P < 0.01 (Student’s t-test). (c) Ratio of the 
CD163+ cells to the CD68+ cells represents the ratio of alternatively activated 
macrophages (M2). Asterisks denote a significant difference compared with non-
cytokine treated control scaffolds. Both IL-4 and IFN-γ increases the number of 
macrophages at the distal end of the scaffold. 
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Figure 4.3: Effect of IFNγ and IL-4 on the macrophages and their phenotypes at the site 
of sciatic nerve injury in the scaffold.   
(a) Magnified merged images of CCR7/CCD68 (green/red) and CD206/CD68 
(green/red). Scale bar = 40 μm . (b) Ratio of the CCR7+ cells to the CD68+ cells 
represents the ratio of classically activated macrophages (M1). Mean ± s.d. n = 4. ***P 
< 0.001 (Student’s t-test). (c) Ratio of the CD206+ cells to the CD68+ cells represents 
the ratio of pro-healing macrophages (M2a and M2c). Mean ± s.d. n = 4. ***P < 0.001 
(Student’s t-test).  
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4.3.2 Effect of Immunomodulatory Cytokines, IFN-γ or IL-4, on the SC infiltration 
and axonal growth, in vivo 
SC infiltration into the nerve gap was investigated by using immunostaining for SC 
protein marker (S100) (Figure 4.4). IL-4 treatment considerably enhanced the SC migration 
toward the middle of the hydrogel as shown in the longitudinally sectioned samples 
(Figure 4.4a). On the other hand, both IFNγ and non-cytokine treatment resulted in less SC 
infiltration and thinner regenerative cable (Figure 4.4a, b). Even in the case of the non-
cytokine treated control, where the cable formation was usually complete, SC rarely 
reached the midpoint (Figure 4.4b). A similar trend was found, based on quantitative 
analysis of fluorescent pixel intensity of immunoreactivity for S100 in the area occupied 
by SCs at the distal end of the scaffold (Figure 4.4c).  
Axons were also visualized by using immunostaining for Neurofilament-160 
(NF160) ( 
Figure 4.5). In contrast to the SC which infiltrate from the both ends of the scaffold, 
axons grow only from the proximal toward the distal end ( 
Figure 4.5a). In the case of IL-4 treated samples, axons reached almost the distal 
end after 3 weeks ( 
Figure 4.5b). Quantitative analysis using cross-sectional samples at the distal end 
of the scaffold showed that number of axons (positively stained for NF160) in the IL-4 
samples were ~20 times higher in comparison to the non-cytokine treated control (n= 4, P 
< 0.001, Student’s t-test) ( 
Figure 4.5c). The number of regenerated axons at the distal end of the scaffold was 
not significantly different from the control in IFNγ treated scaffold. Sections for all of these 
analyses were selected at exact same location on the scaffold and based on the observation 
of biggest difference.  
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Figure 4.4: Effect of IFNγ and IL-4 release on Schwann cell infiltration inside the 
scaffold.  
(a) Longitudinal section of S100 staining for Schwann cell. Scale bar = 1 mm (b) Merged 
magnified images with DAPI at the mid-section. Scale bar = 250 μm (c) Quantitative 
analysis of SCs at the distal end by using S100. Mean ± s.d. n = 3. *P < 0.05 (Student’s 
t-test). Asterisks denote a significant difference compared with non-cytokine treated 
control scaffold. IL-4 treated scaffold significantly enhances the SC infiltration inside 
the scaffold in comparison to the non-treated control scaffold. 
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Figure 4.5: Effect of IFNγ and IL-4 release on the axonal growth. 
(a) Longitudinal section of NF160 staining for axons. Scale bar = 1 mm (b) Merged 
magnified images with DAPI magnified images referring to white boxes in panel (a). 
Scale bar = 250 μm (c) Quantitative analysis of NF160 at the distal ends. Mean ± s.d. n 
= 4. ***P < 0.001 (Student’s t-test). Asterisks denote a significant difference compared 
with non-cytokine treated control scaffold. Number of axons at the distal end of the IL-
4 treated scaffold is ~20 times higher in comparison to the non-treated control scaffold.  
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4.3.3 Correlation between the Ratio of CD206+ to CCR+ Macrophages and Number 
of Regenerated Axons, in vivo 
CD206+ and CCR7+ cells represent the populations of macrophages that have pro-
healing (M2a and M2c) and pro-inflammatory (M1) functions, respectively [115,207]. We 
define the ratio of pro-healing to pro-inflammatory population of macrophages 
(CD206+/CCR7+) as the regenerative bias. In the IL-4 containing scaffolds, the 
regenerative bias is approximately twenty times higher than in either the non-cytokine 
treated control or IFNγ containing scaffolds (Figure 4.6). We calculated the regenerative 
bias as well as number of axons at the distal ends for two completely separate conditions 
too: Autograft and Polysulfone scaffold filled with a layer of Poly(acrylonitrile-co-methyl 
acrylate) (PAN-MA) nano-fiber film [76,86] (Figure 4.6). Combined with this new set of 
data, we derived a relationship between the regenerative bias and axonal growth 
(Figure 4.6): 
 
A= 833.7 ˟ RB + 2.088 
R2 = 0.935 
 
where A and RB represent the number of axons and the regenerative bias (the ratio 
of CD206+ to CCR7+ cells) at the distal, respectively. Figure 4.6 shows that there is a 
direct correlation between ratio of pro-healing to pro-inflammatory macrophages and 
number of axons at the distal end of the nerve scaffold in this model. Nevertheless, samples 
with regenerative bias higher than 1.5, especially autografts, start to deviate from this linear 
relationship. 
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Figure 4.6: Regenerative bias correlates with axonal growth.  
At the distal end of nerve stump, the ratio of pro-healing macrophages (CD206+) to pro-
inflammatory macrophages (CCR7+), i.e. regenerative bias, directly correlates to 
(predicts) the final regenerative outcome (axonal growth) with a linear relationship at 
three weeks post-injury time point. The fact that data from autograft and PAN-MA nano-
fiber scaffolds also fit the regenerative bias/axonal growth correlation demonstrates that 
this model can be universally applied across other nerve regeneration approaches.  
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4.4 Discussion 
Injury to the peripheral nervous system (PNS) induces a well-orchestrated cellular 
process that leads to the complete disintegration of the nerve segment distal to the lesion 
site, termed Wallerian degeneration (WD) [208]. WD in the distal nerve segment starts 
within the first 24 h after axotomy, followed by fibrin cable formation, and Schwann cell 
(SC) and fibroblast infiltration from the both proximal and distal nerve stumps [156] 
(Figure 4.7). The SCs migrating from the proximal nerve stump advance along with 
regenerating axons, which grow through the enriched matrix and span the nerve gap. These 
regenerating axons reach the distal nerve stump and eventually make connections to the 
end organ[3]. Almost immediately after peripheral nerve injury, SCs dissociate from axons, 
dedifferentiate, and, along with fibroblasts, secrete cytokines that promote infiltration of 
immune cells. Neutrophils, the first immune cells to infiltrate, accumulate in the distal 
stump within 8 h, but their presence is short-lived [157]. Around the same period of time, 
circulating monocytes are attracted to the injured nerve where they differentiate into 
macrophages, and within days they take over as the dominant leukocyte population and 
play a critical role in ensuring complete WD. They account for the bulk of phagocytosis 
and debris removal, growth factor production, and remodeling of the ECM of the distal 
nerve [158,159].  
WD and subsequent regeneration are significantly influenced by various immune 
cells and the cytokines they secrete. Among all immune cells, macrophages are quite 
abundant during nerve degeneration and regeneration [95,108,129]. Although 
macrophages have long been known to play a vital role in the degenerative process, recent 
work has pointed to their importance in influencing the regenerative capacity of peripheral 
neurons (Figure 4.7) [95,100,101]. Macrophages, in contrast to lymphocytes which 
regulate the later phases of regeneration, modulate the early sequence of cellular events 
which can determine the fate of healing process. They are playing at least two important 
roles during that process: creating a pathway in the distal nerve segment conducive to 
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axonal regeneration and stimulating the axotomized neuronal cell bodies to switch to a 
regenerative phenotype [101]. Macrophages recruited from circulation account for the bulk 
of phagocytosis and play a critical role in debris removal, growth factor production, and 
remodeling of the ECM of the distal nerve [158,159]. However, an increasing number of 
studies in multiple animal models and organ systems have shown that untimely 
macrophage polarization, inhibition of macrophage polarization, or inability to resolve a 
chronic polarization towards the M1 or M2 extreme has a detrimental effect on 
regeneration outcome (Figure 4.7) [105,128,129,131]. That is, macrophages can play both 
beneficial and detrimental roles in the process of tissue remodeling and, in many cases, an 
efficient and timely phenotypic switch is essential for preventing a deleterious or scar tissue 
outcome. Thus, macrophages represent an upstream ‘lever’ to influence downstream axon 
and SC fates and peripheral nerve regeneration. Figure 4.7 represents our new insight 
regarding Wallerian degeneration and role of M1 and M2 macrophages during the 
regeneration process.  
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Figure 4.7: New Insight to Wallerian Degeneration and Axonal Regeneration after 
Injury. A) Uninjured nerve is associated with Schwann cells and resident (inactivated) 
macrophages. B) Immediately after injury, denervated myelinating Schwann cells 
release their myelin. These non-myelinating Schwann cells then proliferate and 
produce cytokines/trophic factors which along with other soluble factors produced 
from injured axons activate resident macrophages and lead to recruitment of 
hematogenous macrophages. The activated macrophages clear myelin and axon debris 
efficiently, change phenotype and produce factors that facilitate Schwann cell 
migration and alignment, and axon regeneration. C) At the later time points, injured 
axons form a growth cone and begin to regenerate along aligned Schwann cells. D). 
Successful regeneration would occur by axonal reinnervation to the peripheral target.  
Moreover, although there is strong evidence to support the notion that macrophages 
modulate regeneration in the nervous system [95,108,129], it is unclear if they support 
[74,169,204] or hinder [209,210] regenerative biochemical cascades after injury [211]. 
This apparent lack of clarity might stem from the ‘double-edged’ characteristics of 
macrophages [108,212–214]. On one hand macrophages, as the primary phagocytes of the 
innate immune system, release inflammatory neurotoxin and cytokines leading to 
degeneration and necrosis. On the other hand, macrophages scavenge debris, stimulate 
trophic factors such as nerve growth factor (NGF) and IL-6 [206,215], and help remodeling 
the ECM [92]. These seemingly opposing effects may be explained by the existence of 
macrophages that are phenotypically and functionally heterogeneous. 
It is not known if phenotype-committed macrophages are selectively recruited to 
the site of injury, or if the phenotype of non-committed macrophages is determined after 
recruitment by locally-present cytokines [67]. Regardless, macrophage phenotypes can be 
dynamically regulated by biological cues from the tissue microenvironment [62]. During 
the course of wound healing in some tissues, such as cutaneous or myocardial tissue, there 
is a well-defined shift in macrophage activation states: from M1 to M2 and subsequent 
secreted products [94,114]. However, in other tissues such as the spinal cord, this shift does 
not occur after injury [129] and hence, it is postulated that this results in impaired recovery 
of those tissues. Although macrophage phenotypes and their roles in the course of 
regeneration after traumatically injured central nervous system (CNS) have been explored 
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[93,129], the effect of macrophage phenotype on PNS regeneration and its associated cells 
(such as SC and axons) remains to be characterized [95,128]. 
To address this gap in our understanding, the effects of modulating macrophage 
phenotype on nerve regeneration were evaluated in a rat sciatic nerve model using 
Polysulfone/Agarose hydrogel scaffolds mixed with two immunomodulatory cytokines, 
IL-4 or IFNγ. Although Agarose hydrogels have previously been demonstrated to support 
regeneration of peripheral nerves [77,216], our study revealed that short-term release of 
anti-inflammatory cytokine (IL-4) in the Polysulfone/Agarose nerve guidance scaffold 
substantially accelerates downstream axon regeneration. 
Our results strongly suggest that rather than the extent of macrophage presence, 
their specific phenotype at the site of injury biases the regenerative outcomes. It can be 
postulated that these results stem from the indirect effect of immunomodulatory cytokines, 
IL-4 or IFNγ, on SC and axons via modulation of macrophages phenotype since neither of 
these two cytokines have any significant direct effect on axonal growth [217] [47] and SC 
migration (see CHAPTER 5 ). We established that modulating the initial inflammatory 
sequence via macrophages can bias the regenerative biochemical cascade in a significant 
manner that obviates the need for the downstream modulation of multiple factors after 
peripheral nerve injury. 
In fact, we defined a new term, regenerative bias, based on the ratio of 
CD206+/CCR7+ ((M2a + M2c)/M1) macrophages and found a direct correlation between 
this number and the rate of SC infiltration and axonal growth in vivo (Figure 4.4 
andFigure 4.6). Our data showed that the number of CD163+ cells (M2 macrophages) and 
CD206+ cells (M2a and M2c macrophages) were both increased by IL-4 treatment; 
however this increase was more drastic in the number of CD206+ cells in comparison to 
CD163+ cells; for this reason, we chose CD206+/CCR7+ ratio to represent inflammatory 
status of the scaffold as the regenerative bias instead of other potential options such as 
CD163+/CCR7+ (M2/M1) or CD206+/CD68+ (M2/M) ratios. Moreover, IL-4 polarizes 
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macrophages toward the M2a subtype, directly, and toward the M2c subtype via M2a 
secretory products such as IL-10 or TGFβ, indirectly [33,93]. CD163 is a common surface 
marker among all the subtype of M2 macrophages while CD206 is the surface marker only 
for M2a and M2c macrophages [93]. Therefore, compared to other potential 
aforementioned options, the ratio of the CD206+/CCR7+ cells better indicates the 
effectiveness of the immunomodulatory cytokine delivery at the site of nerve injury. Both 
CD206 and CCR7 are widely used to characterize the phenotype of macrophages in animal 
and human models [92,115,128,177,218]. CCR7 is also known to be expressed by certain 
subtypes of dendritic and T-cells; however, the level of this expression is much smaller as 
compared to macrophages [92,128,177]. 
It has already been shown that axons can also be directly affected by secretory 
products of different phenotypes of macrophages in the CNS [129,171]. Although CM 
from the unstimulated macrophages has a minimal effect on axonal growth, M1 
macrophages are neurotoxic [129,171]. In contrast, M2 macrophages not only have no 
adverse effect on cortical neurons, but also promote the regenerative response [129]. 
Additionally, Kigerl et al. demonstrated that M2 macrophages can even overcome axonal 
growth inhibition caused by CSPG and myelin [129]. Indirect modulation of macrophages 
toward the M2 phenotype by using fibroblast growth factor (aFGF) can also result in the 
secretion of growth factors that can potentially help axonal regeneration after spinal cord 
injury in rats [219]. It has also been shown that certain cytokines that promote M2 
macrophage formation, such as IL-10, moderately enhance neuroprotection [220]. The 
Schwartz laboratory has demonstrated that appropriate activation of microglia by IL-4 or 
IFNγ differentially induces neurogenesis as well as oligodendrogenesis from adult stem 
cells [21]. However, to the best of our knowledge, exploiting macrophage phenotype 
modulation to promote regeneration in the PNS has not yet been reported. 
Further, to evaluate our regenerative bias/axonal growth model in other nerve 
regeneration approaches, PAN-MA nano-fiber film scaffold and autograft were also 
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studied based on this model. Our data demonstrated that these two completely different 
approaches for regeneration also fit the regenerative bias model which suggests that this 
model, independent of the strategy or kind of regenerative scaffold, can be universally 
applied across other nerve regeneration approaches. However, the noticeable deviation 
from this linear correlation in high-regenerative-capacity conditions, such as autograft, 
clearly indicates the involvement of other critical factors in the process of rapid 
regeneration which this regenerative bias model cannot fully predict. 
Although the axonal growth in the IL-4 containing scaffold in this study (as 
determined by the number of axons at the distal end) is still lower than that for autograft, 
from our experience with alternate strategies to enhance peripheral nerve repair such as 
presenting topographical cues or delivering trophic factors, regulating macrophage 
phenotype using immunomodulatory cytokines resulted in a considerably faster rate of 
axonal regeneration in this critically-sized nerve gap [4,45]. In fact, the axonal growth rate, 
as defined by the length of axons in the nerve gap as a function of time, is faster by a factor 
of 2 compared to the best rate achieved in previous studies [4,32] ( Figure 4.6). This data 
is significant because several studies have already clearly demonstrated that faster axonal 
growth substantially contributes to higher functional recovery [38,77,221,222]. 
This approach, by minimizing the need for sophisticated delivery vehicle(s), 
demonstrates that short and early stimulation of macrophages can significantly influence 
the longer-term regenerative outcomes. The effectiveness of this approach possibly 
originates from the fact that besides the direct effects of different macrophage phenotypes 
on SC infiltration and axonal growth, macrophages play a key role in other aspects of the 
regenerative process. They actively participate in cell replacement via stem cell recruitment 
and homing as well as in the resident progenitor cell differentiation and proliferation 
[74,147]. Their secretory products also influence the different phases of angiogenesis both 
in vivo and in vitro [96,223]. 
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Finally, in this study only three surface markers (CD68, CCR7, and CD206) were 
employed to characterize macrophages and their phenotypes participating in nerve 
regeneration. It is becoming increasingly evident that other ways of examining macrophage 
phenotype(s) including protein (cytokine and chemokine) analysis, and gene profiling can 
help to characterize a specific phenotype better and understand the extent to which each 
phenotype perform. Furthermore, as with most models, the M1/M2 classification scheme 
certainly oversimplifies the complexity of the PNS macrophage response. In fact, the 
present study identified macrophages that co-expressed markers for both or none of the M1 
and M2 macrophage. Although the effects of these intermediate macrophages are unknown 
in the context of PNS regeneration, this model provides a useful conceptual framework. 
Future studies should examine additional macrophage activation markers and cytokine 
expression to more extensively characterize the M1/M2 profile and the role these 
macrophages play in the peripheral nerve regeneration process. Moreover, this study 
introduces the regenerative bias concept and further studies on the other types of nerve 
scaffolds need to be done to evaluate the model more comprehensively. 
4.5 Conclusion 
Our data demonstrates that modulation of macrophage phenotype at the site of 
peripheral nerve injury can favorably bias the endogenous regenerative potential after 
injury that obviates the need for the downstream modulation of multiple factors and has 
significant implications for the treatment of long peripheral nerve gaps. Moreover, the 
present study strongly suggests that more than the extent of macrophage presence, their 
specific phenotype at the site of injury influence the regenerative outcomes. These 
significant results are complementary to a growing body of evidence showing the direct 
correlation between macrophage phenotype and the regeneration outcome in other tissues. 
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CHAPTER 5  INVESTIGATE THE INTERPLAY BETWEEN 
MACROPHAGES PHENOTYPE AND GLIAL CELLS 
FUNCTION. 
5.1 Introduction 
Biomaterial-based tubular nerve conduits (or guidance channels) have been used 
clinically for repairing peripheral nerve injuries [224]. These nerve conduits bridge the 
injured nerve stumps and help form a fibrin cable which provides a substrate for the 
ingrowth of SCs and other cells, such as fibroblasts or macrophages. However, this 
approach is limited in its ability to enable regeneration across nerve gaps that are more 
clinically relevant, and has been unsuccessful in promoting regeneration across gaps longer 
than 10-15 mm in rats. 
In the PNS, the ability to regenerate in response to a nerve injury is determined by 
many factors, including the presence or absence of a permissive environment into which 
axons can elongate, the intrinsic growth capacity of the neuron itself, and the influence of 
non-neuronal cells [225]. Among all the glial cells, Schwann cells, in particular, are playing 
a pivotal role to support axonal growth. 
Schwann cells are support cells that myelinate the axons, forming a multilamellar 
sheath around axons. They also play an important role after a nerve injury. The 
permissiveness of microenvironment at the distal end of nerve is critical for timely and 
successful repair after an injury [37]. Within the distal nerve stump, SCs go through 
multiple changes that are necessary to support axonal outgrowth. After the injury, SCs 
transdifferentiateand become repair cells while losing their myelinating phenotype. Not 
only the expression of their myelin protein goes down, the expression of their growth-
promoting genes, including growth factors and their receptors, and those encoding cell 
adhesion molecules goes up [222,225]. These changes in Schwann cells after injury might 
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happen as a result of axonal signal loss, or might trigger actively as a result of an injury 
cascade [225].  
In a healthy nerve, Schwann cells sustain basal lamina tubes; after injury, these 
tubes (termed bands of Büngner) encourage and guide the growth of regenerating axons. 
However, chronic denervation detrimentally affect bands of Büngner due to SC atrophy 
which results in degeneration of and eventual disappearance of basal lamina tubes 
[225,226]. 
Following nerve injury, Schwann cells become ‘reactive’ and produce a number of 
neurotrophic factors including NGF, BDNF, NT-3, and ciliary neurotrophic factor (CNTF) 
[227]. They also synthesize and secrete extracellular matrix molecules, such as laminin, 
which is known to enhance neurite outgrowth [1]. Schwann cells also express a variety of 
other cell adhesion molecules [228]. For nerve gaps less than the critical length (<10mm) 
all of these processes occur spontaneously, leading to axonal regeneration. However, for 
nerve gaps  longer than10mm, spontaneous nerve regeneration does not occur, most likely 
due to failure of the formation of the fibrin cable and subsequent bands of Büngner [229] .  
Based on the result from chapter 4, we believe that modulating macrophage 
phenotype can affect SC function and activity, and in fact, this might be the principal reason 
for why early modulation of macrophages affect final outcome of axonal growth three 
weeks after implantation. We believe macrophages can stimulate endogenous SC 
migration into the nerve gap which can obviate the need for SC transplantation or 
application of neurotrophic factors. Here we investigated the interplay between 
macrophages phenotype and SC function both in vitro and in vivo to shed some light on 
the potential mechanism of action of macrophage modulation on peripheral nerve 
regeneration. Figure 5.1 depicts the summary of potential interactions between SC and 
axons based on the result presented in this chapter and others [129,171].  
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Figure 5.1: Schematic of effects of M1 and M2 macrophages on SC and axons 
represented by red (dark) and green (light) arrows, respectively.  
M1 and M2 macrophages can modulate proliferation and morphology of axons as well 
as proliferation and secreting products of SCs [129,171,215,230]. 
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5.2 Materials and Methods 
5.2.1 SC Proliferation Study 
Alveolar rat macrophage cells (NR8383) (2 ˟ 105) were placed in serum-free 
medium (F12K with 1% P/S; 1% L-glutamine) and incubated, allowing attachment for 4 h 
(37 °C, 5% CO2). After 4 h, IL-4 or IFNγ (Antigenix America) (50 ng/mL in 1 mL) was 
added and cells were incubated for 24 h (n=4 per group). Then LPS (100 ng/mL) was added 
to IFNγ containing medium and all cells were incubated for an additional 7 h. Then medium 
for all cells was changed to fresh serum-free medium and cells were incubated for another 
24 h (37 °C, 5% CO2). After 24 h, medium was collected and frozen at -80 °C. 2 ˟ 105 
Schwann cells (RSC96) were added to the complete medium (DMEM with 10% FBS; 1% 
P/S; 1% L-glutamine) and incubated for 24 h (37 °C, 5% CO2). After 24 h, the medium 
was removed upon process extension from RSC96 cells, and 250 µL of serum-free medium 
(DMEM with 1% P/S; 1% L-glutamine) and 250 µL of CM from macrophages treated with 
IL-4, IFNγ, or no cytokine (warmed to 37 °C before adding) was added to the cells. Serum-
free DMEM medium (250 µL) was added as the control (n=4 per group). The cells were 
incubated (37°C, 5% CO2) for 72 h. After incubation, medium was removed from top 
without disturbing cells and CCK8 assay (10% CCK8 in 500 mL serum-free DMEM 
medium; 450 nm) was performed on cells attached with a standard (31.25K-500K cells). 
For direct cytokine effect analysis, similar procedure was performed except instead of CM 
addition, 50 ng/mL of IFNγ or IL-4 or 50, 100, or 500 ng/mL of IL-19 was added directly 
to the RSC culture. 
5.2.2 SC Migration Study 
Similar protocol to proliferation study was used to activate the macrophages except 
after activating macrophages with the cytokines, initial media was changed with fresh 
serum-free media and 24-well Boyden chambers (BD Falcon FluoroBlok, 8 mm) were 
inserted into activated macrophage wells and 5 ˟ 104 Schwann cells (RSC96; expressing 
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Green Fluorescent Protein (see A.3.2 for further details)) in 200 µL serum-free medium 
(F12K with 1% P/S; 1% L-glutamine) were added to the top insert which does not have 
any coating. After 72 h incubation, the migrating cells at the bottom of the filters were 
fixed with paraformaldehyde and counted at five random fields per filter (n=4 per group) 
(see Figure 7.4). For direct cytokine effect analysis, similar procedure was performed 
except instead of macrophage culture at the bottom of Boyden Chamber, 50 ng/mL of 
IFNγ, IL-4, or 500 ng/mL of IL-19 was added directly to the bottom chamber. 
5.2.3 RNA Extraction and qRT-PCR Analysis of Macrophages  
Total RNA was extracted from cell pellets obtained from the untreated 
macrophages or macrophages treated with IFNγ + LPS or IL-4 cytokines using the RNEasy 
Mini Kit (Qiagen). Extracted total RNA was quantified using the Quant-iT RiboGreen 
RNA Reagent and Kit (Invitrogen). Two micrograms of the total RNA was converted to 
cDNA using a high capacity cDNA reverse transcription kit (Applied Biosystems). PCR 
primers were designed (Table 7-2) using Primer Express® software (Applied Biosystems) 
and obtained from Integrated DNA Technologies (Coralville, IA). Primer validation and 
qRT-PCR using SYBR green mix (Applied Biosystems) was conducted on a StepOnePlus 
real-time PCR machine (Applied Biosystems) according to methods previously published 
[231,232]. All qRT-PCR reactions were performed in triplicates and fold differences for 
each target gene using comparative CT method were normalized controls (untreated 
macrophages), and the relative fold change was calculated by normalizing against the 
endogenous reference, housekeeping, hypoxanthine phosphoribosyltransferase 1 (HpRT1) 
gene (Figure 5.2). 
5.2.4 RNA Extraction and qRT-PCR Analysis of Schwann Cells (SC)  
Same method as macrophages was used for SC too. However here the conditions 
were SC treated with conditioned media (CM) from IL-4 or IFNγ + LPS macrophages and 
the control was SC treated with CM from untreated macrophages. PCR primers were 
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designed for the genes of interest (Table 7-3) and Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as the endogenous reference gene. 
5.2.5 Scaffold Implantation  
Polysulfone tubes filled with 0.7% Agarose (SeaPrep Lonza) mixed with 1 mg/ml 
rat recombinant cytokine IL-4 (Antigenix America Inc.) or Agarose only were prepared 
(n=6 per group). The scaffolds were kept cooled in 4°C for 1 h. Adult Lewis male rats 
(250−300 g) were induced to anesthetic depth with inhaled isoflurane at 3−4%. Throughout 
surgery, the animals were maintained at 1.5−2% isoflurane. Microscissors were used to 
transect the sciatic nerve, and the nerve stumps were pulled 1 mm into each end of the 17 
mm guidance scaffolds (leaving a 15 mm gap) and fixed into place with a single 10−0 
nylon suture (Ethicon). The muscles were reapposed with 4−0 vicryl sutures (Ethicon) and 
the skin incision was clamped shut with wound clips (Braintree Scientific). After the 
surgery, the rats were placed under a warm light until sternal, and then housed separately 
with access to food and water ad libitum at constant temperature (19−22°C) and humidity 
(40−50%) on a 12:12 h light/dark cycle. To prevent toe chewing, a bitter solution 
(Grannick’s Bitter Apple) was applied when it was necessary to the affected foot. Marcaine 
(0.25% w/v (0.3 ml/animal)) and Buprenorphine SR (1 mg/kg) were administered 
subcutaneously for post-surgical pain relief. Animals were maintained in facilities 
approved by the Institutional Animal Care and Use Committee (IACUC) at the Georgia 
Institute of Technology and in accordance with the current United States Department of 
Agriculture, Department of Health and Human Services, and National Institutes of Health 
regulations and standards. 
5.2.6 Scaffold Explantation and PCR Array Analysis 
1 and 2 weeks after implantation (n=6), scaffolds were explanted and snap-frozen 
and kept frozen at -80°C for gene and protein analysis. The scaffolds were then crushed in 
liquid nitrogen using mortar and pestle, and treated with RNEasy Mini Kit (Qiagen), RNA 
 70 
were extracted, and converted to cDNA similar to 5.2.3. Here, we used Rat RT2 Profiler 
PCR Array (Qiagen) to do a complete screening on each of our scaffolds. 500ng of cDNA 
were used for each Qiagen PCR Array following the protocols therein. For the complete 
list of analyzed genes please see A.4 and A.5.  
5.2.7 Statistical Analysis 
Data were analyzed using the Student’s t-test for unpaired data where appropriate 
or one-way ANOVA followed by a Tukey’s least significant difference post-hoc test where 
warranted to determine significant differences between groups with 95% confidence; A p 
value < 0.05 was considered to represent a statistically significant difference. 
5.3 Results 
5.3.1 Effect of Polarized Macrophages on SC Proliferation/ Migration in vitro 
Using a Boyden Chamber (BC), the effect of M1 or M2 macrophage phenotype on 
SC migration was explored in vitro. Because some of the secretory products of 
macrophages are labile, with short half-lives (e.g., oxygen and nitrogen free radicals), 
media transfer assays may underestimate the migratory potential of conditioned media 
(CM) from macrophages. Therefore, SCs grown on the trans-well of the BC were placed 
in the wells of pro-inflammatory and anti-inflammatory plated macrophages. The 
phenotype of macrophages was confirmed by measuring the amount of nitrite 
production A.2.1 for method) and the ratio of IL-10 to IL-12 gene expression (see A.2.2 
for method) in cells after being exposed to IFNγ and IL-4 cytokines (Figure 5.2). After 
being primed overnight, these macrophages retained their activation state even after being 
washed to remove residual stimulating cytokines (Figure 5.2). The rate of SC migration 
was increased in the presence of CM from either the M1 (treated with IFNγ) or M2 (treated 
with IL-4) macrophages in comparison to CM from the (control) macrophages treated with 
no cytokines (Figure 5.3a). The increase in migration in the presence of CM from M2 
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macrophages was nearly twice that (300% vs. 170%) observed in the presence of CM from 
M1 macrophages. However, exposing SC directly to IL-4 or IFNγ did not have any effect 
of the SC migration (Figure 5.3c) 
To evaluate whether enhanced SC migration was due to enhanced SC proliferation, 
CCK8 assays were performed using the same number of cells treated with the CM from 
M1 and M2 macrophages at 72 h time point. CCK8 measures the metabolic activity of the 
cells which directly correlates with the number of cells. We have shown that our treatment 
does not change metabolic activity of individual cells and therefore the overall metabolic 
activity correlates well with total number of cells and therefore can be used to measure the 
proliferation rate. Although CM from M2 macrophages did not have any significant effect 
on the rate of SC proliferation, CM from M1 macrophages marginally, but significantly 
decreased proliferation rate of the SC compared to the CM from the control (n=4, P < 0.01, 
one-way ANOVA followed by a Tukey’s post-hoc) (Figure 5.3b). Furthermore, although 
direct addition of IFNγ and IL-4 to the SC cultures did not have any effect on the SC 
migration (Figure 5.3c), both of the cytokines significantly decreased the SC proliferation 
(n=4, P < 0.01, Student’s t-test) (Figure 5.3d). 
5.3.2 Effect of Polarized Macrophages on SC phenotype 
Based on our literature review, we chose 12 genes that represent the functional 
status of SC. These genes are playing role in migration, proliferation, myelination, 
adhesion, growth factor production, and immune functions of SCs [225]. The purpose for 
this experiment was to investigate if different phenotype of macrophages might affect any 
of these SC functions and therefore affecting their phenotype. 
We observed an up-regulation in SC expression level of 3 genes by exposing SC to 
CM of M1 macrophages (MCP-1, TGFβ, GFAP), 3 gene by exposing SC to CM of M1 as 
well as M2 macrophages (SDF1, GDNF, MPZ), and down-regulation in expression level 
of 4 genes by exposing SC to CM of M2 macrophages (NGF, NGFr, Krox20, Oct6) relative 
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to CM of MØ macrophage. Among all 12 genes only SDF1 showed more up-regulation in 
expression when exposed to CM of M2 relative to CM of M1 macrophage (n=5). 
  
 
Figure 5.2: Macrophages maintain their phenotype after being exposed to the fresh 
media. 
A) nitrite (NO2-) production in macrophages treated with pro/anti-inflammatory 
cytokines. B) Gene expression of two main pro/anti-inflammatory characteristic 
cytokine, IL-10 and IL-12. The ratio of IL10/IL12 indicates the activation state 
(phenotype) of macrophages. Asterisks denote a significant difference compared with 
non-cytokine treated control scaffold (P < 0.05). 
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Figure 5.3: Polarizing macrophages to M1 and M2 phenotypes indirectly affect 
Schwann cells (SC) and axons in vitro.  
a) Effect of SC migration in CM from macrophages (72 h). Mean ± s.d. n = 4. ***P < 
0.001. *P < 0.05 (one-way ANOVA followed by a Tukey’s post-hoc) b) SC 
proliferation in CM from macrophages. Mean ± s.d. n = 4. ***P < 0.001. **P < 0.01 
(one-way ANOVA followed by a Tukey’s post-hoc) (72h). Direct effect of the 
cytokines on the Schwann cell, c) proliferation and d) migration. Mean ± s.d. n = 4. 
**P < 0.01 (Student’s t-test). Asterisks denote a significant difference. CM from IL-4 
treated macrophages increases the SC migration almost 3 times without affecting the 
SC proliferation in comparison to the control. Direct addition of cytokines to SC does 
not have any effect on their migration but decreases their proliferation. 
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Figure 5.4: Effect of macrophages conditioned media (CM) on SC gene expression 
level. Asterisks denote a significant difference compared with SC treated with CM 
from non-cytokine treated macrophage control scaffold (P < 0.05). 
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5.3.3 PCR Array Analysis of Scaffolds 
The result presented in CHAPTER 4 and in vitro resulted presented in this chapter, 
convinced us that anti-inflammatory cytokine (IL-4) is able to enhance axonal growth 
relative to our conditions and controls. Here, we further explored the effect of IL-4 
containing scaffold on regenerative environment inside the nerve conduit, 7 and 14 days 
after nerve implantation (Figure 5.5, Figure 5.6, and Figure 5.7). 
The Rat Neurotrophins & Receptors RT² Profiler™ PCR Array and the Rat 
Common Cytokines RT² Profiler™ PCR Array were used to profile the expression of 84 
genes related to neuronal processes, and 84 important cytokine genes, respectively. 
 Neurotrophic signaling molecules are represented on Neuroptrophins & Receptors 
Array included neurotrophins and neuropeptides along with their receptors along with 
genes involved in the normal functions of the neuronal system including neuronal cell 
growth and differentiation and neuronal regeneration and survival are included. Also the 
cytokines and receptors involved in neuronal signaling are contained on this array along 
with genes involved in the transmission of nerve impulses, genes involved in neuronal 
apoptosis in response to neurotrophic factors and transcription factors and regulators 
indicative of the activation pathways downstream of the neuronal system.  
Rat Common Cytokines PCR Array included interferons and interleukins as well 
as the bone morphogenetic proteins (BMP) and members of the TGFβ family. Also 
represented are colony-stimulating factors and various growth factors (fibroblast, insulin-
like, platelet-derived, transforming, and vascular endothelial). Tumor necrosis factors were 
also included as well as other cytokine-related genes.  
Expression levels of neurotrophins, neuropeptide, and receptors genes in IL-4 
containing scaffolds, relative to the control scaffold (agarose without cytokine), are shown 
at 7 and 14 days after implantation in Figure 5.5 and Figure 5.6, respectively. Each point 
corresponds to one gene and the diagonal line in the middle represents no change in 
expression. Points above the middle diagonal line represent up-regulation and points below 
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the middle diagonal line represent down-regulation in gene expression of tissue within IL-
4 treated scaffold relative to the control. In both Figure 5.5 and Figure 5.6 the dashed lines 
to either side of the diagonal line represent a two fold change in expression. 
At 7 and 14 days after scaffold implantation, a greater than two fold change in 
expression level was observed for only 5 of 84 genes studied. These genes are Galanin 
Receptor-1, Galr-2, and Fibroblast Growth Factor Receptor Substrate 3 (FRS3) at the seven 
day survival time (Figure 5.5), and Gastrin-Releasing Peptide Receptor (GRPR) and 
Cerebellin 1 Precursor (CBLN1) at the 14 survival time (Figure 5.6). 
However when similar analysis was done on tissue sample of 7 day study using 
common cytokine array, more changes in the expression level of genes were found 
(Figure 5.7). Again each point corresponds to one gene and the diagonal line in the middle 
represents no change in expression. Points above the middle diagonal line represent up-
regulation and dos below the middle diagonal line represent down-regulation in gene 
expression of tissue within IL-4 treated scaffold relative to the control. The guide diagonal 
lines represent 2 folds in change in Figure 5.7. 
Our data show that 9 genes affected by IL-4 containing scaffold 7 days after injury. 
These genes are IL-19, IL-24, and IL-21 which are up-regulated more than two fold in IL-
4 treated scaffold relative to the control, and IL-22, IL17f, IL-13, BMP5, IFNα2, and 
IL36rn which are down-regulated more than two folds due to the treatment (Figure 5.7). 
Among these genes, 5 of them demonstrate more than 4 folds change (IL-19, IL-24, and 
IL-21 up-regulation) and (IFNα2 and IL36rn down-regulation) with IL-19 showing the 
most statistically significant and dramatic up-regulation (statistical analysis was performed 
using Qiagen online web tool for cytokine arrays).  
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Figure 5.5: The Neurotrophins & Receptors RT² Profiler™ PCR Array-7 days. 
Each point corresponds to one gene and the diagonal line in the middle represents no 
change in expression. Points above the middle diagonal line represent up-regulation 
and points below the middle diagonal line represent down-regulation in gene 
expression of tissue within IL-4 treated scaffold relative to the control. The guide 
diagonal lines represent 2 folds in change. 
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Figure 5.6: The Neurotrophins & Receptors RT² Profiler™ PCR Array-14 days.  
Each point corresponds to one gene and the diagonal line in the middle represents no 
change in expression. Points above the middle diagonal line represent up-regulation and 
points below the middle diagonal line represent down-regulation in gene expression of 
tissue within IL-4 treated scaffold relative to the control. The guide diagonal lines 
represent 2 folds in change. 
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Figure 5.7: The Common Cytokines and Chemokines RT² Profiler™ PCR Array-7 
days.  
Each point corresponds to one gene and the diagonal line in the middle represents no 
change in expression. Points above the middle diagonal line represent up-regulation and 
points below the middle diagonal line represent down-regulation in gene expression of 
tissue within IL-4 treated scaffold relative to the control. The guide diagonal lines 
represent 2 folds in change. 
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5.3.4 Investigate the in vitro effect of IL-19 on SC 
The result of our gene screening experiment directed us toward the potential role 
of IL-19. Therefore, we designed an experiment similar to 5.3.1 and 5.3.2 to investigate 
the effect of IL-19 on SC migration and proliferation (Figure 5.8). Interestingly enough, 
although IL-19 does not significantly affect SC proliferation in any of tested doses range 
(50-500 ng/mL) (Figure 5.8c), 500 ng/mL concentration of IL-19 encourages the SC to 
migrate from the top of the BC insert to the bottom 200% more in comparison to the control 
(non-treated cells) (Figure 5.8a,b). This correlation matches the correlation that we 
observed with macrophages conditioned media (Figure 5.3). Similar to 5.3.2, we also 
studied the effect of IL-19 on SC gene expression level in order to better understand its 
effect on SCs function (please refer to A.6). 
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Figure 5.8: Effect of IL-19 on SC migration and proliferation in vitro.  
a) representative images for GFP-RSC migrated to the bottom of Boyden Chamber 
insert, b) effect of IL-19 on SC migration, c) effect of IL-19 on SC proliferation. 
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5.4 Discussion 
Nerve regeneration in the PNS is often incorrectly thought to happen fully and with 
little or no intervention, especially when compared with nerve regeneration in the CNS, 
which as discussed in CHAPTER 1 is extremely limited. Although peripheral axons are 
generally capable of regeneration and formation of functional connections, several factors 
(such as type of injury, delay before intervention, and the patient’s age) can decide the 
extent of functional outcome after repair. We also know that crushed nerves relative to 
transected nerves have much better outcomes, and also nerve recovery is  much worse 
better after proximal injuries than after distal ones, as axons that need to travel longer 
distance to reach their target tissue are less likely to reconnect [36,108,225,226]. 
Recognition of these factors that can affect the final outcome of nerve regeneration has 
been useful in dissect the underlying cellular mechanisms of regenerating neurons both in 
in the CNS and PNS. For axon regrowth to happen, the distal environment needs to be 
supportive of regrowth, and also axons must have the inherent ability to regrow. Schwann 
cells as mentioned in 5.1 are playing a critical role in the former one. 
Recognizing the importance of Schwann cells for axonal sprouting and 
regeneration, many groups have used Schwann cell seeded nerve conduits [227,233,234]. 
The use of pre-seeded Schwann cells bypasses the fibrin cable step and accelerates the 
formation of bands of Büngner. This technique also introduces a persistent source of 
neurotrophic factors. However, the ability of nerve conduits containing Schwann cells to 
facilitate nerve regeneration is dependent on the density of pre-seeded Schwann cells. For 
instance, in repairing an 8 mm long gap in rat sciatic nerve, the required Schwann cell 
density is 80 million cells per ml [234]. Moreover, a secondary surgery is required to obtain 
a small nerve segment that can serve as a source of autologous Schwann cells. Additionally, 
it  takes 5-6 weeks to grow a therapeutically significant number of Schwann cells, during 
which time the injured nerve further degenerates [235]. Therefore, the current techniques 
for utilizing Schwann cells (SC) for repairing long nerve gaps may not be clinically 
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acceptable. Besides SC transplantation, multiple neurotrophins, such as NT-3, have also 
been shown to be capable of enhancing SC infiltration [3]. In fact, NT-3 promotes Schwann 
cell migration, and subsequently neurite outgrowth.  
Here, we showed that M1 and M2 macrophages can also affect SC proliferation 
and migration. Although it has been documented that CM from classically activated (M1) 
macrophages increases SC proliferation [215,236], our study extends the known mitogenic 
effect of activated macrophages on SC to the M2 phenotype. Moreover, since SC 
infiltration is an integral component of axonal regeneration after sciatic nerve injury, we 
studied the effect of modulating macrophage activation states on SC migration too. Both 
M1 and M2 macrophages were shown to promote migration of SC. This result is in 
agreement with an in vitro study showing similar trend of M1 and M2 macrophages in 
recruitment of vessel associated progenitor cells [147]. The study showed that both M1 and 
M2 macrophages can induce chemotaxis of progenitor-like cells but with different 
capability and through different pathways. However, here we also showed that M2 
macrophages increased the migration rate of SC 2-fold more than CM from M1 
macrophages. These results also parallel another study which investigated the effect of CM 
from M1 and M2 macrophages on the migration of mouse myoblast-like cell [177]. 
 Although it is clear that factors in the CM from M2 macrophages boost the 
migration rate, the precise mechanisms by which M2 macrophages trigger such a response 
are still unknown. However, preliminary gene expression analysis indicates that there are 
several genes in SC that are affected by macrophage CM migration (Figure 5.4); in 
particular, stromal cell-derived factor-1 (SDF-1) demonstrates a trend similar to that 
observed with SC. Recently, it was demonstrated that the SDF-1 receptor, CXCR7, is an 
active component of SDF-1 signaling in SC [237], suggesting a possible autocrine 
mechanism. However, further investigation is necessary to identify the precise signaling 
pathway. 
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Moreover, although our results also demonstrate the pro-regenerative effect of anti-
inflammatory macrophages is mediated through macrophages and subsequently SCs, we 
wanted to explore the mechanism by which early modulation of innate immune response 
inside our nerve conduit resulted in significantly improved axonal growth better. As it 
mentioned also earlier, the ability to regenerate in response to a nerve injury is determined 
by many factors, including the presence or absence of a permissive environment into which 
axons can elongate, the intrinsic growth capacity of the neuron itself, and the influence of 
non-neuronal cells [225]. Since our scaffold modulates the immune response locally and 
inside the scaffold, the focus was concentrated on the local players which potentially made 
the environment more permissive for regeneration. Based on this assumption we chose two 
PCR profiler kits to cover both general wound healing aspect of regeneration as well as 
neural tissue specific. Among the genes analyzed with the PCR profiler kits, IL-19 
expression demonstrated the most statistically significant and dramatic changes 
(Figure 5.7).  
IL-19, a member of the IL-10 cytokine family, is a relatively novel cytokine In 
addition to IL-19, the IL-10 family encompasses IL-20, IL-22, IL-24, and IL-26 [238]. IL-
19 is primarily produced by monocytes [239] but little is known about the effects of this 
cytokine, although studies to date have shown that it possesses a pleiotropic nature, 
dependent on the type of tissue and disease with which it is associated (Figure 5.9). IL-19 
has been shown to up-regulate the production of IL-6, TNFα, and reactive oxygen species 
[238,240,241]. However, IL-19 has also been shown to increase the levels of Th2 cytokines 
in uraemic patients [242], vascular inflammatory diseases [243], inflammatory bowel 
diseases [244], asthma patients [238], and autoimmune diseases [245].  IL-19 has also been 
linked to poor prognoses in cancer patients through its promotion of cancer cell 
proliferation and migration [246,247].  The production of both inflammatory and anti-
inflammatory cytokines further proves the dual nature of IL-19.  IL-19 has also been shown 
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to down-regulate the production of IFNγ, a cytokine which has been shown to induce an 
M1 pathway [244,248,249]. 
 
 
 
Figure 5.9: Schematic showing pleiotropic nature of IL-19 
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Although IL-19 has proved to be therapeutic in many different kinds of tissue, its 
effect in the peripheral nervous system has never been studied. The potential up-regulation 
of Th2 cytokines by IL-19 stimulation has the potential of promoting an M2 pathway, and 
thus promoting regeneration.   
Recent studies have looked at the role of IL-19 in malignant tumors in promoting 
tumor growth. When compared to healthy tissue, neoplastic tissue shows significantly more 
IL-19, and has been stained in many different kinds of carcinoma [246]. A positive 
correlation between IL-19 and the Th2 pathway has also been observed [247]. On the other 
hand, LPS stimulation of macrophages leads to the expression of IL-19. This expression 
was enhanced following treatment with IL-4, but diminished by treatment with IFNγ, 
suggesting a positive relationship between Th2 cells and macrophages [247]. A study on 
the regulation of T cells by IL-19 confirmed that IL-19 increased the number of IL-4 
producing cells in the presence of an infectious challenge. Not only did the number of IL-
4-producing cells increase, but the number of IFNγ-producing cells was also decreased 
[247] which again confirms the role of IL-19 in promoting the production of Th2 cells. 
Another  study showed that repeated stimulation with IL-19, and other cytokines in the IL-
10 family, increased the number of IL-4 and IL-13 producing T cells [250]. This positive 
correlation between IL-19 and IL-4, as well as the negative correlation between IL-19 and 
IFNγ, suggest a positive feedback between IL-19 and Th2 cytokines [247].   
Furthermore, increased production of IL-19 has also been linked to hyper-
proliferation of keratinocytes in psoriatic plaque and, the increased production of IL-4, IL-
5, and IL-13 in asthma patients [251]. Although this increase in cell proliferation and Th2 
cytokine production can prove detrimental in otherwise healthy patients, these results could 
have positive results in sites of injury by promoting an M2 response. Both Th2 cytokine 
production, and an alternatively activated macrophage response occur in response to 
infection in humans (alternatively activated), and have proven beneficial in reducing 
inflammation and promoting regeneration.   
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Moreover, IL-19 is also known to promote the cytokines IL-6 and TNFα [241,248]. 
Although these cytokines are usually associated with inflammation, they have potentially 
therapeutic effects.  These cytokines are linked to the production of angiogenic factors, 
such as VEGF, and TGFβ [249]. 
On the other hand, IL-19 has been linked the production of TNFα as well as cell 
apoptosis [250,252].  This apoptotic effect of IL-19 could be directly related to the 
increased production inflammatory mediators such as TNFα, IL-1, and reactive oxygen 
species [250].  Apoptosis was reduced in monocytes that were stimulated with both IL-19 
and TNFα antibody [240].  However, in contrast to this report of the induction of apoptosis 
by IL-19, studies regarding rheumatoid arthritis and patients with chronic 
rhinosinusitis/nasal polyps reported a reduction of apoptosis. IL-19 has shown a positive 
correlation with STAT3 activation in many studies [242,251,253], which is characterized 
by the prevention of apoptosis, oncogenesis, and cell proliferation.  IL-19 in synovial 
tissue, which originated from both macrophages and fibroblasts, was responsible for the 
induction of STAT3 in rheumatoid arthritis synovial cells.   
Overall, the effects of IL-19 are not completely understood. The potential of IL-19 
as a therapeutic treatment for peripheral nervous system injuries remains unexplored, and 
merits further investigation, both in vitro and in vivo. Modulation of IL-19 cytokines in the 
context of nerve regeneration could have a significant implication for advancing 
regenerative outcomes for patients with PNS injuries.      
5.5 Conclusion 
Our in vitro and in vivo data suggest that the beneficiary effect of M2 macrophage 
on peripheral nerve regeneration might be due to their effect on enhancing the 
permissiveness of the nerve conduit to growth, mainly though increasing SCs migration. 
We also believe that IL-19 which is mainly a Th2 cytokine and secreted by 
monocytes/macrophage and cause angiogenesis and cell proliferation might play a 
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principal role in enhancing the SC infiltration inside IL-4 containing/M2 encouraging nerve 
conduit. Therefore IL-19 might be a key factor in the context of enhancing peripheral nerve 
regeneration by modulating innate immune response using anti-inflammatory IL-4 
cytokine.  
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CHAPTER 6  DETERMINE THE EFFECT OF MONOCYTE 
RECRUITING FACTOR ON STIMULATING NERVE 
REGENERATION 
6.1 Introduction 
Each year, nearly hundred thousand patients undergo peripheral nerve surgeries in 
Europe and United Sates [254]. Although there are ample microsurgery techniques 
available for short nerve lesions, our ability to bridge long peripheral nerve gaps remains 
unsatisfactory. Plastic and hand surgeons as well as neurosurgeons use either autografts, or 
more recently cadaver derived grafts to bridge peripheral nerve gaps [255]. However, both 
sources are inadequate, and present challenges of containing inhibitory CSPGs that need 
removing via processing. These challenges lead to more than 50% of individuals not 
recovering fully by functional terms [4,256]. Rate of regeneration as well as degree of 
reinnervation determine the outcome of functional recovery after PNS injuries [3,225]. 
Several studies have shown that delays in repair after injury contributes to poor functional 
recovery [35,37,225,257]. Hence, there is critical need to enhance both the extent and rate 
of regeneration after peripheral nerve injury.  
Our laboratory has been investigating the possibility of designing ‘tissue 
engineered’ nerve bridges, matching the performance of autografts to functionally bridge 
10 mm gaps in rodents [4,87,89].  However, when we applied this strategy to a more 
challenging and clinically relevant 15 mm nerve gap in rodents, the performance fell short.  
[77,86]. The best way to approach nerve repair was previously hypothesized to be through 
recreating the physical and biochemical milieu extant in development. Approaches such as 
hydrogels or aligned polymer fibers and controlled release of NGF or BDNF were no 
longer the best and the hypothesis needed to be revisited  [108].  
Our results show that it is more productive to bias the inflammation/immune 
reaction towards a regenerative biochemical cascade instead of trying to recreate a complex 
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combination of ECM proteins, angiogenic factors and neurotrophic factors. The biased 
reaction will lead to the creation of a permissive environment for growth. This approach 
focuses on upstream modulation of inflammation after injury to attain repair by effective 
activation of the intrinsic growth capacity of peripheral neurons [108,230,258].  
 Under homeostatic conditions and depending on the tissue, maintenance of the 
resident macrophage population occurs by either local proliferation or recruitment and 
differentiation of blood monocytes [259,260]. However after an inflammatory insult, 
macrophages that accumulate at the site of injury appear to be largely derived from 
circulating monocytes [259,260]. The ability of monocytes to mobilize and traffic to where 
they are needed is central for their function in promoting immune defense as well as tissue 
regeneration [113]. In the rat, monocytes include two major subsets which have been 
identified on the basis of chemokine receptor expression and CD43 levels [31,261,262]: a 
CD43lowCCR2+CX3CR1low inflammatory subtype of monocyte recruited to inflamed 
tissues and a CD43hiCCR2−CX3CR1hi patrolling and anti-inflammatory reparative subtype 
recruited to non-inflamed tissues [31,195]. Inflammatory monocytes phagocytose debris 
and clear damaged cells, whereas anti-inflammatory monocytes promote tissue 
regeneration [195]. Anti-inflammatory monocytes are also the larger population (80-90%) 
in the rat blood [262].  
Monocytes of different subsets appear to be specialized for different functions, but 
also may be predisposed to differentiate into macrophages of different phenotypes 
[114,259,260]. In fact, different subtypes of monocytes can be recruited by distinct cues 
into inflamed tissues, where they can differentiate into classically activated M1 or 
alternatively activated M2 macrophages, respectively [195]. M1 macrophages produce 
high levels of oxidative metabolites as well as pro-inflammatory cytokines, and M2 
macrophages support tissue repair by producing anti-inflammatory cytokines which 
mediate angiogenesis and matrix remodeling [32,206]. M1 and M2 subtype of 
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macrophages represent a simplistic depiction of a continuum spectrum between two 
activation states [33]. 
Moreover, recruited monocytes differentiate to macrophages, and recent studies 
have shown that monocytes may also have cell-specific activities that are yet to be defined. 
For example, emerging data suggest that monocytes can promote angiogenesis and 
arteriogenesis [263] and therefore, they themselves might also function as short-lived 
effector cells within tissues [264]. Thus, therapies that target sources of inflammation, such  
as monocytes, may lead to favorable results due to the short tissue residence time of 
monocytes in acute inflammation and the large-scale continuous cell recruitment. After the 
first hours of injury, manipulating monocyte recruitment could induce resolution of 
lingering inflammation and help with further tissue repair. 
The premise is that preferential recruitment of anti-inflammatory regenerative 
monocytes to the site of injury will bias macrophage response to pro-healing and in turn set 
off a regenerative biochemical cascade involving Schwann cells and neuronal processes 
that lead to repair (Figure 3.1). We have identified a chemokine – Fractalkine (CX3CR1 
ligand) – that can preferentially recruit anti-inflammatory monocytes to the site of nerve 
injury and here we investigated if local delivery of Fractalkine within the lumen of a nerve 
conduit, early after peripheral nerve injury can enhance the regeneration.  
6.2 Materials and Methods 
6.2.1 Scaffold Implantation 
Polysulfone tubes filled with 0.7% Agarose (SeaPrep Lonza) mixed with 10 mg/ml 
rat recombinant chemokine Fractalkine (CCL2), or IL-4 (Antigenix America Inc.) or 
Agarose only were prepared (n=12 per group). The scaffolds were kept cooled in 4°C for 
1 h. Adult Lewis male rats (250−300 g) were induced to anesthetic depth with inhaled 
isoflurane at 3−4%. 15 mm nerve autografts, which were resected and flipped from the rat 
sciatic nerve, were used as our positive control to bridge the 15 mm gap (n=8). Throughout 
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surgery, the animals were maintained at 1.5−2% isoflurane. Microscissors were used to 
transect the sciatic nerve, and the nerve stumps were pulled 1 mm into each end of the 17 
mm guidance scaffolds (leaving a 15 mm gap) or autografts and fixed into place with a 
single 10−0 nylon suture (Ethicon). The muscles were reapposed with 4−0 vicryl sutures 
(Ethicon) and the skin incision was clamped shut with wound clips (Braintree Scientific). 
After the surgery, the rats were placed under a warm light until sternal, and then housed 
separately with access to food and water ad libitum at constant temperature (19−22°C) and 
humidity (40−50%) on a 12:12 h light/dark cycle. To prevent toe chewing, a bitter solution 
(Grannick’s Bitter Apple) was applied when it was necessary to the affected foot. Marcaine 
(0.25% w/v (0.3 ml/animal)) and Buprenorphine SR (1 mg/kg) were administered 
subcutaneously for post-surgical pain relief. Animals were maintained in facilities 
approved by the Institutional Animal Care and Use Committee (IACUC) at the Georgia 
Institute of Technology and in accordance with the current United States Department of 
Agriculture, Department of Health and Human Services, and National Institutes of Health 
regulations and standards. 
6.2.2 Clodronate Liposome Study 
The suspension of clodronate liposomes was purchased from 
http://www.clodronateliposomes.com. To prevent precipitation of liposomes, the 
suspension was shaken before injection. A homogeneous suspension was required in order 
to warrant an equal concentration of liposomes per ml. For intravenous injection, ca 0.1 ml 
of the suspension was injected per 10 grams of animal weight, 48 hours before the 
implantation. Depletion of liver and splenic macrophages is complete after ca 24 hrs. 
6.2.3 Scaffold Explantation and Analysis 
Three weeks post injection, scaffolds or autografts were explanted for histological 
analysis of nerve regeneration (n=5). Since axons grow from the proximal to distal end of 
the scaffold, we only used the distal end (last 2 mm) for histological analysis and the 
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remaining part of scaffold and autograft were snap frozen in liquid nitrogen and stored in 
-80oC for further analysis. Explants were fixed in 4% paraformaldehyde (Sigma Aldrich), 
washed, and stored in 30% sucrose for 24 h. Samples were embedded in O.C.T. gel (Tissue 
Tek) and frozen for cryosectioning (CM30505, Leica). Scaffolds or autografts were 
sectioned transversely or longitudinally at a thickness of 16 μm and reacted with 
immunofluorescent markers to quantify the different cell types, using techniques 
previously described [76]. Briefly, sections were incubated for 1 h at room temperature in 
a blocking solution of goat serum (Gibco) in PBS, incubated overnight at 4°C in a mixture 
of primary antibody and blocking solution, washed and incubated for 1 h at room 
temperature in a solution of secondary antibody mixed in 0.5% triton in PBS. Slides were 
washed twice more with PBS, incubated with DAPI for 10 min and then dried and cover 
slipped for analysis. Primary antibodies NF160 (1:250, mouse IgG1, Sigma), S100 (1:250, 
rabbit, IgG, Dako Cytomation), RECA (1:250, mouse IgG1, Invitrogen), CD68 (1:100, 
mouse IgG1, AbD Serotec (ED1)), CD86 (1:100, mouse IgG1, AbD Serotec), Arginase1 
(1:250, rabbit, IgG, Cell Application), and CD206 (1:100, rabbit, IgG, Santa Cruz 
Biotechnology) were used. The following secondary antibodies were used: goat anti-rabbit 
IgG Alexa 488/594 (1:220, Invitrogen), goat anti-mouse IgG1 Alexa 488/594 (1:220, 
Invitrogen). Previously established immunohistochemistry techniques for quantifying 
fluorescent pixel intensity of aforementioned antibodies will be used to quantify each cell 
[76,92,177,207].  
6.2.4 Statistical Analysis 
Data were analyzed using the Student’s t-test for unpaired data where appropriate 
or one-way ANOVA followed by a Tukey’s least significant difference post-hoc test where 
warranted to determine significant differences among groups with 95% confidence; A p 
value < 0.05 was considered to represent a statistically significant difference. 
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6.3 Results 
6.3.1 Effect of Fractalkine Delivery on Number of Regenerated Axons. 
In this study, we used the same 15 mm gap model that we studies in CHAPTER 4   
but increased the dose of IL-4 to 10 ug/ml and the Agarose hydrogel concentration to 1% 
wt/vol to increase the release time of IL-4. We also added another group in which instead 
of IL-4, Fractalkine (anti-inflammatory monocyte recruiting factor) with similar 
concentration as IL-4 was used. Here, we used IL-4 as our benchmark condition, since we 
have already established the superiority in performance of IL-4 containing scaffold in 
several experiments (CHAPTER 4 and CHAPTER 5 . After four weeks, animals were 
euthanized, and axons were visualized by immunostaining for Neurofilament-160 
(NF160). As it is evident in Figure 6.1a, the number of regenerated axons at the distal end 
of the scaffold is significantly higher than IL-4 treated sample. In fact, the number of 
regenerated axons at the distal end of Fractalkine scaffold is 2 times more than IL-4 
scaffold, only 4 weeks after implantation of nerve conduit. We also observed that 
increasing the concentration of Agarose hydrogel to 1% has a deterimental effect on 
distribution hemogenity of regenerated axons as evident by lack of regeneration in the 
center of nerve cable, most probably due to the higher stiffness of the center (Figure 6.1b) 
[216].   
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Figure 6.1: Effect of Fractalkine release on the axonal growth.  
(a) Immunohistochemical staining of axons (red), laminin (green), and DAPI (blue) at 
the distal end of nerve stump. (b) Number of regenerated axons at the distal end of 
Fractalkine vs. IL-4 loaded scaffold four weeks after injury. Immunohistochemical 
staining of axons (red), laminin (green), and DAPI (blue) at the distal end of nerve stump. 
(c) Approximate location of sectioning. P value= 0.0114 (two-tailed) (n=5). Fractalkine 
dramatically increase the number of regenerated axons relative to IL-4. 
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6.3.2 Effect of Fractalkine Delivery on Number of SC and Endothelial Cells 
Based on the result of our study in CHAPTER 5 , we investigated the effect of 
Fractalkine delivery on affecting the permissiveness of nerve conduit for growth. Here, we 
used number of infiltrated SC and endothelial cells (early indicator for blood vessel) as our 
gauge to evaluate the permissiveness of environment. Our data in Figure 6.2 indicated that 
Fractalkine delivery significantly increased both SC infiltration (Figure 6.2d) and 
endothelial cells migration inside the nerve conduit (Figure 6.2e), 4 weeks after 
implantation of nerve conduit.   
6.3.3 Effect of Fractalkine Delivery on Number and Phenotype of Macrophages 
As we have been investigating the correlation between number of regenerated 
axons and the profile of immune response at the distal end of nerve conduit, here we also 
looked at number of macrophages and their phenotype 4 weeks after nerve conduit 
implantation using already established macrophage markers [76,92,177,207] (Figure 6.3 
and Figure 6.4). As it is shown in Figure 6.3d, number of macrophages at the distal end of 
nerve conduit is significantly lower in the Fractalkine scaffold relative to the IL-4 scaffold. 
Moreover, although the number of pro-healing macrophages (M2a and M2c) determined 
by co-staining with CD68 and Arginase is not significantly different between these two 
conditions (Figure 6.3e), the ratio of pro-healing macrophages to the total number of 
macrophages (Figure 6.3f) is significantly higher in Fractalkine scaffold relative to the IL-
4 scaffold. Also the number and the intensity of mannose receptor (CD206) which is 
another anti-inflammatory/wound healing marker is significantly higher in Fractalkine 
scaffold relative to our bench mark control (IL-4 scaffold) (Figure 6.4d). Moreover, our 
data showed that the number of CD206+CD86+ cells (an indicator for regulatory M2b 
macrophages) is dramatically higher in Fractalkine scaffold relative to the control IL-4 
scaffold. M2b which has both pro- and anti-inflammatory functions can be induced toward 
the end of regeneration process [93]. 
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Figure 6.2: Effect of early Fractalkine release on Schwann cells and endothelial cells. 
a) Combined S100 (green), RECA (red), and DAPI (blue) staining. b) Combined S100 
(green) and DAPI (blue) staining. c) Combined RECA (red) and DAPI (blue) staining. d) 
Quantitative analysis of SCs at the distal end by using S100. P value=0.0243 (two-tailed). e) 
Quantitative analysis of endothelial at the distal end by using RECA. P value=0.0016 (two-
tailed). Fractalkine treated scaffold significantly enhanced both SC infiltration and number 
of endothelial cells inside the nerve conduit in comparison to the IL-4 treated scaffold. 
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Figure 6.3: Effect of early Fractalkine release on number and phenotype of 
macrophages. 
a) Combined Arginase (green), CD68 (red), and DAPI (blue) staining. b) Combined 
CD68 (red) and DAPI (blue) staining. c) Combined Arginase (green) and DAPI (blue) 
staining. d) Quantitative analysis of total macrophage number at the distal end by using 
CD68 marker. P value=0.015 (two-tailed). e) Quantitative analysis of pro-healing 
macrophages at the distal end by double staining with CD68 and Arginase. P 
value=0.288 (two-tailed). f) Calculating the ratio of pro-healing macrophages to the 
total number of macrophages. P value=0.0019. Fractalkine treated scaffold has 
significantly lower number of macrophages but higher ratio of pro-healing macrophage  
relative to IL-4 treated scaffold, 4 weeks after implantation.  
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Figure 6.4: Effect of early Fractalkine release on mannose receptor expression and 
regulatory macrophages. 
a) Combined CD206 (green), CD86 (red), and DAPI (blue) staining. b) Combined 
CD86 (red) and DAPI (blue) staining. c) Combined CD206 (green) and DAPI (blue) 
staining. d) Quantitative analysis of mannose receptor expressing cells at the distal end 
assessed by CD206 marker. P value=0.022 (two-tailed). e) Quantitative analysis of 
regulatory macrophages (M2b) at the distal end by double staining with CD86 and 
Mannose receptor. P value=0.003 (two-tailed). Fractalkine treated scaffold contains 
higher number of mannose recptor expressing cells as well as regulatory macrophages 
relative to IL-4 treated scaffold, 4 weeks after implantation 
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6.3.4 Effect of Macrophage Depletion on Efficiency of Fractalkine Treatment 
Clodronate liposome (Clod-lip) treatment is a well-established methodology to 
deplete circulating monocytes and therefore significantly reduces the number of infiltrating 
macrophages at the site of injury [103,131,265]. In order to completely deplete 
macrophages, several i.v. injection of Clod-lip are required before and right after surgical 
procedure. However since we were only interested to evaluate the relative effect of 
macrophage depletion, we injected the animals with Clod-lip only once 48 hr before nerve 
conduit implantation. Two experimental groups were included: Fractalkine scaffold with 
Clod-lip injection and Fractalkine scaffold with sham PBS injection. Figure 6.5 clearly 
demonstrates the negative effect of macrophage depletion due to Clod-lip treatment on 
axonal regeneration 10 days after implantation in critically sized non-healing 15 mm gap 
model.  
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Figure 6.5: Clodronate Liposome Study. 
A) Demonstrates the axonal regeneration (stained red with NF160 antibody) using 
longitudinally sectioned scaffolds in Clodronate liposome treated animal vs. non-
treated animal. Both scaffolds contain Fractalkine. B) Quantifies the length of axonal 
growth 10 days after scaffold implantation. Partial depletion of macrophages using 
single injection of Clodronate liposome 48 hours before nerve conduit implantation 
significantly reduced the amount of axonal growth implying the central role that 
macrophages play in Fractalkine containing nerve conduit. (Blue = Dapi) 
 
 
 
 
 
 
 
 
 
 
 102 
6.4 Discussion 
After PNS injuries, neurons rapidly respond by changing their activities and 
promoting a regenerative phenotype. At the distal nerve stump, SCs change their phenotype 
and adopt a reparative phenotype. SCs as well as infiltrating and resident macrophages 
remove inhibitory debris which enables new axons sprouting into the degenerated nerve, 
directed by the bands of Büngner. As the result of these events, a healthy environment is 
created for regeneration in the PNS.  
Extended time without axon regeneration causes the target tissue as well as the 
distal end of the nerve stump to become chronically denervated. It also causes the neurons 
to become chronically axotomized which means lacking contact to their target tissue for 
axons. Both chronic denervation and chronic axotomy hamper regeneration, but studies 
have shown that chronic denervation  is particularly defective [37,225,257]. Chronically 
denervated distal stump loses its capability to support axonal growth around 8 weeks after 
the injury, and becomes completely incapable of supporting the growth 6 months after the 
injury [225]. At the same time period, the chronically denervated muscle tissue starts to go 
through atrophy. Therefore it is critical for axons to reach their target muscle during this 
regenerative time window since after this period muscle tissue is less susceptible to support 
the reinnervation [225,266]. 
From clinical point of view, it is important to note that some human nerves require 
extra time to extend to their target tissue due to the long distances, especially in patients 
with proximal nerve injuries. However, it is also important to mention that Schwann cell 
atrophy takes longer in humans than in rodents [225]. Nevertheless, to overcome these 
problems, axons should grow faster, and/or Schwann cells must sustain a regenerative 
conductive environment for longer period.  
Currently, the synthetic biomaterial-based nerve conduits which have already been 
developed as alternatives to autografts [3,76,77,224,267] are only capable of bridging short 
gaps (less than 8 mm). These conduits provide a regenerative conductive environment 
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mainly by supporting fibrin cable formation acting as a migratory substrate for SC and 
fibroblast FB into the nerve gap [156]. These cells help reorganization of the ECM, but 
also provide trophic support for regenerating axons which enables the bridging of the nerve 
gap[229]. However, these nerve conduits have not been very successful in bridging 
critically sized nerve gaps (that are typically greater than 1.3 cm in rodents and greater than 
3 cm in humans). As a result, functional recovery is rarely achieved in those gaps  [3]. Here 
we proposed a new way to maintain the environment permissive to support higher rate as 
well as degree of axonal growth by releasing of anti-inflammatory monocyte recruiting 
factor (Fractalkine) inside nerve conduit. 
Although monocytes and their descendants (macrophages) have long been known 
to play an essential role in the degenerative process, recent work has pointed to their 
importance in influencing the regenerative process [95,101,230]. They are quite abundant 
during nerve degeneration and regeneration and modulate the early sequence of cellular 
events which can determine the fate of healing process [95].  
Monocyte entry into a nerve, distal to the site of injury, is mediated through 
upregulation and release of the major monocyte chemokine, Monocyte Chemoattractant 
Protein (MCP-1) also known as CCL2, by SCs which reaches to its maximum 1 day after 
injury [268,269]. Once the monocytes enter, they differentiate into macrophages and 
phagocytose axonal and myelin debris resulted from the ongoing degenerative process. 
Removal of the debris, which is inhibitory to regenerating axons, is a known prerequisite 
for successful regeneration in vivo [40]. Moreover, Barrette et al. (2008) found that 
decreasing monocyte infiltration into the sciatic nerve decreased the normal axotomy-
induced increase in all four neurotrophins [i.e., NGF, brain-derived neurotrophic factor 
(BDNF), and neurotrophins 3 and 4] [270]. Monocytes also enter into peripheral ganglia 
following nerve injury. Recent work has also suggested that monocyte recruitment around 
axotomized cell bodies helps mediate the conditioning lesion response [100]. In fact, under 
conditions in which monocyte do not enter the dorsal root ganglia, there is no enhanced 
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growth after a conditioning lesion. Thus, monocyte recruitment leads to at least two 
important effects during degeneration and regeneration process: creating a pathway in the 
distal nerve segment conducive to axonal regeneration, and stimulating the axotomized 
neuronal cell bodies to switch to a regenerative phenotype [101].  Therefore, monocytes 
could represent an upstream ‘lever’ to influence downstream axon and SC fates and 
peripheral nerve regeneration. Our focus in this chapter was to modulate the former effect 
of monocytes during nerve regeneration process.  
Anti-inflammatory CD43hi monocytes express CX3CR1 receptor [31] and respond 
to CX3C-chemokine ligand 1 (CX3CL1; also known as Fractalkine). Fractalkine is a 
membrane-bound chemokine that is expressed in the marginal zone of the spleen but also 
in different tissues [113]. The chemokine domain of Fractalkine can be cleaved to create a 
soluble form of the chemokine which acts as a chemoattractant for monocytic cells [271], 
while the membrane-bound form participates in cell adhesion [272]. 
In mice, deletion of CX3CR1 leads into dwindled patrolling of anti-inflammatory 
monocytes [273] and also reduction of the inflammatory monocytes recruitment to splenic 
sites of bacterial infection [274]. CX3CL1 mainly facilitates early recruitment of anti-
inflammatory monocytes to the spleen [274], and CX3CL1/CX3CR1 interaction also 
provides a survival signal for anti-inflammatory monocytes under both  inflammatory and 
steady state conditions.  
In the context of nervous system, it has been shown that following facial nerve 
axotomy, a marked increase in Fractalkine mRNA was observed [271]. In addition, 
expression of Fractalkine receptor CX3CR1 in macrophages has been shown to 
dramatically increase in the sciatic nerve proximal to site of injury but also in the DRG, 
after sciatic nerve section (axotomy) [275]. In addition, it has been shown than axotomy 
triggers an anti-inflammatory immune response [160]. In fact, the signal supporting the 
alternative macrophage environment is produced immediately after nerve damage and 
appears to be present within the nerve, well before monocytes infiltration [160]. Therefore, 
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it is rational to hypothesize that mimicking the axotomy immune response (anti-
inflammatory) in the synthetic nerve gap by exogenous delivery of Fractalkine early after 
injury would be an effective way to create a permissive environment for neural 
regeneration.  
In fact, exogenous application of Fractalkine has been proven to be neuroprotective 
in models of ischemic stroke in rats [276] and to cause significant delay in the development 
of allodynia [275]. Fractalkine administration also increased neuronal survival, and 
contributed to angiogenesis through promoting endothelial cell proliferation, thus leading 
to better functional recovery [276].  
It is also important to mention that Fractalkine is the only ligand known to bind and 
activate the CX3CR1 receptor, and does not bind to any other known mammalian 
chemokine receptors [277]. Thus, the normal indiscrimination that characterizes the 
chemokine superfamily is not present for Fractalkine which suggests the roles that are 
played by Fractalkine and CX3CR1 are non-redundant and probably are critically 
important for nerve regeneration. 
The question of in situ conversion versus sequential recruitment of inflammatory 
or anti-inflammatory monocytes in tissues other than cardiac and skeletal muscle has not 
been systematically investigated [98] and to the best of our knowledge, the role of 
Fractalkine and its receptor in monocyte/macrophage accumulation in injured peripheral 
nerve has not been elucidated. Unraveling the process of monocyte recruitment after 
peripheral nerve injuries can provide insights for the development of new therapeutics 
which can  manipulate the number and distribution of these cells ,and can subsequently 
leads into the enhancement of pro-regenerative immune response or reduction of 
detrimental inflammatory response [113].  
Moreover, although it has been determined in some other tissues such as skin, 
muscle, and cardiac [98], the mechanism by which anti-inflammatory 
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monocytes/macrophages accumulate in peripheral nerve injury site(selective recruitment 
or in situ conversion) has not been determined yet.  
Finally, it is debatable whether inflammatory macrophages travel to the site of 
inflammation, and change phenotypes to regulatory and wound-healing macrophages 
[127], or whether the recruited macrophages change their functional phenotype in response 
to the dynamic signals of the injured tissue during the course of regeneration [62]. The 
kinetics and mechanisms of recruitment of blood monocyte populations to injured tissues 
remain to be elucidated. 
Regarding macrophage depletion experiment using Clod-lip, although most 
investigators prefer PBS or saline liposomes for control experiments and referees are 
usually asking for such controls if omitted, it is important to note that administration of 
PBS or saline liposomes does not represent the right control experiment in most cases. 
Compared to an experiment in macrophage depleted animals, the control animals should 
have normal healthy, non-blocked, non-suppressed and non-activated macrophages. 
Liposomes, as most other particulate compounds may block phagocytosis by saturation for 
certain periods of time. Moreover, it is not known exactly which other macrophage 
functions will be suppressed or reversely activated and for what duration. To mimic 
depletion treatments without affecting healthy macrophages, sham operations and 
injections of e.g. NaCl are sufficient. Overall, our Clod-lip study strongly highlights the 
central role that macrophages play during the nerve regeneration process enhanced by 
Fractalkine. 
6.5 Conclusion 
Although macrophage phenotype is heavily dependent on external stimuli, such as 
cytokine exposure [33], a contribution of monocyte lineage to macrophage phenotypic 
determination has also been suggested [260]. Here, we demonstrated that release of anti-
inflammatory monocyte recruiting factor (Fractalkine), early after nerve injury, can 
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dramatically enhance the permissiveness of nerve conduits and stimulate axonal growth 4 
weeks after the axotomy. Moreover, we reconfirmed the correlation between number and 
phenotype of major innate immune cells (macrophages) and nerve repair outcome. While 
we cannot conclusively confirm that the effect of Fractalkine is due to the 
recruitment/modulation of anti-inflammatory monocytes, we believe our results 
(histological and functional) presented here are intriguing enough to warrant investigating 
this possibility in the future. 
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CHAPTER 7  CONCLUSIONS AND FUTURE DIRECTIONS 
7.1 Conclusions 
Peripheral nerve injuries lead to long term disability and decreased function in 
approximately 2.8% of all trauma patients [278]. This is followed often by neuropathic 
pain which significantly affects the quality of life for individuals suffering from peripheral 
nerve injuries. Even though there have been considerable advances made in microsurgical 
techniques, bridging of long peripheral nerve gaps remains a continuing clinical challenge. 
Autografts are the current standard technique to bridge the long gaps but several drawbacks 
limit their use. Their use can lead to donor site complication such as sensory defect, scar, 
pain as well as requirements for multiple surgeries if the gaps are long [3]. Furthermore, 
due to modality mismatch, dimensions, etc., functional recovery approaching closer to pre 
injury levels is not achieved. These limitations of autografts have led to exploring 
substitutes to bridging peripheral nerve gaps.  
With the advances made in the field of regenerative medicine, alternatives to using 
autographs have been explored. Several synthetic and natural guidance channels are 
currently used in clinical as well as research settings to bridge nerve gaps. These techniques 
have shown to improve nerve regeneration in small gaps but fail when the gaps are longer. 
Despite the innovative efforts over the last several decades coupled to development of 
refined surgical techniques and understanding nerve injury, we do not have a suitable 
replacement for autograft. Historically, advances in the field of regenerative medicine and 
even in peripheral nerve repair have come due to a better understanding of the physiology 
and the underlying mechanisms that affect the regeneration process. Tissue engineering 
strategies to bridge long gaps have shown promise but very little is known with regard to 
how these technologies interact with the endogenous repair mechanism(s).  
Our group has pioneered the use of hydrogels, micro-scale lipid microtubes, and 
topographical cues to bridge nerve gaps longer than 12 mm [3,4,76,77,86–90]. To create 
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new and effective therapies that stimulate complete regeneration, we focused on many 
different constraints of peripheral nerve regeneration. Several strategies could potentially 
be utilized to support regeneration. These strategies includes but not limited to: enhancing 
the rate of axonal outgrowth as well as the intrinsic ability of axons to overcome inhibitory 
signals; increasing neuron survival; preventing atrophy of the target tissue as well as 
chronic dystrophic changes, so as to promote reinnervation; and inhibiting SC and basal 
lamina atrophy or replacing atrophied SCs with an appropriate bioengineered scaffold 
[225].  
We have come to realize, and our data attests to this, that instead of trying to 
recreate a complex combination of ECM proteins, angiogenic factors and neurotrophic 
factors in the nerve gap, it might be more effective to bias inflammation/immune reaction 
after injury towards a regenerative biochemical cascade in order to create a permissive 
environment for growth. This change is a marked shift in approach – rather than identifying 
the critical factors affecting nerve repair downstream and introducing them in the nerve 
gap, we focus on upstream modulation of inflammation after injury to attain repair by 
effective activation of the intrinsic growth capacity of peripheral neurons [108,230,258].  
The shift in our understanding of the macrophages role in tissue remodeling after 
injury is reflected in recent tissue engineering approaches; rather than seeking means for 
macrophage elimination or prevention of their infiltration to the injured tissue, current 
efforts have shifted to identifying means for boosting their controlled recruitment and 
modulation. In contrast to many conventional views regarding tissue inflammation and 
tissue remodeling, it has been suggested that strategies that promote the spatially, 
temporally, and phenotypically controlled recruitment of monocytes as well as timely 
modulation of macrophages may support functional recovery instead of tissue damage and 
injury expansion. In fact, this study and others confirm that the downstream “host 
response” to biomaterials is a result of of not simply the presence and number of 
macrophages but their spatial and temporal phenotype distribution.  
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The incredible plasticity of macrophages/monocytes makes them an interesting 
target for modulation in the context of immunoengineering for peripheral nerve repair. 
Therapies that target source of inflammation, such monocytes, may lead to favorable 
results due to the short tissue residence time of monocytes in acute inflammation and the 
large-scale continuous cell recruitment. After the first hours of injury, modulation of 
macrophage phenotype or preferential recruitment of specific monocyte subtype(s) could 
induce resolution of lingering inflammation and help with further tissue repair. In fact, 
dysfunction of macrophage plasticity, has been suggested as an elemental mechanism to a 
number of diseases including cancer, atherosclerosis, fibrosis, and insulin resistance [128]. 
As mentioned earlier, it is still debatable if migrated inflammatory macrophages 
give rise to regulatory and wound-healing [127] or if they alter their phenotype based on 
receiving progressive signals of inflammatory process [62]. However we know that the 
dynamic plasticity of macrophages can be regulated based on the type, duration, and 
concentration of the stimulating signals. Therefore, it is not surprising that examination of 
the macrophage population at any given time point shows a combination of macrophage 
phenotypes and/or transient macrophages (that express both M1 and M2 markers).  
In addition to potential effects of phagocytosis, macrophage phenotype is regulated 
by the biochemical milieu, including cytokine exposure [33],and by the mechanical 
properties of the environment, such as strain or substrate stiffness [183,187,188]. Thus, the 
phenotypic transition that occurs in monocytes/macrophages from the inflammatory to the 
regenerative phase may be driven, in part, by release of soluble products from neutrophils 
or other cells [279],autocrine or cell-intrinsic anti-inflammatory feedback mechanisms, 
and/or changes in the mechanical, cellular, and biochemical makeup of the granulation 
tissue [98]. The relative contribution of each of these factors and the precise molecules and 
signaling pathways involved in regulation of macrophage phenotype during in vivo tissue 
repair remain to be determined. Moreover, in vitro-differentiated, M1/M2 macrophages are 
not identical to inflammatory-phase tissue repair monocytes/macrophages [98,280], and 
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cell culture conditions generally do not accurately mimic the complex tissue repair 
environment. Thus, caution must be used when interpreting in vitro studies of macrophage 
phenotypic regulation 
We know the timing of the switch between M1 and M2 phenotypes is important for 
repair. While M1 promotes clearing of debris, and the subsequent switch to a more M2-
like phenotype facilitates regeneration, some studies have shown committed M1 
macrophages hardly switch phenotype to M2 [62,281]. Therefore it might be 
fundamentally important to intervene with the development of inflammation early on and 
that might be the reason for dramatic effect of our therapy. In fact, during the course of 
wound healing in cutaneous or myocardial tissues for example, there is a well-defined shift 
in macrophage activation states: from M1 to M2 and their secreted products [94,114]. Also 
interestingly, advanced age and diabetes which have shown to be related with impaired 
wound healing, have also been shown to have a reduced ability for  an M1 to an M2 
phenotype transition [142,143]. This is also the case with injuries to other tissues such as 
the spinal cord, where this shift does not occur after injury [129], thereby contributing to 
impaired recovery.  
In conclusion, we want to emphasize that the current treatment options available 
for patients with peripheral nerve injury are unsatisfactory. Off the shelf availability of long 
synthetic grafts would revolutionize the acute management of complex peripheral nerve 
injuries such as traumatic plexus injuries allowing surgeons to immediately bridge multiple 
nerves at the time of injury. The same could be said for complex tumor resections in axilla 
(brachial plexus) or groin (sacral plexus). Here, we described an innovative approach, 
which uses the endogenous capacity of the body for healing using its own immune cells. 
We believe our research presented here has the therapeutic potential for making significant 
progress toward addressing these critical problems. We also believe that the macrophage 
modulatory scaffold design discussed in this document is a significant advance in the state-
of-the-art for biomaterials for immunomodulation and regeneration.  
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7.2 Future Directions 
Understanding the M1/M2 polarization patterns is the first step in furthering our 
knowledge with regard to the contributions of these cells. Macrophage polarization and 
their contribution to healing can be fully assessed by examining multiple gene expressions, 
and cell surface markers in addition to understanding the effects of paracrine interactions 
with other cells. Also, when determining the outcome of certain conditions, effects of 
temporal and spatial distribution of macrophages may become very significant. It is highly 
beneficial to study the exceedingly complex pathways of macrophage phenotypes and their 
secreted products during tissue regeneration process. Understanding of this pattern will 
also allow for the development of novel therapeutic strategies. Therapies that target cell 
production, such as the splenic niche, may lead to favorable results due to the short tissue 
residence time of monocytes in acute inflammation and the large-scale continuous cell 
recruitment. After the initial hours of injury, manipulating monocyte phenotype 
recruitment could induce resolution of lingering inflammation and help with further tissue 
repair. 
Despite the body of evidence that support the difference between the paracrine 
effects of different phenotype of macrophages, it is still not clear if the conflicting 
outcomes correlated with distinct phenotype of macrophages are the result of the paracrine 
or primary functions of these cells. For example, recent studies suggest that macrophages 
may play a significant role in tissue remodeling process since they might be capable of 
myeloid to mesenchymal transition [282–284]. These studies have revealed that 
macrophages assimilate progenitor cells despite their singular pro-inflammatory 
placement.  
Moreover, contradictory outcomes which can be correlated with distinct 
macrophage phenotypes might be detectable by routine histology. In fact, it is important to 
determine the function of these cells with a plethora of different tools and not rely only on 
surface markers. For macrophage classification in contact with biomaterials, cytokine 
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release is a more reliable criterion in comparison to surface-markers since classification 
via only surface marker expression may be misleading [186]. For example, scavenger 
receptors (CD163) have a broad variety of biological activities [285] and their expression 
by macrophages should not be the only criterion for a proper assessment of the state of 
inflammatory response. It has been shown that depending on material characteristics, M1 
classified macrophages may release anti-inflammatory and pro-angiogenic signals, while 
M2 classified macrophages may release pro-inflammatory cytokines [186]. Therefore, as 
cytokines act on various other cell types [286] and tissues [287], cytokine release profile 
seems more relevant and decisive in evaluating the macrophage response to biomaterials. 
Thus, a wide array of analyses needs to be performed in order to better understand the 
mechanisms involved in nerve regeneration with our immunomodulatory nerve conduit. 
Finally, although it is known that chemical modification of biomaterials (such as 
crosslinking with non-degradable agents) can prevent the formation of the beneficial M2 
response [92], the effect of biomaterial degradation products on modulating macrophage 
phenotypes has not been extensively studied yet. Since monocytes/macrophages contribute 
to biomaterial degradation as well as are affected by degradation products, it is logical to 
assume that degradation can play a major role in modulating macrophage phenotype. 
Therefore, an in-depth understanding of events on these lines may provide a better 
biomaterial design strategy by which a constructive and functional downstream outcome 
can be promoted. 
The question of in situ conversion versus sequential recruitment of inflammatory 
or anti-inflammatory monocytes in tissues other than cardiac and skeletal muscle has not 
been systematically investigated [98] and to the best of our knowledge, the role of 
Fractalkine and its receptor in monocyte/macrophage accumulation in injured peripheral 
nerve has not been elucidated. Therefore, analyzing the process of monocyte recruitment 
can offer insights for the development of new therapeutics that can modulate the number 
and distribution of monocytes, and therefore enhancement of pro-regenerative immune 
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response [113]. Moreover, investigations on these lines have been conducted in some other 
tissues such as skin, muscle, and cardiac [98], however the mechanism by which anti-
inflammatory monocytes/macrophages accumulate in peripheral nerve injury site 
(selective recruitment or in situ conversion) is yet to be determined. 
Additionally, studies comparing the efficacy of different modes of macrophage 
activation, along with an improved understanding of the phenotypic fate of exogenous 
macrophages, may help to optimize macrophage-based therapies for healing of different 
tissues and bring these promising treatments closer to widespread clinical reality. 
Finally, from a translational perspective there is value in the ‘scaffold’ not 
containing biochemical elements so that the scaffold can be classified as a ‘device’ (instead 
of a ‘biologic’ or ‘combination’ product). However, given that the clinical gold standard, 
autografts, only achieve full functional recovery in 40% of the cases, it seems beneficial 
and rational to push the limits of our previously established biomimetic nanofibers-based 
scaffold by incorporating the studied immunoengineering approach to match or even 
exceed the performance of autografts. Future designs to combine biomimetic nanofiber 
approach with the immunoengineering strategy should be considered to investigate 
whether synergy between biochemical and topographical cues significantly enhances nerve 
guide function to the point that the need for autografts in bridging long gaps is obviated 
(Figure 7.1). It is important to note that accelerating regeneration of peripheral nerves, 
without any change in the nature or extent of regenerated fibers, would have significant 
clinical implications, as it would lessen the extent of atrophy of the distal muscle. We 
believe our immunoengineering strategy investigated here is compatible with the nanofiber 
enhanced nerve guide approach, and if successful, would add a new ‘arm’ to the current 
approaches for inducing repair across long gaps.  
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Figure 7.1: Next generation of nerve conduit which includes both topographical and 
immunomodulatory cues. The black lines on the blue substrate represents the aligned 
nanofiber film which provides topographical cues for the SCs infiltration and red tubes 
represent the lipid microtubes containing immunomodulatory factor (e.g. IL-4, 
Fractalkine, or etc.) which provides biochemical and immunomodulatory cues.  
 
 
 
 
 
 
 
 
 
 
 
Table 7-1 represents the areas that needs to be studied in future works. There are 3 main 
categories that require more in-depth studies following the work in this thesis: 1- Cellular 
analyses; in the context of macrophage modulation using factors such as IL-4, it is 
necessary to investigate if the observed regenerative effect is due to macrophage 
polarization or enhancement in in situ proliferation of anti-inflammatory macrophages. In 
the context of reparative monocyte recruitment, it is essential to execute acute studies to 
show that we preferentially recruited reparative monocytes using chemokine Fractalkine. 
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2- Functional analyses; in order to show that this study is clinically meaningful, it is 
important to demonstrate functional data for reinnervated nerves. Electroneurography and 
Electromyography need to be done at later time points after applying these 
immunomodulatory molecules in order to assess the functional recovery of damaged nerve. 
3- More clinically relevant models; the majority of nerve damages require delayed 
intervention rather than acute and it is clinically relevant to investigate the capability of our 
approach for those cases. We believe our intervention represents an upstream approach that 
can be applied to other injured tissues and maybe even regeneration of the whole organ. 
Salamanders have the remarkable ability to regenerate complex structures such as limbs, 
tails, retina, and spinal cord, along with some sections of the heart and brain, during any 
stage of their life cycle and recently it has been shown that macrophages are the key player 
in enabling salamander to regenerate itself [103]. Now the question is, can we use the 
immunomodulatory approach represented here in order to mimic the regenerative 
capability of salamanders for other mammals and particularly humans?  
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Table 7-1: Proposed areas for future studies 
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APPENDIX 
A.1. Cytokine Release Profile from Scaffold 
Polysulfone tubes filled with 0.7% Agarose (SeaPrep Lonza) mixed with 1 μg/ml 
rat recombinant cytokine IFN-γ. The two ends of the 17 mm tubes were closed to mimic 
the effect of suturing in vivo.  Then the tubes were incubated in 1 L PBS at 37oC and 
removed from the PBS at 8, 24, 48 and 72 hr (n=4) and kept at -20oC. After the final time 
point, all the tubes were slowly equilibrated to the room temperature, were cut and put 
inside the 24-wells plate containing 100k NR8383 macrophages. The amount of nitrite 
produced by macrophages treated with the tubes was measured using the Griess reagent 
system. Since macrophages exposed to IFN- γ become inflammatory and produce nitrite, 
this number were used as an indicator for the residual IFN- γ remained in the tubes after 
different incubation time in the PBS (Fig S2). 
 
 
 
 
 
 
 
 
 
 119 
 
 
Figure 7.2: Release of IFNγ from the 0.7% based on nitrite production of macrophages.  
Agarose/Polysulfone tube is measured by adding the tube containing initial 1ug/ml 
concentration of IFN-γ incubated in 37oC PBS at different time points. 
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A.2. Macrophage Phenotype Verification 
A.2.1. Quantitative Analysis of Nitrite Production of Macrophages 
Griess reagent system (Promega) were used to quantify the amount of nitrite 
production of activated macrophages. The serum-free media of macrophages (F12k) 
treated with cytokines (20 (or 80) ng/mL IL-4 or 20 (or 80) ng/mL IFN-γ + 100 ng/mL 
LPS) were changed with fresh media and amount of  NO2
- in the media were measured 
after 24 hr (Figure 7.3). 
A.2.2. RNA Extraction and qRT-PCR Analysis of Macrophages 
Total RNA was extracted from cell pellets obtained from the untreated 
macrophages or macrophages treated with IFN-γ +LPS or IL-4 cytokines using the Qiagen 
RNEasy Mini Kit (Qiagen, Valencia, CA). Extracted total RNA was quantified using the 
Quant-iT RiboGreen RNA Reagent and Kit (Invitrogen). Two micrograms of the total 
RNA was converted to cDNA using a highcapacity cDNA reverse transcription kit 
(Applied Biosystems, Foster City, CA). PCR primers were designed (Table 7-2) using 
Primer Express® software (Applied Biosystems) and obtained from Integrated DNA 
Technologies (Coralville, IA). Primer validation and qRT-PCR using SYBR green mix 
(Applied Biosystems) was conducted on a StepOnePlus real-time PCR machine (Applied 
Biosystems) according to methods previously published [231,232]. All qRT-PCR reactions 
were performed in triplicates and fold differences for each target gene using comparative 
CT method were normalized controls (untreated macrophages), and the relative fold 
change was calculated by normalizing against the endogenous reference, housekeeping, 
hypoxanthine phosphoribosyltransferase 1 (HpRT1) gene. 
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Figure 7.3: Effect of two different concentration of IL-4 and IFNγ on rat aleveloar 
macrophages to secrete nitrite.  
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A.3. Schwann Cells Analysis 
A.3.1. RNA Extraction and qRT-PCR Analysis of Schwann Cells (SC) 
Same method as macrophages were used for SC too. However here the conditions 
were SC treated with conditioned media (CM) from IL-4 or IFN-γ+ LPS macrophages and 
the control was SC treated with CM from untreated macrophages. PCR primers were 
designed for the genes of interest (Table 7-3) and Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as the endogenous reference gene (Fig. S3). 
A.3.2. Transfection of RSC-96 Cells with Green Fluorescent Protein (GFP) 
RSC-96  Schwann cells were grown in DMEM supplemented with 10% FBS.  For 
transfection, cells were seeded the previous day to achieve 70% confluence in tissue culture 
dishes.  The cells were transfected with pEGFP-C1(Clontech) using Effectene (Qiagen) as 
per the manufacturer’s protocol.  The transfected cells were allowed to grow for an 
additional 60 h at which point they were dissociated using Trypsin-EDTA and seeded in 
multi-well culture plates to achieve one cell/well.  For selection, the growth medium was 
supplemented with G418 (Gemini Bio-Products) at a concentration of 500 µg/ml and added 
to the cultures.  The cultures were routinely monitored microscopically for growth as well 
as for GFP expression.  Cultures exhibiting high level of fluorescence were further 
expanded to generate the cell line that is used in the study. 
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Table 7-2: Primer sets for qRT-PCR of macrophages 
 
 
 
 
Table 7-3: Primer sets for qRT-PCR of Schwann Cell 
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Figure 7.4: Boyden Chamber Schematic. Schematic representing the Boyden Chamber 
(BC) system used to analyze SC migration. SCs were cultured on the top of the insert 
(green cells) and polarized macrophages at the bottom of the well. Right image 
demonstrated the SEM image of SC crawling toward the holes of BC insert.  
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A.4. List of Genes Profiled by Neurotrophins and Receptor PCR Array 
A.4.1. Neurotrophins and Receptors:  
Adcyap1r1, Artn, Bdnf, Cntf, Cntfr, Crh, Crhbp, Crhr1, Crhr2, Frs2, Frs3, Gdnf, Gfra1, 
Gfra2, Gfra3, Gmfb, Gmfg, Hcrtr1, Hcrtr2, Mt3, Ngf, Ngfr, Ngfrap1, Nr1i2, Nrg1 (Hgl), 
Nrg2, Ntf3, Ntf4, Ntrk1, Ntrk2, Pspn, Ptger2, Tfg, Cd40 (Tnfrsf5), Fas (Tnfrsf6), Ucn, 
Vgf, Zfp110, Zfp91. 
A.4.2. Neuropeptides and Receptors:  
Galanin Receptors: Galr1, Galr2. 
Neuropeptide Y Receptors: Npy1r, Npy2r, Ppyr1. 
Other Neuropeptides and Receptors: Cckar, Grpr, Npffr2 (Gpr74), Ntsr1, Hcrt, Mc2r, 
Npy, Nrg1 (Hgl), Tacr1. 
A.4.3. Neurogenesis:  
Central Nervous System Development: Cxcr4, Fgfr1, Ngfr, Ntf3. 
Peripheral Nervous System Development: Artn, Gdnf, Gfra3, Ngf, Nrg1 (Hgl), Ntf3. 
Axon Guidance: Artn, Gfra3, Ngfr. 
Gliogenesis: Fgf2 (bFGF), Nrg1 (Hgl), Ntf3. 
Dendrite Morphogenesis: Bdnf, Mt3. 
Other Neurogenesis Genes: Bax, Fos, Cbln1, Galr2, Gfra1, Gfra2, Nell1, Ntf4, Ntrk1, 
Ntrk2. 
A.4.4. Cell Growth and Differentiation:  
Growth Factors and Receptors: Artn, Bdnf, Fgf2 (bFGF), Fgf9, Fgfr1, Gdnf, Gmfb, 
Gmfg, Il10, Il1b, Il6, Lif, Mt3, Ngf, Nrg2, Ntf3, Ntf4, Pspn, Tgfa, Tgfb1, Tgfb1i1, Tp53, 
Vgf. 
Cell Cycle: Fgf2 (bFGF), Fgf9, Il1b, Ntrk1, Tgfa, Tgfb1, Tp53. 
Cell Proliferation: Bax, Cxcr4, Fgf2 (bFGF), Fgf9, Grpr, Il10, Il1b, Myc, Stat4, Tgfa, 
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Tgfb1, Tp53. 
Cell Differentiation: Cntf, Fgf2 (bFGF), Fgf9, Nf1, Nrg1 (Hgl), Stat3, Tp53, Zfp91. 
A.4.5. Cytokines and Receptors:  
Cx3cr1, Cxcr4, Il10, Il10ra, Il1b, Il1r1, Il6, Il6r, Il6st (Gp130), Lif, Lifr,. 
A.4.6. Apoptosis:  
Bax, Bcl2, Bdnf, Cd40 (Tnfrsf5), Hspb1 (Hsp27), Il10, Il6, Myc, Ngfr, Ngfrap1, Fas 
(Tnfrsf6), Tp53. 
A.4.7. Inflammatory Response:  
Il10, Il1b, Il6, Stat3, Tgfb1. 
A.4.8. Immune Response: 
Il10, Cd40 (Tnfrsf5), Lif, Fas (Tnfrsf6). 
A.4.9. Transcription Factors and Regulators:  
Fos, Fus, Maged1, Myc, Nr1i2, Ntf3, Stat1, Stat2, Stat3, Stat4, Tp53, Tgfb1i1, Zfp110. 
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A.5. List of Genes Profiled by Common Cytokines and Chemokines PCR Array 
A.5.1. Interferons:  
Ifna1, Ifna2, Ifna4, Ifnb1, Ifng, LOC690891 (Ifna5). 
A.5.2. Interleukins:  
Il10, Il11, Il12a, Il12b, Il13, Il15, Il16, Il17b, Il17f, Il18, Il19, Il1a, Il1b, Il1f10, Il1f5, 
Il1f6, Il1f8, Il1rn, Il2, Il21, Il24, Il3, Il4, Il5, Il6, Il7, Il9, Il17a (Il17), Il20, Il22, Il27, 
Il1f9. 
A.5.3. Bone Morphogenic Proteins (BMPs) and TGF-ß Family:  
Bmp1, Bmp10, Bmp2, Bmp3, Bmp4, Bmp5, Bmp6, Bmp7, Gdf1, Gdf10, Gdf11, Gdf15, 
Gdf5, Mstn, Gdf9, Inha, Inhba, LOC306312 (Gdf2), Gdf3. 
A.5.4. TNF Superfamily:  
Cd70 (Tnfsf7), Tnfsf13b, Lta, Ltb, Tnf, Tnfrsf11b, Tnfsf10, Tnfsf11, Tnfsf12, Tnfsf13, 
Tnfsf15, Tnfsf18, Tnfsf4, Cd40lg (Tnfsf5), Faslg (Tnfsf6), Tnfsf9. 
A.5.5. Other Growth Factors/Cytokines:  
Csf1, Csf2, Ctf1, Ctf2, Fgf10, Lif, Fbrs, Mif, Nodal, Scgb3a1, Aimp1. 
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A.6. Effect of IL-19 on SC phenotype 
 
 
Figure 7.5: Effect of IL-19 treatment (500 ng/mL) on gene expression level of RSCs. 
IL-19 enhances MPZ which is the myelin precursor gene as well as NGFr which is the 
Nerve Growth Factor (NGF) receptor gene. 
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A.7. Correlation Between Regeneration and Macrophage Phenotype in other 
Scaffolds 
 
 
 
Figure 7.6: The panel of images demonstrating status of immune response and 
regeneration at the distal end of other scaffolds. S100 stains for SCs, ED1 for 
macrophages, CD206 for anti-inflammatory, and CD80 for inflammatory cells. All 
images are captured from the sections at the distal end of the scaffold. Autograft and 
Integra represent the clinical gold standard and commercially available tube, 
respectively.  
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Figure 7.7: The correlation between number of SCs at the distal end of the scaffold and 
ratio of pro- to anti-inflammatory immune cells. SCs number demonstrates an inverse 
correlation to the ratio of pro- to anti-inflammatory immune cells both at the distal and 
proximal end of the scaffold.  The left axis represent total fluorescently positive area in 
µm2. 
 
 
 
 
 
 
 
 131 
REFERENCES 
[1] Thanos PK, Okajima S, Terzis JK. Ultrastructure and cellular biology of nerve 
regeneration. J Reconstr Microsurg 1998;14:423–36. 
[2] Terzis JK, Sun DD, Thanos PK. Historical and basic science review: past, present, 
and future of nerve repair. J Reconstr Microsurg 1997;13:215–25. 
[3] Mukhatyar V, Karumbaiah L, Yeh J, Bellamkonda R. Tissue Engineering Strategies 
Designed to Realize the Endogenous Regenerative Potential of Peripheral Nerves. 
Adv Mater 2009;19:4670–9. 
[4] Bellamkonda R V. Peripheral nerve regeneration: an opinion on channels, scaffolds 
and anisotropy. Biomaterials 2006;27:3515–8. 
[5] Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and 
regeneration. Nature 2008;453:314–21. 
[6] Ferguson MWJ, O’Kane S. Scar-free healing: from embryonic mechanisms to adult 
therapeutic intervention. Philos Trans R Soc Lond B Biol Sci 2004;359:839–50. 
[7] Yiu G, He Z. Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 
2006;7:617–27. 
[8] Odelberg SJ. Unraveling the molecular basis for regenerative cellular plasticity. 
PLoS Biol 2004;2:E232. 
[9] Belmadani A, Tran PB, Ren D, Miller RJ. Chemokines regulate the migration of 
neural progenitors to sites of neuroinflammation. J Neurosci 2006;26:3182. 
 132 
[10] Harty M, Neff AW, King MW, Mescher AL. Regeneration or scarring: an 
immunologic perspective. Dev Dyn 2003;226:268–79. 
[11] Nodder S, Martin P. Wound healing in embryos: a review. Anat Embryol (Berl) 
1997;195:215–28. 
[12] Gurtner GC, Callaghan MJ, Longaker MT. Progress and potential for regenerative 
medicine. Annu Rev Med 2007;58:299–312. 
[13] DiPietro LA. Wound healing: the role of the macrophage and other immune cells. 
Shock 1995;4:233–40. 
[14] Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and 
disease. Br J Pharmacol 2006;147:S232–40. 
[15] Donnelly DJ, Popovich PG. Inflammation and its role in neuroprotection, axonal 
regeneration and functional recovery after spinal cord injury. Exp Neurol 
2008;209:378–88. 
[16] Wilgus TA. Immune cells in the healing skin wound: influential players at each stage 
of repair. Pharmacol Res 2008;58:112–6. 
[17] Baum CL, Arpey CJ. Normal cutaneous wound healing: clinical correlation with 
cellular and molecular events. Dermatologic Surg 2005;31:674–86. 
[18] Eubank TD, Marsh CB. Cytokines and Growth Factors in the Regulation of Wound 
Inflammation. Adv Wound Care 2010;1:211–6. 
[19] Cameron B, Landreth GE. Inflammation, microglia, and alzheimer’s disease. 
Neurobiol Dis 2009;37:503–9. 
 133 
[20] Colton CA. Heterogeneity of microglial activation in the innate immune response in 
the brain. J Neuroimmune Pharmacol 2009;4:399–418. 
[21] Butovsky O, Ziv Y, Schwartz A, Landa G, Talpalar AE, Pluchino S, et al. Microglia 
activated by IL-4 or IFN-[gamma] differentially induce neurogenesis and 
oligodendrogenesis from adult stem/progenitor cells. Mol Cell Neurosci 
2006;31:149–60. 
[22] Mountziaris PM, Mikos AG. Modulation of the inflammatory response for enhanced 
bone tissue regeneration. Tissue Eng Part B Rev 2008;14:179–86. 
[23] Butovsky O, Talpalar AE, Ben-Yaakov K, Schwartz M. Activation of microglia by 
aggregated [beta]-amyloid or lipopolysaccharide impairs MHC-II expression and 
renders them cytotoxic whereas IFN-[gamma] and IL-4 render them protective. Mol 
Cell Neurosci 2005;29:381–93. 
[24] Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JPY. TNF 
promotes proliferation of oligodendrocyte progenitors and remyelination. Nat 
Neurosci 2001;4:1116–22. 
[25] Belmadani A, Tran PB, Ren D, Miller RJ. Chemokines regulate the migration of 
neural progenitors to sites of neuroinflammation. J Neurosci 2006;26:3182. 
[26] Cashen AF, Lazarus HM, Devine SM. Mobilizing stem cells from normal donors: 
is it possible to improve upon G-CSF? Bone Marrow Transplant 2007;39:577–88. 
[27] To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of 
blood stem cells. Blood 1997;89:2233–58. 
 134 
[28] Yan YP, Sailor KA, Lang BT, Park SW, Vemuganti R, Dempsey RJ. Monocyte 
chemoattractant protein-1 plays a critical role in neuroblast migration after focal 
cerebral ischemia. J Cereb Blood Flow Metab 2006;27:1213–24. 
[29] Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and 
the Th1/Th2 paradigm. J Immunol 2000;164:6166–73. 
[30] Mosser DM. The many faces of macrophage activation. J Leukoc Biol 2003;73:209–
12. 
[31] Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 
2005;5:953–64. 
[32] Edwards JP, Zhang X, Frauwirth KA, Mosser DM. Biochemical and functional 
characterization of three activated macrophage populations. J Leukoc Biol 
2006;80:1298–307. 
[33] Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat 
Rev Immunol 2008;8:958–69. 
[34] Krarup C, Archibald SJ, Madison RD. Factors that influence peripheral nerve 
regeneration: an electrophysiological study of the monkey median nerve. Ann 
Neurol 2002;51:69–81. 
[35] Höke A, Brushart T. Introduction to special issue: Challenges and opportunities for 
regeneration in the peripheral nervous system. Exp Neurol 2010;223:1–4. 
[36] Verdú E, Ceballos D, Vilches JJ, Navarro X. Influence of aging on peripheral nerve 
function and regeneration. J Peripher Nerv Syst 2000;5:191–208. 
 135 
[37] Fu SY, Gordon T. Contributing factors to poor functional recovery after delayed 
nerve repair: prolonged denervation. J Neurosci 1995;15:3886. 
[38] Fu SY, Gordon T. The cellular and molecular basis of peripheral nerve regeneration. 
Mol Neurobiol 1997;14:67–116. 
[39] Groves ML, McKeon R, Werner E, Nagarsheth M, Meador W, English AW. Axon 
regeneration in peripheral nerves is enhanced by proteoglycan degradation. Exp 
Neurol 2005;195:278–92. 
[40] Zuo J, Hernandez YJ, Muir D. Chondroitin sulfate proteoglycan with neurite-
inhibiting activity is up-regulated following peripheral nerve injury. J Neurobiol 
1998;34:41–54. 
[41] Patel MN, McNamara JO. Selective enhancement of axonal branching of cultured 
dentate gyrus neurons by neurotrophic factors. Neuroscience 1995;69:763–70. 
[42] Kennedy TE, Tessier-Lavigne M. Guidance and induction of branch formation in 
developing axons by target-derived diffusible factors. Curr Opin Neurobiol 
1995;5:83–90. 
[43] Horner PJ, Gage FH. Regenerating the damaged central nervous system. Nature 
2000;407:963–70. 
[44] Richardson PM, McGuinness UM, Aguayo AJ. Axons from CNS neurons 
regenerate into PNS grafts. Nature 1980;284:264–5. 
[45] David S, Aguayo AJ. Axonal elongation into peripheral nervous system“ bridges” 
after central nervous system injury in adult rats. Science (80- ) 1981;214:931. 
[46] Siegel GJ. Basic neurochemistry. Little Brown and Company; 1981. 
 136 
[47] Schwab ME, Thoenen H. Dissociated neurons regenerate into sciatic but not optic 
nerve explants in culture irrespective of neurotrophic factors. J Neurosci 
1985;5:2415. 
[48] Vargas ME, Barres BA. Why is Wallerian degeneration in the CNS so slow? Annu 
Rev Neurosci 2007;30:153–79. 
[49] Barres BA, Jacobson MD, Schmid R, Sendtner M, Raff MC. Does oligodendrocyte 
survival depend on axons? Curr Biol 1993;3:489–97. 
[50] Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: 
hiding in plain sight. Immunol Rev 2006;213:48–65. 
[51] Galea I, Bechmann I, Perry VH. What is immune privilege (not)? Trends Immunol 
2007;28:12–8. 
[52] Gage FH. Mammalian neural stem cells. Science 2000;287:1433–8. 
[53] Gaiano N, Fishell G. Transplantation as a tool to study progenitors within the 
vertebrate nervous system. J Neurobiol 1998;36:152–61. 
[54] Nakatomi H, Kuriu T, Okabe S, Yamamoto S, Hatano O, Kawahara N, et al. 
Regeneration of hippocampal pyramidal neurons after ischemic brain injury by 
recruitment of endogenous neural progenitors. Cell 2002;110:429–41. 
[55] McDonald JW, Liu XZ, Qu Y, Liu S, Mickey SK, Turetsky D, et al. Transplanted 
embryonic stem cells survive, differentiate and promote recovery in injured rat 
spinal cord. Nat Med 1999;5:1410–2. 
[56] Vescovi AL, Parati EA, Gritti A, Poulin P, Ferrario M, Wanke E, et al. Isolation and 
Cloning of Multipotential Stem Cells from the Embryonic Human CNS and 
 137 
Establishment of Transplantable Human Neural Stem Cell Lines by Epigenetic 
Stimulation* 1. Exp Neurol 1999;156:71–83. 
[57] Keirstead HS. Stem cell transplantation into the central nervous system and the 
control of differentiation. J Neurosci Res 2001;63:233–6. 
[58] Folkman J, Klagsbrun M. Angiogenic factors. Science (80- ) 1987;235:442–7. 
[59] Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-
specific growth factors and blood vessel formation. Nature 2000;407:242–8. 
[60] Hobson MI, Green CJ, Terenghi G. VEGF enhances intraneural angiogenesis and 
improves nerve regeneration after axotomy. J Anat 2001;197:591–605. 
[61] Gratchev A, Kzhyshkowska J, Köthe K, Muller-Molinet I, Kannookadan S, Utikal 
J, et al. M [phi] 1 and M [phi] 2 can be re-polarized by Th2 or Th1 cytokines, 
respectively, and respond to exogenous danger signals. Immunobiology 
2006;211:473–86. 
[62] Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J. Macrophages 
sequentially change their functional phenotype in response to changes in 
microenvironmental influences. J Immunol 2005;175:342–9. 
[63] Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate 
immunity. Trends Immunol 2007;28:138–45. 
[64] Liu Y, Teige I, Birnir B, Issazadeh-Navikas S. Neuron-mediated generation of 
regulatory T cells from encephalitogenic T cells suppresses EAE. Nat Med 
2006;12:518–25. 
 138 
[65] Herz J, Zipp F, Siffrin V. Neurodegeneration in autoimmune CNS inflammation. 
Exp Neurol 2010;225:9–17. 
[66] Noël W, Raes G, Hassanzadeh Ghassabeh G, De Baetselier P, Beschin A. 
Alternatively activated macrophages during parasite infections. Trends Parasitol 
2004;20:126–33. 
[67] Schwartz M, Butovsky O, Brück W, Hanisch UK. Microglial phenotype: is the 
commitment reversible? Trends Neurosci 2006;29:68–74. 
[68] Shaked I, Tchoresh D, Gersner R, Meiri G, Mordechai S, Xiao X, et al. Protective 
autoimmunity: interferon- enables microglia to remove glutamate without evoking 
inflammatory mediators. J Neurochem 2005;92:997–1009. 
[69] Brück W, Brück Y, Friede RL. TNF-[alpha] suppresses CR3-mediated myelin 
removal by macrophages. J Neuroimmunol 1992;38:9–17. 
[70] Saha RN, Liu X, Pahan K. Up-regulation of BDNF in astrocytes by TNF- : a case 
for the neuroprotective role of cytokine. J Neuroimmune Pharmacol 2006;1:212–22. 
[71] O’Kusky JR, Ye P, D’Ercole AJ. Insulin-like growth factor-I promotes neurogenesis 
and synaptogenesis in the hippocampal dentate gyrus during postnatal development. 
J Neurosci 2000;20:8435–42. 
[72] Deonarine K, Panelli MC, Stashower ME, Jin P, Smith K, Slade HB, et al. Gene 
expression profiling of cutaneous wound healing. J Transl Med 2007;5:11. 
[73] Lichtenwalner RJ, Forbes ME, Bennett SA, Lynch CD, Sonntag WE, Riddle DR. 
Intracerebroventricular infusion of insulin-like growth factor-I ameliorates the age-
related decline in hippocampal neurogenesis. Neuroscience 2001;107:603–13. 
 139 
[74] Napoli I, Neumann H. Protective effects of microglia in multiple sclerosis. Exp 
Neurol 2009;225:24–8. 
[75] McNeeley KM, Karathanasis E, Annapragada A V, Bellamkonda R V. Masking and 
triggered unmasking of targeting ligands on nanocarriers to improve drug delivery 
to brain tumors. Biomaterials 2009;30:3986–95. 
[76] Kim Y-T, Haftel VK, Kumar S, Bellamkonda R V. The role of aligned polymer 
fiber-based constructs in the bridging of long peripheral nerve gaps. Biomaterials 
2008;29:3117–27. 
[77] Dodla MC, Bellamkonda R V. Differences between the effect of anisotropic and 
isotropic laminin and nerve growth factor presenting scaffolds on nerve regeneration 
across long peripheral nerve gaps. Biomaterials 2008;29:33–46. 
[78] Jain A, Kim YT, McKeon RJ, Bellamkonda R V. In situ gelling hydrogels for 
conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord 
injury. Biomaterials 2006;27:497–504. 
[79] Lee SK, Wolfe SW. Peripheral nerve injury and repair. J Am Acad Orthop Surg 
2000;8:243–52. 
[80] Jenq CB, Coggeshall RE. Sciatic nerve regeneration after autologous sural nerve 
transplantation in the rat. Brain Res 1987;406:52–61. 
[81] Millesi H. Factors affecting the outcome of peripheral nerve surgery. Microsurgery 
2006;26:295–302. 
 140 
[82] Fine EG, Decosterd I, Papaloïzos M, Zurn AD, Aebischer P. GDNF and NGF 
released by synthetic guidance channels support sciatic nerve regeneration across a 
long gap. Eur J Neurosci 2002;15:589–601. 
[83] Lee AC, Yu VM, Lowe JB, Brenner MJ, Hunter DA, Mackinnon SE, et al. 
Controlled release of nerve growth factor enhances sciatic nerve regeneration. Exp 
Neurol 2003;184:295–303. 
[84] Rodríguez FJ, Verdú E, Ceballos D, Navarro X. Nerve guides seeded with 
autologous Schwann cells improve nerve regeneration. Exp Neurol 2000;161:571–
84. 
[85] Nie X, Zhang YJ, Tian WD, Jiang M, Dong R, Chen JW, et al. Improvement of 
peripheral nerve regeneration by a tissue-engineered nerve filled with 
ectomesenchymal stem cells. Int J Oral Maxillofac Surg 2007;36:32–8. 
[86] Clements IP, Kim Y, English AW, Lu X, Chung A, Bellamkonda R V. Thin-film 
enhanced nerve guidance channels for peripheral nerve repair. Biomaterials 
2009;30:3834–46. 
[87] Hoffman-Kim D, Mitchel JA, Bellamkonda R V. Topography, cell response, and 
nerve regeneration. Annu Rev Biomed Eng 2010;12:203–31. 
[88] Mukhatyar VJ, Salmerón-Sánchez M, Rudra S, Mukhopadaya S, Barker TH, García 
AJ, et al. Role of fibronectin in topographical guidance of neurite extension on 
electrospun fibers. Biomaterials 2011;32:3958–68. 
[89] Yu X, Bellamkonda R V. Tissue-engineered scaffolds are effective alternatives to 
autografts for bridging peripheral nerve gaps. Tissue Eng 2003;9:421–30. 
 141 
[90] Crompton KE, Goud JD, Bellamkonda R V, Gengenbach TR, Finkelstein DI, Horne 
MK, et al. Polylysine-functionalised thermoresponsive chitosan hydrogel for neural 
tissue engineering. Biomaterials 2007;28:441–9. 
[91] Rodero MP, Khosrotehrani K. Skin wound healing modulation by macrophages. Int 
J Clin Exp Pathol 2010;3:643–53. 
[92] Badylak SF, Valentin JE, Ravindra AK, McCabe GP, Stewart-Akers AM. 
Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue 
Eng Part A 2008;14:1835–42. 
[93] David S, Kroner A. Repertoire of microglial and macrophage responses after spinal 
cord injury. Nat Rev Neurosci 2011;12:388–99. 
[94] Deonarine K, Panelli MC, Stashower ME, Jin P, Smith K, Slade HB, et al. Gene 
expression profiling of cutaneous wound healing. J Transl Med 2007;5:11. 
[95] Gaudet AD, Popovich PG, Ramer MS. Wallerian degeneration: gaining perspective 
on inflammatory events after peripheral nerve injury. J Neuroinflammation 
2011;8:110. 
[96] Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and 
angiogenesis. J Leukoc Biol 1994;55:410–22. 
[97] Chazaud B, Brigitte M, Yacoub-Youssef H, Arnold L, Gherardi R, Sonnet C, et al. 
Dual and beneficial roles of macrophages during skeletal muscle regeneration. Exerc 
Sport Sci Rev 2009;37:18–22. 
[98] Novak ML, Koh TJ. Phenotypic transitions of macrophages orchestrate tissue repair. 
Am J Pathol 2013;183:1352–63. 
 142 
[99] Dong L, Wang C. Harnessing the power of macrophages/monocytes for enhanced 
bone tissue engineering. Trends Biotechnol 2013;31:342–6. 
[100] Niemi JP, DeFrancesco-Lisowitz A, Roldan-Hernandez L, Lindborg JA, Mandell D, 
Zigmond RE. A Critical Role for Macrophages Near Axotomized Neuronal Cell 
Bodies in Stimulating Nerve Regeneration. J Neurosci 2013;33:16236–48. 
[101] DeFrancesco-Lisowitz a, Lindborg J a, Niemi JP, Zigmond RE. The 
neuroimmunology of degeneration and regeneration in the peripheral nervous 
system. Neuroscience 2014:In Press. 
[102] Brown MC, Lunn ER, Perry VH. Consequences of slow Wallerian degeneration for 
regenerating motor and sensory axons. J Neurobiol 1992;23:521–36. 
[103] Godwin JW, Pinto AR, Rosenthal N a. Macrophages are required for adult 
salamander limb regeneration. Proc Natl Acad Sci 2013;110:9415–20. 
[104] Goh YPS, Henderson NC, Heredia JE, Red Eagle A, Odegaard JI, Lehwald N, et al. 
Eosinophils secrete IL-4 to facilitate liver regeneration. Proc Natl Acad Sci U S A 
2013;110:9914–9. 
[105] Mirza R, DiPietro LA, Koh TJ. Selective and specific macrophage ablation is 
detrimental to wound healing in mice. Am J Pathol 2009;175:2454–62. 
[106] Gerstein AD, Phillips TJ, Rogers GS, Gilchrest BA. Wound healing and aging. 
Dermatol Clin 1993;11:749–57. 
[107] Redd MJ, Cooper L, Wood W, Stramer B, Martin P. Wound healing and 
inflammation: embryos reveal the way to perfect repair. Philos Trans R Soc Lond B 
Biol Sci 2004;359:777–84. 
 143 
[108] Mokarram N, Bellamkonda R V. Overcoming endogenous constraints on neuronal 
regeneration. IEEE Trans Biomed Eng 2011;58:1900–6. 
[109] Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth 
factors and cytokines in wound healing. Wound Repair Regen 2008;16:585–601. 
[110] Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of 
monocytes, macrophages, and dendritic cells. Science 2010;327:656–61. 
[111] Tsou C-L, Peters W, Si Y, Slaymaker S, Aslanian AM, Weisberg SP, et al. Critical 
roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and 
recruitment to inflammatory sites. J Clin Invest 2007;117:902–9. 
[112] Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, et al. 
Local macrophage proliferation, rather than recruitment from the blood, is a 
signature of TH2 inflammation. Science 2011;332:1284–8. 
[113] Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat 
Rev Immunol 2011;11:762–74. 
[114] Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo J-
LL, et al. The healing myocardium sequentially mobilizes two monocyte subsets 
with divergent and complementary functions. J Exp Med 2007;204:3037–47. 
[115] Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine 
system in diverse forms of macrophage activation and polarization. Trends Immunol 
2004;25:677–86. 
[116] Park JE, Barbul A. Understanding the role of immune regulation in wound healing. 
Am J Surg 2004;187:11S – 16S. 
 144 
[117] Brown BN, Badylak SF. Expanded applications, shifting paradigms and an 
improved understanding of host-biomaterial interactions. Acta Biomater 
2013;9:4948–55. 
[118] Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity 
and polarization in tissue repair and remodelling. J Pathol 2013;229:176–85. 
[119] Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23–35. 
[120] Harel-Adar T, Ben Mordechai T, Amsalem Y, Feinberg MS, Leor J, Cohen S. 
Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes 
improves infarct repair. Proc Natl Acad Sci U S A 2011;108:1827–32. 
[121] Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection 
and inflammation. J Leukoc Biol 2007;81:584–92. 
[122] Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, 
heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 
2009;27:669–92. 
[123] Lucas T, Waisman A, Ranjan R, Roes J, Krieg T, Müller W, et al. Differential roles 
of macrophages in diverse phases of skin repair. J Immunol 2010;184:3964–77. 
[124] Tidball JG, Wehling-Henricks M. Macrophages promote muscle membrane repair 
and muscle fibre growth and regeneration during modified muscle loading in mice 
in vivo. J Physiol 2007;578:327–36. 
[125] Porcheray F, Viaud S, Rimaniol A-C, Léone C, Samah B, Dereuddre-Bosquet N, et 
al. Macrophage activation switching: an asset for the resolution of inflammation. 
Clin Exp Immunol 2005;142:481–9. 
 145 
[126] Stout RD, Suttles J. Functional plasticity of macrophages: reversible adaptation to 
changing microenvironments. J Leukoc Biol 2004;76:509–13. 
[127] Bellingan GJ, Xu P, Cooksley H, Cauldwell H, Shock A, Bottoms S, et al. Adhesion 
molecule-dependent mechanisms regulate the rate of macrophage clearance during 
the resolution of peritoneal inflammation. J Exp Med 2002;196:1515–21. 
[128] Brown BN, Ratner BD, Goodman SB, Amar S, Badylak SF. Macrophage 
polarization: an opportunity for improved outcomes in biomaterials and regenerative 
medicine. Biomaterials 2012;33:3792–802. 
[129] Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. 
Identification of two distinct macrophage subsets with divergent effects causing 
either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 
2009;29:13435–44. 
[130] Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune 
system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol 
2010;298:R1173–87. 
[131] Summan M, Warren GL, Mercer RR, Chapman R, Hulderman T, Van Rooijen N, et 
al. Macrophages and skeletal muscle regeneration: a clodronate-containing 
liposome depletion study. Am J Physiol Regul Integr Comp Physiol 
2006;290:R1488–95. 
[132] Fraccarollo D, Galuppo P, Bauersachs J. Novel therapeutic approaches to post-
infarction remodelling. Cardiovasc Res 2012;94:293–303. 
[133] Chien KR, Domian IJ, Parker KK. Cardiogenesis and the complex biology of 
regenerative cardiovascular medicine. Science 2008;322:1494–7. 
 146 
[134] Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct 
inflammation and repair after myocardial infarction. Circulation 2010;121:2437–45. 
[135] Leuschner F, Rauch PJ, Ueno T, Gorbatov R, Marinelli B, Lee WW, et al. Rapid 
monocyte kinetics in acute myocardial infarction are sustained by extramedullary 
monocytopoiesis. J Exp Med 2012;209:123–37. 
[136] Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T, et al. 
CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses 
critical to healing myocardial infarcts. Circ Res 2005;96:881–9. 
[137] Kaikita K, Hayasaki T, Okuma T, Kuziel W a, Ogawa H, Takeya M. Targeted 
deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after 
experimental myocardial infarction. Am J Pathol 2004;165:439–47. 
[138] Majmudar MD, Keliher EJ, Heidt T, Leuschner F, Truelove J, Sena BF, et al. 
Monocyte-directed RNAi targeting CCR2 improves infarct healing in 
atherosclerosis-prone mice. Circulation 2013;127:2038–46. 
[139] Leuschner F, Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G, et 
al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat 
Biotechnol 2011;29:1005–10. 
[140] Adamson R. Role of macrophages in normal wound healing: an overview. J Wound 
Care 2009;18:349–51. 
[141] Fadok VA, McDonald PP, Bratton DL, Henson PM. Regulation of macrophage 
cytokine production by phagocytosis of apoptotic and post-apoptotic cells. Biochem 
Soc Trans 1998;26:653–6. 
 147 
[142] Mahbub S, Deburghgraeve CR, Kovacs EJ. Advanced age impairs macrophage 
polarization. J Interf Cytokine Res 2012;32:18–26. 
[143] Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu 
Rev Physiol 2010;72:219–46. 
[144] Wehling M, Spencer MJ, Tidball JG. A nitric oxide synthase transgene ameliorates 
muscular dystrophy in mdx mice. J Cell Biol 2001;155:123–31. 
[145] Arnold L, Henry A, Poron F, Baba-Amer Y, van Rooijen N, Plonquet A, et al. 
Inflammatory monocytes recruited after skeletal muscle injury switch into 
antiinflammatory macrophages to support myogenesis. J Exp Med 2007;204:1057–
69. 
[146] Li Y-P. TNF-alpha is a mitogen in skeletal muscle. Am J Physiol Cell Physiol 
2003;285:C370–6. 
[147] Lolmede K, Campana L, Vezzoli M, Bosurgi L, Tonlorenzi R, Clementi E, et al. 
Inflammatory and alternatively activated human macrophages attract vessel-
associated stem cells, relying on separate HMGB1- and MMP-9-dependent 
pathways. J Leukoc Biol 2009;85:779–87. 
[148] Serrano AL, Baeza-Raja B, Perdiguero E, Jardí M, Muñoz-Cánoves P. Interleukin-
6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell 
Metab 2008;7:33–44. 
[149] Torrente Y, El Fahime E, Caron NJ, Del Bo R, Belicchi M, Pisati F, et al. Tumor 
necrosis factor-alpha (TNF-alpha) stimulates chemotactic response in mouse 
myogenic cells. Cell Transplant 2003;12:91–100. 
 148 
[150] Szalay K, Rázga Z, Duda E. TNF inhibits myogenesis and downregulates the 
expression of myogenic regulatory factors myoD and myogenin. Eur J Cell Biol 
1997;74:391–8. 
[151] Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, et al. Interleukin 
6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in 
interleukin 6 transgenic mice. J Clin Invest 1996;97:244–9. 
[152] St Pierre BA, Tidball JG. Differential response of macrophage subpopulations to 
soleus muscle reloading after rat hindlimb suspension. J Appl Physiol 1994;77:290–
7. 
[153] Strle K, McCusker RH, Tran L, King A, Johnson RW, Freund GG, et al. Novel 
activity of an anti-inflammatory cytokine: IL-10 prevents TNFalpha-induced 
resistance to IGF-I in myoblasts. J Neuroimmunol 2007;188:48–55. 
[154] Villalta SA, Nguyen HX, Deng B, Gotoh T, Tidball JG. Shifts in macrophage 
phenotypes and macrophage competition for arginine metabolism affect the severity 
of muscle pathology in muscular dystrophy. Hum Mol Genet 2009;18:482–96. 
[155] Villalta SA, Deng B, Rinaldi C, Wehling-Henricks M, Tidball JG. IFN-γ promotes 
muscle damage in the mdx mouse model of Duchenne muscular dystrophy by 
suppressing M2 macrophage activation and inhibiting muscle cell proliferation. J 
Immunol 2011;187:5419–28. 
[156] Williams LR, Longo FM, Powell HC, Lundborg G, Varon S. Spatial‐ temporal 
progress of peripheral nerve regeneration within a silicone chamber: Parameters for 
a bioassay. J Comp Neurol 1983;218:460–70. 
 149 
[157] Perkins N., Tracey D. Hyperalgesia due to nerve injury: role of neutrophils. 
Neuroscience 2000;101:745–57. 
[158] Mueller M, Leonhard C, Wacker K, Ringelstein EB, Okabe M, Hickey WF, et al. 
Macrophage response to peripheral nerve injury: the quantitative contribution of 
resident and hematogenous macrophages. Lab Investig 2003;83:175–85. 
[159] Griffin JW, George R, Ho T. Macrophage systems in peripheral nerves. A review. J 
Neuropathol Exp Neurol 1993;52:553–60. 
[160] Ydens E, Cauwels A, Asselbergh B, Goethals S, Peeraer L, Lornet G, et al. Acute 
injury in the peripheral nervous system triggers an alternative macrophage response. 
J Neuroinflammation 2012;9:176. 
[161] Janssens S, Burns K, Tschopp J, Beyaert R. Regulation of interleukin-1- and 
lipopolysaccharide-induced NF-kappaB activation by alternative splicing of 
MyD88. Curr Biol 2002;12:467–71. 
[162] Van den Bossche J, Bogaert P, van Hengel J, Guérin CJ, Berx G, Movahedi K, et al. 
Alternatively activated macrophages engage in homotypic and heterotypic 
interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes. 
Blood 2009;114:4664–74. 
[163] Vidal PM, Lemmens E, Dooley D, Hendrix S. The role of “anti-inflammatory” 
cytokines in axon regeneration. Cytokine Growth Factor Rev 2013;24:1–12. 
[164] Besser M, Wank R. Cutting edge: clonally restricted production of the neurotrophins 
brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune 
cells and Th1/Th2-polarized expression of their receptors. J Immunol 
1999;162:6303–6. 
 150 
[165] Uçeyler N, Tscharke A, Sommer C. Early cytokine gene expression in mouse CNS 
after peripheral nerve lesion. Neurosci Lett 2008;436:259–64. 
[166] Deboy C a, Xin J, Byram SC, Serpe CJ, Sanders VM, Jones KJ. Immune-mediated 
neuroprotection of axotomized mouse facial motoneurons is dependent on the IL-
4/STAT6 signaling pathway in CD4(+) T cells. Exp Neurol 2006;201:212–24. 
[167] De Simone R, Ambrosini E, Carnevale D, Ajmone-Cat MA, Minghetti L. NGF 
promotes microglial migration through the activation of its high affinity receptor: 
modulation by TGF-beta. J Neuroimmunol 2007;190:53–60. 
[168] Rolls A, Shechter R, Schwartz M. The bright side of the glial scar in CNS repair. 
Nat Rev Neurosci 2009;10:235–41. 
[169] Shechter R, London A, Varol C, Raposo C, Cusimano M, Yovel G, et al. Infiltrating 
blood-derived macrophages are vital cells playing an anti-inflammatory role in 
recovery from spinal cord injury in mice. PLoS Med 2009;6:e1000113. 
[170] Schwartz M. “Tissue-repairing” blood-derived macrophages are essential for 
healing of the injured spinal cord: from skin-activated macrophages to infiltrating 
blood-derived cells? Brain Behav Immun 2010;24:1054–7. 
[171] Gensel JC, Nakamura S, Guan Z, van Rooijen N, Ankeny DP, Popovich PG. 
Macrophages promote axon regeneration with concurrent neurotoxicity. J Neurosci 
2009;29:3956–68. 
[172] Bomstein Y, Marder JB, Vitner K, Smirnov I, Lisaey G, Butovsky O, et al. Features 
of skin-coincubated macrophages that promote recovery from spinal cord injury. J 
Neuroimmunol 2003;142:10–6. 
 151 
[173] Lazarov-Spiegler O, Solomon AS, Zeev-Brann AB, Hirschberg DL, Lavie V, 
Schwartz M. Transplantation of activated macrophages overcomes central nervous 
system regrowth failure. FASEB J 1996;10:1296–302. 
[174] Rapalino O, Lazarov-Spiegler O, Agranov E, Velan GJ, Yoles E, Fraidakis M, et al. 
Implantation of stimulated homologous macrophages results in partial recovery of 
paraplegic rats. Nat Med 1998;4:814–21. 
[175] Schwartz M, Yoles E. Immune-based therapy for spinal cord repair: autologous 
macrophages and beyond. J Neurotrauma n.d.;23:360–70. 
[176] Ziv Y, Avidan H, Pluchino S, Martino G, Schwartz M. Synergy between immune 
cells and adult neural stem/progenitor cells promotes functional recovery from 
spinal cord injury. Proc Natl Acad Sci U S A 2006;103:13174–9. 
[177] Brown BN, Londono R, Tottey S, Zhang L, Kukla KA, Wolf MT, et al. Macrophage 
phenotype as a predictor of constructive remodeling following the implantation of 
biologically derived surgical mesh materials. Acta Biomater 2012;8:978–87. 
[178] Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. 
Nat Rev Immunol 2011;11:723–37. 
[179] Fukano Y, Usui ML, Underwood RA, Isenhath S, Marshall AJ, Hauch KD, et al. 
Epidermal and dermal integration into sphere-templated porous poly(2-
hydroxyethyl methacrylate) implants in mice. J Biomed Mater Res A 
2010;94:1172–86. 
[180] Madden LR, Mortisen DJ, Sussman EM, Dupras SK, Fugate J a, Cuy JL, et al. 
Proangiogenic scaffolds as functional templates for cardiac tissue engineering. Proc 
Natl Acad Sci U S A 2010;107:15211–6. 
 152 
[181] Underwood RA, Usui ML, Zhao G, Hauch KD, Takeno MM, Ratner BD, et al. 
Quantifying the effect of pore size and surface treatment on epidermal incorporation 
into percutaneously implanted sphere-templated porous biomaterials in mice. J 
Biomed Mater Res A 2011;98:499–508. 
[182] Bryers JD, Giachelli CM, Ratner BD. Engineering biomaterials to integrate and 
heal: the biocompatibility paradigm shifts. Biotechnol Bioeng 2012;109:1898–911. 
[183] Bota PCS, Collie AMB, Puolakkainen P, Vernon RB, Sage EH, Ratner BD, et al. 
Biomaterial topography alters healing in vivo and monocyte/macrophage activation 
in vitro. J Biomed Mater Res A 2010;95:649–57. 
[184] Chen S, Jones JA, Xu Y, Low H-Y, Anderson JM, Leong KW. Characterization of 
topographical effects on macrophage behavior in a foreign body response model. 
Biomaterials 2010;31:3479–91. 
[185] Paul NE, Skazik C, Harwardt M, Bartneck M, Denecke B, Klee D, et al. 
Topographical control of human macrophages by a regularly microstructured 
polyvinylidene fluoride surface. Biomaterials 2008;29:4056–64. 
[186] Bartneck M, Heffels K-H, Pan Y, Bovi M, Zwadlo-Klarwasser G, Groll J. Inducing 
healing-like human primary macrophage phenotypes by 3D hydrogel coated 
nanofibres. Biomaterials 2012;33:4136–46. 
[187] Barth K a, Waterfield JD, Brunette DM. The effect of surface roughness on RAW 
264.7 macrophage phenotype. J Biomed Mater Res A 2013;101:2679–88. 
[188] Blakney AK, Swartzlander MD, Bryant SJ. The effects of substrate stiffness on the 
in vitro activation of macrophages and in vivo host response to poly(ethylene 
glycol)-based hydrogels. J Biomed Mater Res A 2012;100:1375–86. 
 153 
[189] Franz S, Rammelt S, Scharnweber D, Simon JC. Immune responses to implants - a 
review of the implications for the design of immunomodulatory biomaterials. 
Biomaterials 2011;32:6692–709. 
[190] Das A, Segar CE, Hughley BB, Bowers DT, Botchwey E a. The promotion of 
mandibular defect healing by the targeting of S1P receptors and the recruitment of 
alternatively activated macrophages. Biomaterials 2013;34:9853–62. 
[191] Rao AJ, Nich C, Dhulipala LS, Gibon E, Valladares R, Zwingenberger S, et al. Local 
effect of IL-4 delivery on polyethylene particle induced osteolysis in the murine 
calvarium. J Biomed Mater Res A 2013;101:1926–34. 
[192] Wang Y, Zhou R, Wu N, Mou Y, Li R, Deng Z. Interleukin-4 and osteoprotegerin 
suppress polyethylene wear debris-induced osteolysis in a murine air pouch model. 
Nan Fang Yi Ke Da Xue Xue Bao 2011;31:1709–13. 
[193] Rao AJ, Gibon E, Ma T, Yao Z, Smith RL, Goodman SB. Revision joint 
replacement, wear particles, and macrophage polarization. Acta Biomater 
2012;8:2815–23. 
[194] Hughes JE, Srinivasan S, Lynch KR, Proia RL, Ferdek P, Hedrick CC. Sphingosine-
1-phosphate induces an antiinflammatory phenotype in macrophages. Circ Res 
2008;102:950–8. 
[195] Awojoodu AO, Ogle ME, Sefcik LS, Bowers DT, Martin K, Brayman KL, et al. 
Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory 
monocytes to microvessels during implant arteriogenesis. Proc Natl Acad Sci U S 
A 2013;110:13785–90. 
 154 
[196] Landesman-Milo D, Peer D. Altering the immune response with lipid-based 
nanoparticles. J Control Release 2012;161:600–8. 
[197] Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of 
alternatively activated macrophages. Exp Hematol 2009;37:1445–53. 
[198] Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous 
hMSCs improve myocardial infarction in mice because cells embolized in lung are 
activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009;5:54–
63. 
[199] Barminko J, Kim JH, Otsuka S, Gray A, Schloss R, Grumet M, et al. Encapsulated 
mesenchymal stromal cells for in vivo transplantation. Biotechnol Bioeng 
2011;108:2747–58. 
[200] Nakajima H, Uchida K, Guerrero AR, Watanabe S, Sugita D, Takeura N, et al. 
Transplantation of mesenchymal stem cells promotes an alternative pathway of 
macrophage activation and functional recovery after spinal cord injury. J 
Neurotrauma 2012;29:1614–25. 
[201] Pfister B, Gordon T, Loverde J, Kochar A, MacKinnon S, Kacy Cullen D. 
Biomedical engineering strategies for peripheral nerve repair: Surgical applications, 
state of the art, and future challenges. Crit Rev Biomed Eng 2011;39:81–124. 
[202] Madaghiele M, Sannino A, Yannas I V, Spector M. Collagen‐ based matrices with 
axially oriented pores. J Biomed Mater Res Part A 2008;85:757–67. 
[203] Spivey EC, Khaing ZZ, Shear JB, Schmidt CE. The fundamental role of subcellular 
topography in peripheral nerve repair therapies. Biomaterials 2012;33:4264–86. 
 155 
[204] Prewitt CMF, Niesman IR, Kane CJM, Houlé JD. Activated macrophage/microglial 
cells can promote the regeneration of sensory axons into the injured spinal cord. Exp 
Neurol 1997;148:433–43. 
[205] Shen ZL, Lassner F, Bader A, Becker M, Walter GF, Berger A. Cellular activity of 
resident macrophages during Wallerian degeneration. Microsurgery 2000;20:255–
61. 
[206] Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and 
functions. Immunity 2010;32:593–604. 
[207] Brown BN, Valentin JE, Stewart-Akers AM, McCabe GP, Badylak SF. Macrophage 
phenotype and remodeling outcomes in response to biologic scaffolds with and 
without a cellular component. Biomaterials 2009;30:1482–91. 
[208] Rotshenker S. Wallerian degeneration: the innate-immune response to traumatic 
nerve injury. J Neuroinflammation 2011;8:109. 
[209] Popovich PG, Guan Z, Wei P, Huitinga I, van Rooijen N, Stokes BT. Depletion of 
hematogenous macrophages promotes partial hindlimb recovery and 
neuroanatomical repair after experimental spinal cord injury. Exp Neurol 
1999;158:351–65. 
[210] Gris D, Marsh DR, Oatway MA, Chen Y, Hamilton EF, Dekaban GA, et al. 
Transient blockade of the CD11d/CD18 integrin reduces secondary damage after 
spinal cord injury, improving sensory, autonomic, and motor function. J Neurosci 
2004;24:4043–51. 
 156 
[211] Crutcher KA, Gendelman HE, Kipnis J, Perez-Polo JR, Perry VH, Popovich PG, et 
al. Debate:“is increasing neuroinflammation beneficial for neural repair?.” J 
Neuroimmune Pharmacol 2006;1:195–211. 
[212] Friedman SL. Mac the knife? Macrophages-the double-edged sword of hepatic 
fibrosis. J Clin Invest 2005;115:29–32. 
[213] Morganti-Kossmann MC, Rancan M, Stahel PF, Kossmann T. Inflammatory 
response in acute traumatic brain injury: a double-edged sword. Curr Opin Crit Care 
2002;8:101–5. 
[214] Chen JJW, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, et al. Tumor-associated 
macrophages: the double-edged sword in cancer progression. J Clin Oncol 
2005;23:953–64. 
[215] Lindholm D, Heumann R, Meyer M, Thoenen H. Interleukin-l regulates synthesis 
of nerve growth factor in non-neuronal cells of rat sciatic nerve. Lett to Nat 
1987;330:658–9. 
[216] Balgude AP, Yu X, Szymanski A, Bellamkonda R V. Agarose gel stiffness 
determines rate of DRG neurite extension in 3D cultures. Biomaterials 
2001;22:1077–84. 
[217] Gölz G, Uhlmann L, Lüdecke D, Markgraf N, Nitsch R, Hendrix S. The 
cytokine/neurotrophin axis in peripheral axon outgrowth. Eur J Neurosci 
2006;24:2721–30. 
[218] Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the 
human monocyte-to-macrophage differentiation and polarization: new molecules 
and patterns of gene expression. J Immunol 2006;177:7303–11. 
 157 
[219] Kuo H-SS, Tsai M-JJ, Huang M-CC, Chiu C-WW, Tsai C-YY, Lee M-JJ, et al. Acid 
fibroblast growth factor and peripheral nerve grafts regulate th2 cytokine 
expression, macrophage activation, polyamine synthesis, and neurotrophin 
expression in transected rat spinal cords. J Neurosci 2011;31:4137–47. 
[220] Bethea JR, Nagashima H, Acosta MC, Briceno C, Gomez F, Marcillo AE, et al. 
Systemically administered interleukin-10 reduces tumor necrosis factor-alpha 
production and significantly improves functional recovery following traumatic 
spinal cord injury in rats. J Neurotrauma 1999;16:851–63. 
[221] English AW, Chen Y, Carp JS, Wolpaw JR, Chen XY. Recovery of 
electromyographic activity after transection and surgical repair of the rat sciatic 
nerve. J Neurophysiol 2007;97:1127–34. 
[222] Krick K, Tammia M, Martin R, Höke A, Mao H-QQ. Signaling cue presentation and 
cell delivery to promote nerve regeneration. Curr Opin Biotechnol 2011;22:741–6. 
[223] Nucera S, Biziato D, Palma M. The interplay between macrophages and 
angiogenesis in development, tissue injury and regeneration. Int J Dev Biol 
2011;55:495–503. 
[224] Taras JS, Nanavati V, Steelman P. Nerve conduits. J Hand Ther n.d.;18:191–7. 
[225] Scheib J, Höke A. Advances in peripheral nerve regeneration. Nat Rev Neurol 
2013;9:668–76. 
[226] Ide C. Peripheral nerve regeneration. Neurosci Res 1996;25:101–21. 
 158 
[227] Xu XM, Guénard V, Kleitman N, Bunge MB. Axonal regeneration into Schwann 
cell-seeded guidance channels grafted into transected adult rat spinal cord. J Comp 
Neurol 1995;351:145–60. 
[228] Bunge RP. Expanding roles for the Schwann cell: ensheathment, myelination, 
trophism and regeneration. Curr Opin Neurobiol 1993;3:805–9. 
[229] Lundborg G, Dahlin LB, Danielsen N, Gelberman RH, Longo FM, Powell HC, et 
al. Nerve regeneration in silicone chambers: influence of gap length and of distal 
stump components. Exp Neurol 1982;76:361–75. 
[230] Mokarram N, Merchant A, Mukhatyar V, Patel G, Bellamkonda R V. Effect of 
modulating macrophage phenotype on peripheral nerve repair. Biomaterials 
2012;33:8793–801. 
[231] Karathanasis E, Chan L, Karumbaiah L, McNeeley K, D’Orsi CJ, Annapragada A 
V, et al. Tumor vascular permeability to a nanoprobe correlates to tumor-specific 
expression levels of angiogenic markers. PLoS One 2009;4:e5843. 
[232] Karumbaiah L, Anand S, Thazhath R, Zhong Y, Mckeon RJ, Bellamkonda R V. 
Targeted downregulation of N‐ acetylgalactosamine 4‐ sulfate 6‐ O‐
sulfotransferase significantly mitigates chondroitin sulfate proteoglycan‐ mediated 
inhibition. Glia 2011;59:981–96. 
[233] Hadlock T, Sundback C, Hunter D, Cheney M, Vacanti JP. A polymer foam conduit 
seeded with Schwann cells promotes guided peripheral nerve regeneration. Tissue 
Eng 2000;6:119–27. 
 159 
[234] Guénard V, Kleitman N, Morrissey TK, Bunge RP, Aebischer P. Syngeneic 
Schwann cells derived from adult nerves seeded in semipermeable guidance 
channels enhance peripheral nerve regeneration. J Neurosci 1992;12:3310–20. 
[235] Levi AD, Sonntag VK, Dickman C, Mather J, Li RH, Cordoba SC, et al. The role of 
cultured Schwann cell grafts in the repair of gaps within the peripheral nervous 
system of primates. Exp Neurol 1997;143:25–36. 
[236] Baichwal RR, Bigbee JW, DeVries GH. Macrophage-mediated myelin-related 
mitogenic factor for cultured Schwann cells. Proc Natl Acad Sci 1988;85:1701–5. 
[237] Ödemis V, Boosmann K, Heinen A, Küry P, Engele J. CXCR7 is an active 
component of SDF-1 signalling in astrocytes and Schwann cells. J Cell Sci 
2010;123:1081–8. 
[238] Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, 
IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 
2008;121:1108–11. 
[239] Nagalakshmi ML, Murphy E, McClanahan T, de Waal Malefyt R. Expression 
patterns of IL-10 ligand and receptor gene families provide leads for biological 
characterization. Int Immunopharmacol 2004;4:577–92. 
[240] Liao Y-C, Liang W-G, Chen F-W, Hsu J-H, Yang J-J, Chang M-S. IL-19 induces 
production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. 
J Immunol 2002;169:4288–97. 
[241] Hsing C-H, Hsu C-C, Chen W-Y, Chang L-Y, Hwang J-C, Chang M-S. Expression 
of IL-19 correlates with Th2 cytokines in uraemic patients. Nephrol Dial Transplant 
2007;22:2230–8. 
 160 
[242] Hsing C-H, Kwok FA, Cheng H-C, Li C-F, Chang M-S. Inhibiting interleukin-19 
activity ameliorates esophageal squamous cell carcinoma progression. PLoS One 
2013;8:e75254. 
[243] Yamamura M, Modlin RL, Ohmen JD, Moy RL. Local expression of 
antiinflammatory cytokines in cancer. J Clin Invest 1993;91:1005–10. 
[244] Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: 
tumor-associated macrophages as a paradigm for polarized M2 mononuclear 
phagocytes. Trends Immunol 2002;23:549–55. 
[245] Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage 
polarization in tumour progression. Semin Cancer Biol 2008;18:349–55. 
[246] Hsing C-H, Li H-H, Hsu Y-H, Ho C-L, Chuang S-S, Lan K-M, et al. The distribution 
of interleukin-19 in healthy and neoplastic tissue. Cytokine 2008;44:221–8. 
[247] Gallagher G, Eskdale J, Jordan W, Peat J, Campbell J, Boniotto M, et al. Human 
interleukin-19 and its receptor: a potential role in the induction of Th2 responses. 
Int Immunopharmacol 2004;4:615–26. 
[248] Chen Y-Y, Li C, Yeh C-H, Chang M, Hsing C. Interleukin-19 in breast cancer. Clin 
Dev Immunol 2013;2013:294–320. 
[249] Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 
2001;357:539–45. 
[250] Oral HB, Kotenko S V, Yilmaz M, Mani O, Zumkehr J, Blaser K, et al. Regulation 
of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-
20, IL-22, IL-24 and IL-26. Eur J Immunol 2006;36:380–8. 
 161 
[251] Azuma Y-T, Nakajima H, Takeuchi T. IL-19 as a Potential Therapeutic in 
Autoimmune and Inflammatory Diseases. Curr Pharm Des 2011;17:3776–80. 
[252] Hsing C-H, Cheng H-C, Hsu Y-H, Chan C-H, Yeh C-H, Li C-F, et al. Upregulated 
IL-19 in breast cancer promotes tumor progression and affects clinical outcome. 
Clin Cancer Res 2012;18:713–25. 
[253] Sakurai N, Kuroiwa T, Ikeuchi H, Hiramatsu N, Maeshima a, Kaneko Y, et al. 
Expression of IL-19 and its receptors in RA: potential role for synovial hyperplasia 
formation. Rheumatology (Oxford) 2008;47:815–20. 
[254] Schlosshauer B, Dreesmann L, Schaller H-E, Sinis N. Synthetic nerve guide 
implants in humans: a comprehensive survey. Neurosurgery 2006;59:740–7; 
discussion 747–8. 
[255] Urgery S, Ncorporated I, Graft N, Conduit C, Axogen A, Giusti G, et al. Return of 
Motor Function After Segmental Nerve Loss in a Rat Model : Comparison of 
Autogenous 2012:410–7. 
[256] Sabatier MJ, To BN, Rose S, Nicolini J, English AW. Chondroitinase ABC reduces 
time to muscle reinnervation and improves functional recovery after sciatic nerve 
transection in rats. J Neurophysiol 2012;107:747–57. 
[257] Fu SY, Gordon T. Contributing factors to poor functional recovery after delayed 
nerve repair: prolonged axotomy. J Neurosci 1995;15:3876–85. 
[258] Mokarram N, Bellamkonda R V. A perspective on immunomodulation and tissue 
repair. Ann Biomed Eng 2014;42:338–51. 
 162 
[259] Cortez-Retamozo V, Etzrodt M, Pittet MJ. Regulation of macrophage and dendritic 
cell responses by their lineage precursors. J Innate Immun 2012;4:411–23. 
[260] Yona S, Jung S. Monocytes: subsets, origins, fates and functions. Curr Opin 
Hematol 2010;17:53–9. 
[261] Ahuja V, Miller SE, Howell DN. Identification of two subpopulations of rat 
monocytes expressing disparate molecular forms and quantities of CD43. Cell 
Immunol 1995;163:59–69. 
[262] Strauss-Ayali D, Conrad SM, Mosser DM. Monocyte subpopulations and their 
differentiation patterns during infection. J Leukoc Biol 2007;82:244–52. 
[263] Avraham-Davidi I, Yona S, Grunewald M, Landsman L, Cochain C, Silvestre JS, et 
al. On-site education of VEGF-recruited monocytes improves their performance as 
angiogenic and arteriogenic accessory cells. J Exp Med 2013;210:2611–25. 
[264] Jakubzick C, Gautier EL, Gibbings SL, Sojka DK, Schlitzer A, Johnson TE, et al. 
Minimal differentiation of classical monocytes as they survey steady-state tissues 
and transport antigen to lymph nodes. Immunity 2013;39:599–610. 
[265] Valentin JE, Stewart-Akers AM, Gilbert TW, Badylak SF. Macrophage 
participation in the degradation and remodeling of extracellular matrix scaffolds. 
Tissue Eng Part A 2009;15:1687–94. 
[266] Ma CHE, Omura T, Cobos EJ, Latrémolière A, Ghasemlou N, Brenner GJ, et al. 
Accelerating axonal growth promotes motor recovery after peripheral nerve injury 
in mice. J Clin Invest 2011;121:4332–47. 
 163 
[267] Siemionow M, Bozkurt M, Zor F. Regeneration and repair of peripheral nerves with 
different biomaterials: Review. Microsurgery 2010;30:574–88. 
[268] Perrin FE, Lacroix S, Avilés-Trigueros M, David S. Involvement of monocyte 
chemoattractant protein-1, macrophage inflammatory protein-1alpha and 
interleukin-1beta in Wallerian degeneration. Brain 2005;128:854–66. 
[269] Toews AD, Barrett C, Morell P. Monocyte chemoattractant protein 1 is responsible 
for macrophage recruitment following injury to sciatic nerve. J Neurosci Res 
1998;53:260–7. 
[270] Barrette B, Hébert M-A, Filali M, Lafortune K, Vallières N, Gowing G, et al. 
Requirement of myeloid cells for axon regeneration. J Neurosci 2008;28:9363–76. 
[271] Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, et al. Role 
for neuronally derived fractalkine in mediating interactions between neurons and 
CX3CR1-expressing microglia. Proc Natl Acad Sci U S A 1998;95:10896–901. 
[272] Fong BAM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, et al. 
Fractalkine and CX 3 CR1 Mediate a Novel Mechanism of Leukocyte Capture , 
Firm Adhesion , and Activation under Physiologic Flow 1998;188:1413–9. 
[273] Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, Kayal S, et al. Monitoring 
of blood vessels and tissues by a population of monocytes with patrolling behavior. 
Science 2007;317:666–70. 
[274] Auffray C, Fogg DK, Narni-Mancinelli E, Senechal B, Trouillet C, Saederup N, et 
al. CX3CR1+ CD115+ CD135+ common macrophage/DC precursors and the role 
of CX3CR1 in their response to inflammation. J Exp Med 2009;206:595–606. 
 164 
[275] Holmes FE, Arnott N, Vanderplank P, Kerr NCH, Longbrake EE, Popovich PG, et 
al. Intra-neural administration of fractalkine attenuates neuropathic pain-related 
behaviour. J Neurochem 2008;106:640–9. 
[276] Qin W, Li Z, Luo S, Wu R, Pei Z, Huang R. Exogenous fractalkine enhances 
proliferation of endothelial cells, promotes migration of endothelial progenitor cells 
and improves neurological deficits in a rat model of ischemic stroke. Neurosci Lett 
2014;569:80–4. 
[277] Stievano L, Piovan E, Amadori A. C and CX3C chemokines: cell sources and 
physiopathological implications. Crit Rev Immunol 2004;24:205–28. 
[278] Belkas JS, Shoichet MS, Midha R. Peripheral nerve regeneration through guidance 
tubes. Neurol Res 2004;26:151–60. 
[279] Daley JM, Reichner JS, Mahoney EJ, Manfield L, Henry WL, Mastrofrancesco B, 
et al. Modulation of Macrophage Phenotype by Soluble Product(s) Released from 
Neutrophils. J Immunol 2005;174:2265–72. 
[280] Novak ML, Koh TJ. Macrophage phenotypes during tissue repair. J Leukoc Biol 
2013;93:875–81. 
[281] Fenn AM, Hall JCE, Gensel JC, Popovich PG, Godbout JP. IL-4 Signaling Drives a 
Unique Arginase+/IL-1β+ Microglia Phenotype and Recruits Macrophages to the 
Inflammatory CNS: Consequences of Age-Related Deficits in IL-4Rα after 
Traumatic Spinal Cord Injury. J Neurosci 2014;34:8904–17. 
[282] Charrière GM, Cousin B, Arnaud E, Saillan-Barreau C, André M, Massoudi A, et 
al. Macrophage characteristics of stem cells revealed by transcriptome profiling. 
Exp Cell Res 2006;312:3205–14. 
 165 
[283] Seta N, Kuwana M. Derivation of multipotent progenitors from human circulating 
CD14+ monocytes. Exp Hematol 2010;38:557–63. 
[284] Zhao Y, Glesne D, Huberman E. A human peripheral blood monocyte-derived 
subset acts as pluripotent stem cells. Proc Natl Acad Sci U S A 2003;100:2426–31. 
[285] Onofre G, Kolácková M, Jankovicová K, Krejsek J. Scavenger receptor CD163 and 
its biological functions. Acta Medica (Hradec Kralove) 2009;52:57–61. 
[286] Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C, Zernecke A, 
et al. Functional contribution of elevated circulating and hepatic non-classical 
CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One 
2010;5:e11049. 
[287] Mullarky IK, Szaba FM, Berggren KN, Kummer LW, Wilhelm LB, Parent MA, et 
al. Tumor necrosis factor alpha and gamma interferon, but not hemorrhage or 
pathogen burden, dictate levels of protective fibrin deposition during infection. 
Infect Immun 2006;74:1181–8.  
 
 
 
 
 
 
